,PageNo,Text
0,page_0,"Protocol I1F-MC-RHCF (a) A 52 -Week Multicenter, Randomized, Open- Label, Parallel -Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease -Modifying Anti- Rheumatic Drug Naïve NCT03151551 Approval Date: 26- May-2017"
1,page_1,"I1F-MC-RHCF(a) Clinical Protocol Page 1 LY2439821Protocol I1F-MC-RHCF (a) A 52-Week Multicenter, Randomized, Open -Label, Parallel - Group Study Evaluating the Efficacy and Safety of Ixekizumab versus A dalimumab in Patients with Psoriatic Arthritis Who A re Biologic Disease -Modifying A nti-Rheumatic Drug Naive Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of ixekizumab (LY2439821), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities : This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public rele ase. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Ixekizumab (LY243 9821 ) Study I1F -MC-RHCF is aPhase 3b/4, multicenter, randomized, open -label, parallel -group study with blinded outcomes assessment s evaluating the efficacy and safety of ixekizumab versus adalimumab in patient s with psoriatic arthritis who are biologic disease -modifying anti-rheumatic drug naive during a 52 -week treatment period. Eli Lilly and Company Indianapolis, Indiana USA 46285 Protocol Electronically Signed and Approved by Lilly on 06 March 2017 Protocol Amendment (a) Electronically Signed and Approved b y Lilly on date provided below. Approval Date: 26-May-2017 GMT"
2,page_2,I1F-MC-RHCF(a) Clinical Protocol Page 2 LY2439821Table of Contents Section Page Table of Contents ........................................................................................................................ 2 1. Synopsis ............................................................................................................................. 9 2. Schedule of Act ivities....................................................................................................... 13 3. Introduction ...................................................................................................................... 20 3.1. Study Rati onale ............................................................................................................ 20 3.2. Background .................................................................................................................. 20 3.3. Benefit /Risk Assessment .............................................................................................. 23 4. Object ives and Endpo ints.................................................................................................. 24 5. Study Design ..................................................................................................................... 26 5.1. Overall Design ............................................................................................................. 26 5.1.1. Screening Period (Period 1) .................................................................................. 28 5.1.2. Open -Label Treatm ent Peri od (Peri od 2) .............................................................. 28 5.1.3. Post-Treatment Follow -Up Pe riod (Peri od 3) ....................................................... 29 5.2. Number of Participants .................................................................................................30 5.3. End of Study Definit ion............................................................................................... 30 5.4. Scientific Rationale for Study Design ........................................................................... 30 5.5. Justification for Dose ................................................................................................... 30 6. Study Popul ation............................................................................................................... 33 6.1. Inclusio n Cri teria.......................................................................................................... 33 6.2. Exclusio n Cri teria........................................................................................................ 34 6.3. Lifest yle Restrict ions.................................................................................................... 39 6.4. Screen Failures ............................................................................................................. 39 7. Treatments ........................................................................................................................ 40 7.1. Treatment s Administered ............................................................................................. 40 7.1.1. Administrati on of Investi gational Product ............................................................ 41 7.1.2. Packaging and Labeling ....................................................................................... 41 7.2. Method of Treatment Assignment ................................................................................ 42 7.2.1. Selection and Timing o f Doses ............................................................................. 42 7.3. Blinding ....................................................................................................................... 42 7.4. Dosage Modification .................................................................................................... 43 7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 43 7.6. Treatment Compliance .................................................................................................43 7.7. Concomitant Therapy ................................................................................................... 44 7.8. Treatment after the End of the Study ............................................................................ 48
3,page_3,"I1F-MC-RHCF(a) Clinical Protocol Page 3 LY24398217.8.1. Study Extensio ns.................................................................................................. 48 7.8.2. Continued Access .................................................................................................48 7.8.3. Speci al Treatm ent Consi derat ions........................................................................ 49 8. Discontinuati on Cri teria .................................................................................................... 50 8.1. Discontinuati on from Study Treatm ent......................................................................... 50 8.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 50 8.1.2. Temporary Discont inuat ion from Study Treatm ent............................................... 52 8.1.3. Discontinuati on of Inadvertent ly Enrolled Patients ............................................... 52 8.2. Discontinuati on from the Study .................................................................................... 52 8.3. Lost to Follow -Up........................................................................................................ 53 9. Study Assessments and Procedures ................................................................................... 54 9.1. Efficacy Assessments ................................................................................................... 54 9.1.1. Primary Efficacy Assessments ............................................................................. 54 9.1.1.1. Combined Endpo int of American Co llege of Rheumatology 50 Responder Index and Psoriasis Area and Severit y Index 100 ................................................................................... 54 9.1.2. Secondary Efficacy Assessments .......................................................................... 54 9.1.2.1. Psori asis Area and Severit y Index (PASI 75, PASI 90, PASI 100) ....................................................................................................... 54 9.1.2.2. Percentage of Body Surf ace Area ................................................................... 55 9.1.2.3. American Co llege of Rheumatology 20 Responder Index ............................... 55 9.1.2.3.1. American College of Rheumatology Core Set ........................................... 55 9.1.2.4. American Co llege of Rheumatology 50 and 70 Responder Index ............................................................................................. 57 9.1.2.5. Individual Co mponents of the American Co llege of Rheumatology Core Set.................................................................................. 57 9.1.2.6. Psori atic Arthri tic Response Criteria ............................................................... 57 9.1.2.7. Minimal Disease Act ivity............................................................................... 57 9.1.2.8. Modified Composite Psoriatic Disease Act ivity Index .................................... 58 9.1.2.9. Leeds Enthesit is Index .................................................................................... 58 9.1.2.10. Spondyloarthrit is Research Consortium o f Canada ......................................... 58 9.1.2.11. Leeds Dact ylitis Index -Basic .......................................................................... 58 9.1.2.12. Nail Psoriasis Severit y Index Fingernails ........................................................ 59 9.1.2.13. Disease Act ivity Score based on C -React ive Protein ....................................... 59 9.1.2.14. Static Physician Global Assessment ................................................................ 59 9.1.3. Appropriateness of Assessments .......................................................................... 60 9.2. Adverse Events ............................................................................................................ 60 9.2.1. Serious Adverse Events ........................................................................................ 61 9.2.1.1. Adverse Events of Special Interest .................................................................. 61"
4,page_4,I1F-MC-RHCF(a) Clinical Protocol Page 4 LY24398219.2.1.2. Suspected Unexpected Serious Adverse React ions.......................................... 63 9.2.2. Com plaint Handling ............................................................................................. 63 9.3. Treatment of Overdose .................................................................................................63 9.4. Safety........................................................................................................................... 63 9.4.1. Vital Signs........................................................................................................... 63 9.4.2. Laboratory Tests .................................................................................................. 64 9.4.3. Columbia Suici de Severi ty Rating Scal e............................................................... 64 9.4.4. Other Tests ........................................................................................................... 64 9.4.4.1. Physical Examinat ion..................................................................................... 64 9.4.4.2. Chest X -Ray and Tuberculosis Test ing........................................................... 64 9.4.5. Safety Moni toring ................................................................................................ 65 9.4.5.1. Hypertensio n.................................................................................................. 65 9.4.5.2. Hepati c Moni toring........................................................................................ 66 9.4.5.3. Neutropenia .................................................................................................... 66 9.4.5.4. Hepati tis B Monitoring ................................................................................... 67 9.5. Pharmacokinet ics......................................................................................................... 67 9.6. Pharmacodynamics ...................................................................................................... 67 9.7. Genet ics....................................................................................................................... 68 9.8. Biomarkers ................................................................................................................... 68 9.9. Heal th Outcom e/Quali ty of Life Measures ................................................................... 68 9.9.1. Itch Numeric Rat ing Scale .................................................................................... 68 9.9.2. Fatigue Severit y Numeri c Rat ing Scale Score ....................................................... 68 9.9.3. Medical Outcomes Study 36-Item Short Form Heal th Survey Physical Co mponent Summary and Mental Co mponent Summary Scores .................................................................................................. 68 9.9.4. European Qualit y of Life —5 Dimensi ons 5 Level [EQ - 5D- 5L])...................................................................................................................... 68 9.9.5. Derm atology Life Qualit y Index........................................................................... 69 9.9.6. Treatment Satisfact ion Quest ionnaire ................................................................... 69 10. Statistical Considerations .................................................................................................. 70 10.1. Sample Si ze Determinat ion.......................................................................................... 70 10.2. Popul ations for Analyses .............................................................................................. 70 10.3. Statistical Analyses ...................................................................................................... 71 10.3.1. General Statist ical Considerat ions........................................................................ 71 10.3.1.1. General Considerations for Analyses during Period 2 (Open -Label Treatment Period) ...................................................................... 71 10.3.1.2. Missing Data Im putati on................................................................................ 71 10.3.1.2.1. Nonresponder Imputation .......................................................................... 71 10.3.1.2.2. Last Observat ion Carried Forward ............................................................ 72
5,page_5,"I1F-MC-RHCF(a) Clinical Protocol Page 5 LY243982110.3.1.3. Adjustment for Multiple Com parisons ............................................................ 72 10.3.2. Treatment Group Comparabilit y........................................................................... 72 10.3.2.1. Patient Disposi tion.......................................................................................... 72 10.3.2.2. Patient Characteri stics.................................................................................... 72 10.3.2.3. Concomitant Therapy ..................................................................................... 73 10.3.2.4. Treatment Compliance .................................................................................... 73 10.3.3. Efficacy Analyses ................................................................................................ 73 10.3.3.1. Primary Analysis Method ............................................................................... 73 10.3.3.1.1. Categorical Variables ................................................................................ 73 10.3.3.1.2. Continuous Variables ................................................................................ 73 10.3.3.2. Secondary Analysis Method ........................................................................... 74 10.3.3.2.1. Categorical Variables ................................................................................ 74 10.3.3.2.2. Continuous Variables ................................................................................ 74 10.3.3.3. Methodol ogy for Noninferi ority Test .............................................................. 74 10.3.4. Safety Analyses .................................................................................................... 74 10.3.4.1. Adverse Events ............................................................................................... 75 10.3.4.2. Clinical Laboratory Tests ................................................................................ 75 10.3.4.3. Vital Signs, Physical Findings, and Other Safet y Evaluat ions..................................................................................................... 76 10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 76 10.3.6. Other Analyses ..................................................................................................... 76 10.3.6 .1. Subgroup Analyses ......................................................................................... 76 10.3.7. Interim Analyses .................................................................................................. 76 11. References ........................................................................................................................ 78 12. Appendices ....................................................................................................................... 83"
6,page_6,I1F-MC-RHCF(a) Clinical Protocol Page 6 LY2439821List of Tables Table Page Table RHCF.2.1. Study Drug Administration Schedule ............................................................. 18 Table RHCF.4.1. Object ives and Endpo ints............................................................................... 24 Table RHCF.7.1. Treatment Regimens ...................................................................................... 40 Table RHCF.7.2. Concomitant Medications Permitted/Not Permitted in the Open -Label Treatment Period from Week 0 to Week 24 for Treatment of PsA and Chronic Con ditions........................................................................................ 44 Table RHCF.7.3. Concomitant Medications Permitted/Not Permitted in the Open -Label Treatment Period from Week 24 to Week 52 for Treatment of PsA and Chronic Condit ions........................................................................................ 46 Table RHCF.7.4. Allowed Conco mitant Medi cations in the Post -Treatment Foll ow-Up Period (Peri od 3) ............................................................................................ 47
7,page_7,I1F-MC-RHCF(a) Clinical Protocol Page 7 LY2439821List of Figures Figure Page Figure RHCF.5.1. Illustrati on of study design for Clinical Protocol I1F -MC-RHCF. ............. 27
8,page_8,"I1F-MC-RHCF(a) Clinical Protocol Page 8 LY2439821List of Appendices Appendix Page Appendix 1. Abbreviat ions and Definit ions........................................................................ 84 Appendix 2. Clinical Laboratory Tests ............................................................................... 89 Appendix 3. Study Governance Considerat ions.................................................................. 90 Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 93 Appendix 5. Protocol Amendment I1F -MC-RHCF(a) Summary: A 52 -Week Multicenter, Randomized, Open -Label , Parallel -Group Study Evaluat ing the Efficacy and Safet y of Ixekizumab versus Adalimumab in Pat ients with Psor iatic Arthrit is Who Are Bio logic Disease- Modifying Ant i-Rheumat ic Drug Naive ......................................................... 94"
9,page_9,"I1F-MC-RHCF(a) Clinical Protocol Page 9 LY24398211.Synopsis Title of Study: A 52-Week Multicenter, Randomized, Open -Label ,Parallel -Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who A re Biologic Disease -Modifying Anti-Rh eumatic Drug N aive Rationale: The purpose of this trial is to compare the efficacy and s afety of ixekizumab with adalimumab in patients with psoriatic arthritis (PsA) wh o are biologic disease -modifying anti -rheumatic drug (bDMARD) naive . Adalimumab, a widely used tumor necrosis factor inhibitor, was chosen as an active comparator because of its well -established efficacy and safety profile; treatment with adalimumab is a standard of care. Asadditional therapies become available, an important question is whether agents with different mechanisms of action have comparable clinical efficacy and safety. To date, no results of a direct comparator study in patients with PsA comparing 2 bDMARD s have been published . This type of study design is important forinforming evidence -based treatment decisions with regard stoa tumo r necrosis factor inhibitor. Objective(s)/Endpoints: Objectives Endpoints Primary To assess whether ixekizumab is superior to adali mumab at Week 24 in the treatment of patients with active PsA as measured by American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI 100) Proportio n ofpatients simultaneously achieving ACR50 and PASI 100 at Week 24 Major Secondary Objectives: To assess whether ixekizumab is noninferior to adali mumab at Week 24 in the treatment of patients with active PsA as measured by ACR50 To assess whether ixekizumab is superior to adalimumab at Week 24 in the treatment of patients with active PsA as measured by PASI 100Proportio n of patients achieving ACR50 in each treatment group at Week 24 Proportio n of patients achieving PASI 100 in each treatment group at Week 24 Other Secondary Objectives: To assess the effect of treatment with ixekizumab compared with adalimumab as measured by efficacy and quality of life outcomesPsA Endpoints Time course of response to treatment over 52 weeks as measured by: Proportio n of patients achieving ACR20, ACR50, and ACR70 responses Change f rom baseline in individual components of the American College of Rheumatology (ACR )Core Set -tender joint count, swol len joint count, patient ’ s pain assessment, Patient ’s Global Assessment of Disease Activity , Physician ’sGlobal Assessment of Disease Activity ,"
10,page_10,"I1F-MC-RHCF(a) Clinical Protocol Page 10 LY2439821Objectives Endpoints C-reactive protein ( CRP), and Health Assessment Questionnaire ‒Disability Index ( HAQ - DI)score Proportio n of pati ents simultaneously a chieving ACR50 and PASI 100response Change from baseline in the Disease Activity Score (28 diarthrodial joint count) based on C -reactive protein ( DAS28 -CRP ) Proportio n of patients achieving Minimal Disease Activity (MDA) Proportio n ofpatients achieving Psoriatic Arthritis Response Criteria (PsARC) Change f rom baseline inModified Composite Psoriatic Dise ase Activity Index (CPDAI) score Proportio n of patients achieving low disease activity or remission according to the Modified Compos ite Psoriatic Disease Activity Index definitio n Proportio n of patients with HAQ -DI improvement ≥0.35 Change f rom baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC )Enthesitis Index score in patients with enthesitis at baseline (ie, baseline SPARCC Enthesitis Index score >0) Change f rom baseline in the Leeds Enthesitis Index (LEI )score in patients with enthesitis at baseline (ie, baseline LEI score >0) Proportio n of patients with resolution in enthesitis in the subgroup of patients with enthesitis at baseline as measured by the SPARCC Enthesitis Index (ie, baseline SPARCC Enthesitis Index score >0) Proportio n of patients with resolution in enthesitis in the subgroup of patients with enthesitis at baseline as measured by the LEI (ie, baseline LEI score >0) Change f rom baseline in the Leeds Dactylitis Index -Basic (LDI -B) score in patients with dactylitis at baseline (ie,baseline LDI-Bscore >0) Proportio n of patients with resolution in dactylitis in the subgroup of patients with d actylitis at baseline as measured by the LDI -B (ie, baseline LDI-Bscore >0) Psoriasis/Nail Endpoints Time course of response to treatment over 52 weeks as measured by: Change f rom baseline in body surface area (BSA) Proportio n of patients who achieve the following PASI score s: PASI 75, PASI 90, or PASI 100 (defined as 75%, 90% ,and 100% improvement from baseline in PASI criteria, respectively) Proportio n of patients achieving an absolute PASI score ≤1 or ≤2 or ≤3 Change f rom baseline in the Nail Psoriasis Severity Index ( NAPSI ) Fingernails score in the subgroup of patients with fingernail involvement at baseline (ie, baseline NAPSI Fingernails score >0) QoL Endpoints Time course of response to treatment over 52 weeks as measured by: Change f rom baseline in the Itch Numeric Rating Scale (NRS) score Proportio n of patients with Itch NRS score equal to 0 Change f rom baseline in Fatigue Severity NRS score"
11,page_11,"I1F-MC-RHCF(a) Clinical Protocol Page 11 LY2439821Objectives Endpoints Change f rom baseline in Medical Outcomes Study 36 -Item Short Form Health Survey (SF -36) oPhysical Component Summary score oMental Component Summary score Change f rom baseline in measures of health utility (European Quality of Life–5Dimensio ns 5 Level health outcomes instrument [EQ- 5D-5L]) Change f rom baseline in Dermatology Life Quality Index (DLQI) total score Change f rom baseline in Treatment Satisfaction Questionnaire Safety Change f rom baseline in Columbia ‒Suicide Severity Rating Scale (C -SSRS) Summary of Study Design: Study I1F -MC -RHCF is a Phase 3b/4, multicenter, randomized, open -label, parallel -group study with blinded outcomes assessments evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with PsA who are bDMARD naive during a 52 -week treatment period. Treatment Groups and Duration: Ixekizumab: 80 mg subcutaneous (SC) injection A starting dose of ixekizumab 160 mg (two 80-mg SC injections) will be administered at randomization (Visit 2 [Week 0]) for all patients Patients with moderate -to-severe plaque psoriasis (Ps), defined as PASI ≥12, static Phys ician’s Global Assessment (sPGA) ≥3, and BSA ≥10%, will receive ixekizumab 80 mg given as 1SC injection every 2weeks (Q2W) from Week 2 to Week 12 and ever y 4 weeks (Q4W) thereafter Patients not meeting criteria for moderate -to-severe plaque Ps at randomiz ation will receive ixekizumab 80mg given as 1 SC injection Q4W starting at Week 4 Adalimumab: 40 mg SC injection Patients with moderate -to-severe plaque Ps, defined as PASI ≥12, sPGA ≥3, and BSA ≥10%, will receive a starting dose of adalimumab 80 mg (two 40 -mg SC injections) administered at randomization (Visit 2 [Week 0]) followed by 40 mg given as 1 SC injection Q2 W starting at Week 1 Patients not meeting criteria for moderate -to-severe plaque Ps will receive a starting dose of adalimumab 40 mg given as 1 SC injection at randomization (Visit 2 [Week 0]) followed by 40 mg given as 1 SC injection Q2W starting at Wee k 2"
12,page_12,"I1F-MC-RHCF(a) Clinical Protocol Page 12 LY2439821The study will consist of 3 periods: Period 1: Screening Period (Visit 1) up to 28 days before randomization (Visit 2) Period 2: Open -Label Treatment Period (Visit 2 through Visit 11) f rom Week 0 to Week 52 Period 3: Post- Treatment Follow -Up Perio d occurring from last treatment visit during Period 2 or Early Termination Visit (ETV) up to a minimum of 12 weeks after that visit Number of Planned Patients : Enrolled/Randomized: 550 (275 ixekizumab; 275 adalimumab) Statistical Analysis: The total sample size for the study will be 550patients randomized in a 1:1 ratio to ixekizumab or adalimumab (patients per treatment group) in Period 2. A significance level of 0.05 is assumed for testing ixekizumab v ersus adalimumab . Sample size was c alculated assuming the proportion of patients simultaneously achieving ACR50 and PASI 100as 13.6% and 31.3%in the adalimumab and ixekizumab treatment groups, respectively ,as observed in the conventional synthetic disease - modifying anti -rheumatic drug ( csDMARD )-experienced population from Study RHAP . According to the nQuery sof tware, a total sample size of 550 patients (with 275 patients per treatment group) using a 2 -sided Fisher's exact test at a0.05 leve l of significance would yield approximately 99% power for testing ixekizumab versus adalimumab. This sample size would yield 78% power for testing thenoninferio rity of ixekizumab to adalimumab at a one-sided 0.025 level of significance based o n a no ninferiority margin of –12% and using ACR50 response rates of 43.8% and 44.1% as observed for the ixekizumab and adalimumab treatment groups , respectively ,in the csDMARD - experienced population from Study RHAP . For testing superiority of ixekizumab to adalimumab based on PASI 100 response rates of 46.9% and 23.7% as observed for ixekizumab and adalimumab in the csDMARD -experienced populatio n fromStudy RHAP, this sample size would yield 99% power using a 2 -sided Fisher's exact test at 0.05 level of significance ."
13,page_13,"I1F-MC-RHCF(a) Clinical Protocol Page 13 LY24398212.Schedule of A ctivities Study Schedul e, Protocol I1F -MC-RHCF Screen - ing Period 1Treatment Phase: Study Drug Administration Baseline Open -Label Treatment Period 2a Visit No (V) V1 V2 V3bV4 V5 V6 V7 V8 Study Week (W) W0 W1 W4 W8 W12 W16 W24 Study Days -28d 0d 7 ± 2d 28± 2d 56 ± 2d 84± 4d 112± 4d168 ± 4d Informed consent X Complete medical history X Review preexisting conditio nsX Age, sex X Physical examinationcX X PsA classification criteria (CASPAR criteria)X Inclu sion/exclusion criteria X X HeightX Temperature X Weight X Sitting blood pressure and pulseX XdX X X X X Habits (tobacco , alcohol use)X Concomitant medications X X X X X X X X Review adverse events X X X X X X X X Randomization X Administer Study Drug See Table RHCF.2.1e Dispense Study Drug and Study Drug Administration LogX X X X X X Collect/Review/Enter Data from Study Drug Administration LogX X X X X X Clinical Efficacy Patient -Rated Assessments Patient’s Assessment of Pain VASX X X X X X Patient’s Global Assessment of Disease Activity VASX X X X X X HAQ -DI X X X X X X Itch NRS X X X X X X SF-36 X X X X X"
14,page_14,I1F-MC-RHCF(a) Clinical Protocol Page 14 LY2439821Screen - ing Period 1Treatment Phase: Study Drug Administration Baseline Open -Label Treatment Period 2a Visit No (V) V1 V2 V3bV4 V5 V6 V7 V8 Study Week (W) W0 W1 W4 W8 W12 W16 W24 Study Days -28d 0d 7 ± 2d 28± 2d 56 ± 2d 84± 4d 112± 4d168 ± 4d EQ-5D-5L X X X X X Fatigue Severity NRS X X X X X DLQI X X X X X X Clinician-Rated or Administered Assessments TJC/SJC (68/66 joints) X X X X X X X Physician’s Global Assessment of Disease Activity VASX X X X X X PASI X X X X X X % Body Surface Area X X X X X X X Enthesitis Assessment (SPARCC and LEI)X X X X X X LDI-B X X X X sPGA X NAPSI Fingernails X X X X C-SSRS X X X X X X X Self-Harm Supplement Form and Self -Harm Follow -Up FormX X X X X X X Treatment Satisfaction QuestionnaireX X Laboratory Tests Administer TB testfX Chest x- ray Xg ECG Xh FSH Xi HIV/HCV X HBV PaneljX HBV DNAkX X X X Serum pregnancy testlX Urine pregnancy testmX X X Serum chemistry X XnX X X Hematology X X X X X Urinaly sis X X X RF X hs-CRP X X X X X X
15,page_15,"I1F-MC-RHCF(a) Clinical Protocol Page 15 LY2439821Study Schedule, Protocol I1F -MC -RHCF Treatment Phase : Study Drug Administration Open -Label Treatment Period 2a Visit No (V) V9 V10 V11 ETV Study Week (W) W32 W40 W52 Study Days 224 ± 4d 280± 4d 364 ± 4d Physical examinationcX X Weight X X Sitting blood pressure and pulse X X X X Concomitant medications X X X X Review adverse events X X X X Administer Study Drug See Table RHCF.2.1e Dispense Study Drug and Study Drug Administration LogX X Collect/Review/Enter Data from the Study Drug Administration LogX X X X Clinical Efficacy Patient -Rated Assessments Patient’s Assessment of Pain VAS X X X X Patient’s Global Assessment of Disease Activity VASX X X X HAQ -DI X X X X Itch NRS X X X X SF-36 X X X EQ-5D-5L X X X Fatigue Severity NRS X X X DLQI X X X X Clinician-Rated or Administered Assessments TJC/SJC (68/66 joints) X X X X Physician’s Global Assessment of Disease Activity VASX X X X PASI X X X X % Body Surface Area X X X X Enthesitis Assessment (SPARCC and LEI) X X X X LDI-B X X X X NAPSI Fingernails X X X X C-SSRS X X X X Self-Harm Supplement Form and Self -Harm Follow -Up FormX X X X Treatment Satisfaction Questionnaire X X Laboratory Tests HBV DNAkX X X Urine pregnancy testmX X X X Serum chemistry X X X Hematology X X X Urinaly sis hs-CRP X X X X"
16,page_16,"I1F-MC-RHCF(a) Clinical Protocol Page 16 LY2439821Study Schedule, Protocol I1F -MC -RHCF Post-Treatment Follow -Up Perio d 3o Required Visits As Needed Visit No (V) V801 V802 V803 Study Week (W) LTV + 4W LTV + 12W LTV + 24W Study Days +/- 14d +/- 14d +/- 14d Concomitant medications X X X Review adverse events X X X Clinician-Rated or Administered Assessments C-SSRS X X X Self-Harm Supplement Form and Self -Harm Follow -Up FormX X X Vital Signs/ Laboratory Tests Sitting blood pressure and pulse X X X HBV PaneljX HBV DNAkX Serum chemistry X X X Hematology X X X Abbreviations: CASPAR = Classification for Psoriatic Arthritis; C-SSRS = Columbia –Suicide Severity Rating Scale ; d= day ; DLQI = Dermatology Life Quality Index; DNA = deoxyribonucleic acid ; ECG =electrocardiogram; EQ-5D-5L = Europea n Quality of Life –5 Dimensions 5 Level health outcomes instrument; ETV = Early Termination Visit; Fatigue Severity NRS =Fatigue Severity Numeric Rating Scale; FSH = follicle -stimulating hormone ;HAQ -DI= Health Assessment Questionnaire ‒Disability Index ; HBcAb =anti-hepatitis B core antibody ;HBsAg =hepatitis B surface antigen ;HBV =hepatitis B virus ; HCV =hepatitis C virus ;HIV = human immunodeficiency virus; hs- CRP = high sensitivity (assay) C -reactive protein ;ItchNRS = Itch Numeric Rating Scale; LDI-B= Leeds Dactylitis Index -Basic; LEI= Leeds Enthesitis Index; LTV =last treatment visit during Period 2 or Early Termination Visit; NAPSI Fingernails = Nail Psoriasis Severity Index Fingernails; PASI =Psoriasis Area and Severity Index; PPD =purifie d protein derivative ; PsA =psoriatic arthritis; RF=rheumatoid factor; SF-36 = Medical Outcomes Study 36 -Item ShortForm Health Survey ; SJC= swollen joint count; SPARCC = Spondyloarthritis Research Consortium of Canada; sPGA =static Physician Global Assessment of psoriasis ;TB= tuberculosis ; TJC = tender joint count; VAS = visual analog scale. aIf a patient discontinues the study drug early , the patient will complete the ETV and then e nter the Post -Treatment Follow -Up Period of the protocol. bVisit 3 will be a phone visit. cOne complete physical examination (excluding pelvic ,rectal , and breast examinations) will be performed at Visit 1 (screening). All remaining physical examinations throughout the study should include a symptom -directed physical evaluation as well as an examination of the heart, lungs, and abdomen and a visual examination of theskin. dSitting blood pressure and pulse ratemust be measured before study drug dosing and 1 hour post dose at Visit 2 (Week 0 ). eAt randomization (Visit 2) for patients randomized to ixekizumab and for patients with moderate -to-severe plaque Ps sy mptoms randomized to adalimumab, the second injection of study drug will be administered by the patient or caregiver under site personnel supervision for injection training purposes. Thereafter, study drug will be administered by the patient or caregiver. fIn countries where the QuantiFERON ®-TB Gold test or T -SPOT ®is available, either test may be used instead of the purified PPD TB test . The QuantiFERON ®-TB Gold test may be performed locally or centrally; the T-SPOT ®must be performed locally. PPD tests must be read 48 to 72 hours after Visit 1. See Section 9.4.4.2 for TB testing details ."
17,page_17,"I1F-MC-RHCF(a) Clinical Protocol Page 17 LY2439821Study Schedule, Protocol I1F -MC -RHCF gA chest x- ray(posterior -anterior view) will be taken at screening (Visit 1) and assessed locally, unless one has been obtained within the past 6 months and the x-ray or results are available for review. hObtain ECG within 1 week of Visit 2 (prior to the first dose); assessed locally. iFor female patients ≥40 and <60 years of age who have had a cessation of m enses for at least 12 months, a follicle - stimulating hormone (FSH )test will be performed to confirm nonchildbearing potential (FSH ≥40mIU/mL). jAll patients will be tested for HBV. kPatients who meet criteria for HBV monitoring (see Section 9.4.5.4 ) will be identified by the central laboratory at baseline and monitored according to the study schedule. lOnly for females of childbearing potential. mOnly for females of childbearing potential. Additional urine pregnancy testing can be performed at the investigator’s discretion or per applicable regulations/guidance. nVisit 2 should be a fasting visit. oPatients receiving study drug who discontinue at any time prior to the end of the study or who complete the study (Week 52) will enter the Post - Treatment Follow -Up Period occurring from last treatment visit or ETV up to a minimum of 12 weeks after that visit. Visit 803 will only occur if a patient ’s neutrophil counts hav enot returned to the criteria defined in Section s 5.1.3 and 8.1.1."
18,page_18,I1F-MC-RHCF (a)Clinical Protocol Page 18 LY2439821Table RHCF. 2.1. Study Drug A dministration Schedule Visit 2 3 4 5 6 7 8 Weeks 0a1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Ixekizumab 80 mg Q2W/Q4W Moderate -to-Severe Plaque PsbX (160 mg)X X X X X X X X X Ixekizumab 80 mg Q4WcX (160 mg)X X X X X X Adalimumab 40 mg Q2WdX (40mg)X X X X X X X X X X X X Adalimumab 40 mg Q2W Moderate -to-Severe Plaque PseX (80mg)X X X X X X X X X X X X Visit 9 10 11 Weeks 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 Ixekizumab 80 mg Q2W/Q4W Moderate -to-Severe Plaque PsbX X X X X X Ixekizumab 80 mg Q4Wc X X X X X X Adalimumab 40 mg Q2Wd X X X X X X X X X X X X X Adalimumab 40 mg Q2W Moderate -to-Severe Plaque PseX X X X X X X X X X X X X X Abbreviations: BSA =body surface area; PASI =Psoriasis Area and Severity Index ; Ps= pso riasis; Q2W = ever y 2 weeks; Q4W = every 4 weeks ; SC=subcutaneous; sPGA =static Physician Global Assessment of psoriasis . aStarting dose .
19,page_19,"I1F-MC-RHCF (a)Clinical Protocol Page 19 LY2439821Study Drug Administration Schedule bPatients with moderate -to-severe plaque Ps, defined as PASI ≥12, sPGA ≥3,and BSA ≥10%, will receive ixekizumab 80 mg given as 1 SC injection Q2W from Week 2 toWeek 12 and Q4W thereafter . cPatients not meeting criteria for moderate -to-severe plaque Ps will receive ixekizumab 80 mg given as 1 SC injection Q4W starting at W eek 4 . dPatients not meeting criteria for moderate -to-severe plaque Ps will receive a starting dose of adalimumab 40 mg given as 1 SC injection at randomization (Visit 2 [Week 0] ) followed by 40 mg given as 1 SC injection Q2W starting at Week 2 . ePatients with moderate -to-severe plaque Ps, defined as PASI ≥12, sPGA ≥3,and BSA ≥10%, will receive a starting dose of adalimumab 80 mg (two 40 -mg SC injections) administered at randomization (Visit 2 [Week 0] ) followed by 40 mg given as 1 SC injection Q2W starting at Week 1 ."
20,page_20,"I1F-MC-RHCF (a)Clinical Protocol Page 20 LY24398213.Introduction 3.1. Study Rationale During the l ast decade, the treatment of psoriatic arthrit is (PsA) has significant ly changed . Methotrexate (MTX) or other conventio nal synt hetic disease -modifying anti -rheumat ic drugs (csDMARD) such as sulfasalazine or leflun omide areusually init iated as a firstline o f treatm ent. In pati ents wi th active PsA and an inadequate response or intol erance to a csDMARD ,the use of a bio logic DMARD (bDMARD) is recommended according to the European League Against Rheumatism (EULAR) and Group for Research and Assessment of Psoriasis and Psoriat ic Arthri tis (GRAPPA) working group (Gossec et al. 2016; Coates etal. 2016) . Based on curr ent treatment recommendations, a tumor necrosis factor (TNF) inhibitor is the usual first option for a bDMARD, mainly because of the long-term experi ence and the well-established efficacy and safet y profile o f these agents . Five TNF inhibitors have been approved and are available in major markets for the treatment of PsA to-date: etanercept, infliximab, adalimumab, golimumab ,and certolizumab. In addit ion, biosimilars of infliximab , etanercept , and adalimumab (Amjevita package insert, 2016) have been rec ently approved for use in PsA. New bDMARDs targeting different mechanisms of act ion have also been approved for the treatm ent of PsA, wi th ustekinumab targeting the IL -12/IL -23 pathway , secukinumab and brodal umab targeting the IL -17 pathway , and apremilas t, an oral molecule, inhibit ing phosphodiesterase 4 (PDE 4). As addit ional therapi es beco me available, an important question is whether bDMARDs with different mechanisms o f acti on have com parable clinical efficacy and safet y. Ixekizumab has been studied in pat ients with active PsA in a study that included adalimumab as an act ive control reference arm (Mease et al. 2017). Yet to date, no results of a direct com parator study in pat ients with PsA co mparing 2 bDMARDs have been published. This type of study design is important for informing evidence -based treatment decisions with regard to a TNF inhibitor . In thi s study , adalimumab has been chosen as the active comparator, as it is recognized as a standard of care for a bDMARD in the treatment of active PsA. 3.2. Background PsA is an immune -mediated chronic inflammatory disorder commo nly associated wi th psoriasis (Ps) that occurs in 0.04% to 1% of the general populat ion but in 6% to 42% of patients with psori asis. It i s a progressive, destructive disease that re sults in deformit ies, impaired physical funct ion, loss o f QoL, and increased mortalit y (Kavanaugh et al 2016). PsA also has a considerable negat ive impact on mult iple physical and emot ional aspects of patients’ lives (Gladman et al . 2005; Rosen et al . 201 2). Pati ents wi th PsA have reported poorer health -related QoL compared to the general populat ion and to Ps patients (Husted et al. 1997; Rosen et al. 2012) and suffer from a similar level o f functional impairment to patients with rheumatoid arthri tis (RA) (Husted et al . 2013). The current standard of care for PsA includes nonsteroidal ant i-inflammatory drugs; intra-articular and/or systemic glucocorti coids; convent ional synt hetic disease -modifying"
21,page_21,"I1F-MC-RHCF (a)Clinical Protocol Page 21 LY2439821anti-rheumat ic drugs (csDMARDs) such as MTX, sulfasalazine (SSZ), lefluno mide, and cyclosporine A; and bio logic agents such as TNF inhibitors (Gossec et al. 2012; Smo len et al. 2014, Gossec et al. 2016). Although leflunomide has been shown to be effect ive in improving signs and symptoms of PsA as assessed by Psoriatic Arthrit ic Response Criteria (PsARC) and American Co llege of Rheumatology 20 score (ACR20), there is only weak evidence that other csDMARDs are effect ive, though limited controlled clinical trial d ata are available (Gossec et al. 2012; Mease and Armstrong 2014, Gossec et al. 2016). In a recent randomized controlled trial of patients wi th PsA treated wi th MTX, no si gnificant improvement was demonstrated in peripheral arthri tis (Kaltwasser et al. 200 4, Kingsley et al . 2012). Addi tionally, csDMARDs have not demonstrated efficacy in treating axial invo lvement, enthesit is, or dactylit is, though limited data are available ( Gossec etal. 2012; Mease and Armstrong 2014). SSZ was effect ive for axial manife stations in an open -label trial, but not for enthesit is or dactylit is (Clegget al. 1996; Dougados et al. 1995). Data on radiographic progression on MTX has not been conclusive and only analyzed in a small case -control study; for SSZ, radiographic progres sion was not prevented in a small case -control study of 20SSZ-treated pati ents and 20 m atched controls ( Ash et al. 2012). In pati ents wi th PsA, TNF inhibitors are effect ive in treating signs and symptoms, inhibit ing or slowing structural progressi on (main ly bone degradation), and improving skin lesio ns (Kavanaugh et al. 2006; Mease et al. 2005; Mease et al. 2000; Mease et al. 2004; Kavanaugh etal. 2009; Antoni et al. 2005a; Antoni et al. 2005b). However, between 30% and 40% of patients wi th PsA have a pa rtial response while others become resistant or intolerant to treatment and cont inue to accrue disabilit y (Rudwaleit et al. 2010; Nash and Clegg 2005). In addition, infect ions, m alignancies, blood dyscrasias, peripheral neuropathy , and central nervous sys tem and spinal cord demyelinat ion can present as majo r probl ems in some patients treated with these agents (Deepak et al. 2013; Ruderm an2012; Singh et al. 2011). Therefore, there is an unmet need for alternative effect ive medicat ions with a different mec hanism o f action and an improved safet y profile for patients with PsA. Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 monoclonal ant ibody that neutralizes the cy tokine IL -17A (al so known as IL -17). Ixekizumab was developed by humanizat ion and optimizat ion of a mouse anti -human IL -17 ant ibody . It has a high affinit y for and neutralizes the activit y of both human and monkey IL -17. It has high specificit y to IL -17A and has no cross -reactivit y to other IL -17 family members (IL -17B- F). Ixekizumab blocks IL - 17 binding to the IL -17 receptor (IL -17R). A total o f 7339 patients ( 5689 patients with psoriasis, 532 patients with RA, and 1118 patients with PsA) have been treated with at least 1 dose of ixekizumab . The efficacy o f ixekizumab in patients wi th moderate -to-severe plaque psoriasis has bee n evaluated in 3 large, placebo -controlled, Phase 3 studies ( Studi es RHAZ, RHBA, and RHBC) invo lving a total of 2328 patients treated with ixekizumab and 791 patients treated with place bo. Ixekizumab was found to be superi or to pl acebo in all 3 studies during both the inducti on and maintenance phases. Inthe 2 studi es wi th etanercept as an act ive co mparator during the induction phase, ixekizumab"
22,page_22,"I1F-MC-RHCF (a)Clinical Protocol Page 22 LY2439821was found to be superior to etanercept. Based on these results, ixekizumab has been approved for the treatm ent of moderate -to-severe psoriasis worldwide. In pati ents wi th PsA, Study RHAP was designed to assess whether ixekizumab 80 mg every 2weeks (Q2W) or 80 mg every 4 weeks ( Q4W )was superi or to pl acebo in the treatm ent of bDMARD -naive patients with act ive PsA. Significant ly more pati ents treated with ixekizumab achieved an ACR20 , ACR50, and ACR70 response compared wi th placebo -treated patients at Week 24 (all co mpar isons p≤.001 ; nonresponde r imputati on m ethod): ACR20 response -IXEQ2W (62.1%) ,IXEQ4W (57.9%) versus placebo (30.2%) ACR50 response -IXEQ2W (46.6%) , IXEQ4W (40.2%) versus placebo (15.1%). ACR70 response -IXEQ2W (34.0%) ,IXEQ4W (23.4%) versus placebo (5.7%). Amo ng patients with psori asis at baseline affect ing≥3% body surface area ( BSA ), a significant ly greater percentage of patients achieved PASI 75,PASI 90, and PASI 100 Week 24 (all comparisons (p<.001) . PASI 75 -IXEQ2W (79.7%), IXEQ4W (71.2%) versus placebo (10.4%). PASI 90 -IXEQ2W (67.8%), IXEQ4W (56.2%) versus placebo (6.0%) PASI 100 -IXEQ2W (52.5%), IXEQ4W (42.5%) versus placebo (3.0%) At Week 24, improvements from baseline in physical function, measured by Health Assessment Quest ionnaire -Disabilit y Index (HAQ -DI), were significant ly greater in pat ients receiving IXEQ4W ( −0.44), IXEQ2W (−0.50) than in those receiving placebo (−0.18) (p≤. 001). The improvement from baseline in Short Form (36 Items) Healt h Survey Physical Component Score was also si gnificantly great er at Week 24 for patients receiving IXEQ4W (7.5) and IXEQ2W (8.2) compared with those receiving placebo (2.9) (p ≤.01). For patients with dactylit is and LDI-B >0 at baseline, signi ficantly greater improvements in mean LDI -B scores at Week 24 (post hoc ana lysis) were observed for the IXEQ4W and IXEQ2W groups compared with the placebo group (p ≤.01) and complete resolut ion of dactylit is symptoms (LDI -B=0) at Week 24 (post hoc analysis) occurred at a greater rate in the IXEQ4W (80%) and IXEQ2W (77%) groups than in the placebo group (25%) (p ≤.001). For patients with nail invo lvement at baseline, mean changes fro m baseline in the NAPSI score at Week 24 were sign ificantly greater for the IXEQ4W ( −14.0) and IXEQ2W ( −15.5) groups than for the placebo group ( −2.4) ( p≤.001). Progression of structural damage, measured by changes from baseline in mTSS at Week 24, was significant ly less in the IXEQ4W (0.17) andIXEQ2W (0.08 )groups than in the placebo group (0.49) (p ≤.01) . There was not a statist ically significant dif ference between either ixekizumab group, compared with the pl acebo group, for the major secondary endpoints of change from baseline to Week 12 in Leeds Enthesit is Index (LEI) (Mease et al. 2017). Significant therapeutic effects for the si gns and symptom s of PsA, physical funct ion, progression of structural damage, and skin manifestations of psoriasis were observed for many endpoints as early as 1 week after init iation of therapy . Effects were observed in the overall bDMARD -naive popul ation and the subpopulat ion with csDMARD experience. The findings were clinically"
23,page_23,"I1F-MC-RHCF (a)Clinical Protocol Page 23 LY2439821significant and indicated that ixekizumab offers a potential therapeutic option for patients with active PsA who are bDMARD naive. Although a dalimumab 40 m g Q2W was used as the active control for com parison wi th placebo , this study was not powered to compare ixekizumab wit h adalimumab . In addit ion, the Phase 3 clinical development program conducted in patients with active PsA includes 2 addit ional studi es: Study RHBE in pat ients who are bDMARD experienced, and Study RHBF, a wi thdrawal study conducted in csDMARD -inadequate responder (IR) and bDMARD -naive pat ients. Study I1F-MC-RHCF (RHCF) is a Phase 3b/4, mult icenter, randomized, open -label, parallel- group study with blinded outcomes assessments evaluat ing the efficacy and safet y of ixekizumab versus adalimumab in pat ients with PsA who are bDMARD naive during a 52 -week treatm ent peri od. The primary objective of this study is to assess whether ixekizumab is superior to adalimumab as measured by the proportion of patients simultaneously achieving ACR50 and PASI 100at Week 24 . In addi tion, the effects of ixekizumab on extra -articular m anifestati ons of PsA such as skin, fingernails, enthesit is, dactylit is, and the impact on QoL will be evaluated. This study also eval uates the l ong-term efficacy and saf ety of ixekizumab in PsA for up to 1year. 3.3. Benefit/Risk Assessment More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) and reasona bly ant icipated adverse events (AEs) of ixekizumab are to be found in the Invest igator’s Brochure (IB) and the product labeling . More detailed informat ion about the known and expected benefits and risks of adalimumab may be found in the product l abeling ."
24,page_24,"I1F-MC-RHCF (a)Clinical Protocol Page 24 LY24398214.Objectives and Endpoints Table RHCF. 4.1shows the objectives and endpo ints ofthe study . Table RHCF. 4 .1. Objectives and Endpoints Objectives Endpoints Primary To assess whether ixekizumab is superior to adali mumab at Week 24 in the treatment of patients with active PsA as measured by American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI 100) Proportio n ofpatients simultaneously achieving ACR50 and PASI 100 at Week 24 Major Secondary Objectives: To assess whether ixekizumab is noninferior to adali mumab at Week 24 in the treatment of patients with active PsA as measured by ACR50 To assess whether ixekizu mab is superior to adalimumab at Week 24 in the treatment of patients with active PsA as measured by PASI 100Proportio n of patients achieving ACR50 in each treatment group at Week 24 Proportio n of patients achieving PASI 100 in each treatment group at Week 24 Other Secondary Objectives: To assess the effect of treatment with ixekizumab compared with adalimumab as measured by efficacy and quality of life outcomesPsA Endpoints Time course of response to treatment over 52 weeks as measured by: Proportio n of patients achieving ACR20, ACR50, and ACR70 responses Change f rom baseline in individual components of the American College of Rheumatology (ACR )Core Set -tender joint count, swollen joint count, patient ’ s pain assessment, Patient ’s Global Assessment of Disease Activity , Physician ’sGlobal Assessment of Disease Activity , C-reactive protein ( CRP), and Health Assessment Questionnaire ‒Disability Index ( HAQ - DI)score Proportio n of patients simultaneously a chieving ACR50 and PASI 100response Change from baseline in the Disease Activity Score (28 diarthrodial joint count) based on C -reactive protein ( DAS28 -CRP ) Proportio n of patients achieving Minimal Disease Activity (MDA) Proportio n of patients achieving Psoriatic Arthritis Response Criteria (PsARC) Change f rom baseline inModified Composite Psoriatic Dise ase Activity Index (CPDAI) score Proportio n of patients achieving low disease activity or remission according to the Modified Composite Psoriatic Disease Activity Index definitio n Proportio n of patients with HAQ -DI improvement ≥0.35"
25,page_25,"I1F-MC-RHCF (a)Clinical Protocol Page 25 LY2439821Objectives Endpoints Change f rom baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC )Enthesitis Index score in patients with enthesitis at baseline (ie, baseline SPARCC Enthesitis Index score >0) Change f rom baseline in the Leeds Enthesitis Index (LEI )score in patients with enthesitis at baseline (ie, baseline LEI score >0) Proportio n of patients with resolution in enthesitis in the subgroup of patients with enthesitis at baseline as measured by the SPARCC Enthesitis Index (ie, baseline SPARCC Enthesitis Index score >0) Proportio n of patients with resolution in enthesitis in the subgroup of patients with enthesitis at baseline as measured by the LEI (ie, baseline LEI score >0) Change f rom baseline i n the Leeds Dactylitis Index -Basic (LDI -B) score in patients with dactylitis at baseline (ie,baseline LDI-Bscore >0) Proportio n of patients with resolution in dactylitis in the subgroup of patients with dactylitis at baseline as measured by the LDI -B (ie, baseline LDI-Bscore >0) Psoriasis/Nail Endpoints Time course of response to treatment over 52 weeks as measured by: Change f rom baseline in body surface area (BSA) Proportio n of patients who achieve the following PASI score s: PASI 75, PASI 90, or PASI 100 (defined as 75%, 90% ,and 100% improvement from baseline in PASI criteria, respectively) Proportio n of patients achieving an absolute PASI score ≤1 or ≤2 or ≤3 Change f rom baseline in the Nail Psoriasis Severity Index ( NAPSI ) Fingernails score in the subgroup of patients with fingernail involvement at baseline (ie, baseline NAPSI Fingernails score >0) QoL Endpoints Time course of response to treatment over 52 weeks as measured by: Change f rom baseline in the Itch Numeric Rating Scale (NRS) score Proportio n of patients with Itch NRS score equal to 0 Change f rom baseline in Fatigue Severity NRS score Change f rom baseline in Medical Outcomes Study 36 -Item Short Form Health Survey (SF -36) oPhysical Component Summary score oMental Component Summary sco re Change f rom baseline in measures of health utility (European Quality of Life–5Dimensio ns 5 Level health outcomes instrument [EQ- 5D-5L]) Change f rom baseline in Dermatology Life Quality Index (DLQI) total score Change f rom baseline in Treatment Satisfaction Questionnaire Safety Change f rom baseline in Columbia ‒Suicide Severity Rating Scale (C -SSRS)"
26,page_26,"I1F-MC-RHCF (a)Clinical Protocol Page 26 LY24398215.Study Design 5.1. Overall Design Study RHCF is a Phase 3b/4, multicenter, randomized, open -label, parallel -group stud y with blinded outcomes assessments evaluat ing the effic acy and safet y of ixekizumab versus adalimumab in pat ients with PsA who are bDMARD naive during a 52 -week treatment period. The study will consist of 3 peri ods: Period 1: Screening Period (Visit 1) u p to 28 days before rando mizat ion (Visit 2) Period 2: Open -Label Treatment Period (Visit 2 through Visit 11) from Week 0 to Week 52 Period 3: Post-Treatment Follow -Up Peri od occurring from last treatment visit during Period 2 or Early Terminati on Vi sit (ETV) up to a minimum o f 12 weeks after that visit All patients randomized to ixekizumab will receive a starti ng dose of 160 mg at randomization (Visit 2 [Week 0]) . Patients with moderate -to-severe plaque Ps will receive i xekizumab 80mg Q2W fromWeek 2 toWeek 12 and Q4W thereafter .Patients not meeting criteria for moderate -to-severe plaque Ps at randomizat ion will receive ixekizumab 80 mgQ4W starti ng at Week 4. Patients randomized to a dalimumab withmoderate -to-severe plaque Ps will receive a starti ng dose of 80 mg at randomization (Visit 2 [Week 0] ) followed by 40mg Q2W starting at Week 1 . Patients not m eeting criteria formoderate -to-severe plaque Ps will receive a starting dose of 40mg at randomizat ion (Visit 2) fo llowed by 40 mg Q2W starting at Week 2 (see Section 7.1for details regarding treatments administered). Figure RHCF. 5.1illustrates the study design."
27,page_27,I1F-MC-RHCF (a)Clinical Protocol Page 27 LY2439821Abbreviations: D = days; LTV = last treatment visit during Period 2 or Early Termination Visit; V = visit; W = week. aSee Section 7.1for dosing details. Figure RHCF. 5.1. Illustration of study design for Clinical Protocol I1F -MC-RHCF.
28,page_28,"I1F-MC-RHCF (a)Clinical Protocol Page 28 LY2439821All procedures to be conducted during the study , including timing and sequence (as necessary), are indicated in the Schedule o f Activities(Section 2). Appendix 2 lists the specific laboratory tests that will be performed for this study . Patients di scont inuing fro m study treatm entwho have rec eived at l east 1 dose of investigational product will continue to the ETV before proceeding to the Post -Treatment Follow -Up Peri od (Peri od 3). All treatment groups are described in Sect ion7, and administration of the invest igational product is described in Sect ion7.1. Excluded and restricted therapies are detailed in Section 7.7. 5.1.1. Screening Period ( Period 1) The durati on of the Screening Period (Peri od 1) will be up to 28 days before randomizati on at (Visit 2) in the Open -Label Treatment Period (Period 2) to assess pat ient eligibilit y. The patient will sign the informed consent form (ICF) before any study assessments, examinat ions, or procedures are performed. All inclusio n and exclusion criteria are provided in Sections 6.1and 6.2, respectively. Screening procedures (including co mplete medical history and dem ographi cs) will be performed according to the Schedule of Act ivities(Secti on 2) . See Sectio n9.4.4.2 for details regarding required tuberculosis (TB) testing . Invest igators should review the vaccinat ion status of their patients and fo llow the l ocal guidelines for adul t vaccinat ion with nonlive vaccines intended to prevent infect ious disease before ther apy. 5.1.2. Open -Label Treatment Period (Period 2) The Open -Label Treat ment Period (Peri od 2) will occur from Week 0 (randomizat ion; Visit 2) to Week 52 (Visit 11). See Section 7and Table RHCF. 7.1for treatm ents administered during the Open -Label Treatm ent Peri od. At Week 0 ( randomization, Visit 2),routine safet y assessments, laboratory tests, and clinical efficacy assessments (including height , wei ght, and tem perature , as well as review of habits) will be perform ed on eligible patients according to the Schedule of Act ivities (Section 2). Pati ents will be rando mized at a 1:1 ratio to either ixekizumab 80mg or adalimumab 40 mg. During the Open -Label Treatm ent Peri od, s afety and efficacy parameters in participat ing patients will be evaluated according to the Schedule of Activit ies(Secti on 2) . Patients who perm anent ly discont inue from study treatm ent for any reason during this period will cont inue to the ETV before entering the Post -Treatment Follow -Up Peri od (Period 3; Secti on5.1.3 )."
29,page_29,"I1F-MC-RHCF (a)Clinical Protocol Page 29 LY24398215.1.3. Post -Treatment Follow -Up Period (Period 3) All patients receiving at least 1 dose of invest igational product will enter the Post -Treatment Follow-Up Peri od (Period 3), occurring from last t reatm ent visi t(LTV) during Peri od 2 or ETV up to a minimum o f 12weeks afterthat visit. The requi red study visit sshoul d occur 4 weeks (Visit 801) and 12 weeks (Visit 802) after the last regul arly scheduled visit in Period 2 (or the date of the patient ’s ETV), except for patients with a concurrent infect ion that requires systemic ant i-infective therapy ( described below ). If, at Vi sit 802, a pati ent’s neutrophil count is ≥1500 cells/ L or greater than or equal to the patient’s baseline neutrophil count , the pati ent’s parti cipati on in the study will be considered complete unless the invest igator determines addit ional fo llow-up m ay be necessary . An additional study visit (Visit 803) 12 weeks after Visit 802 may be required. If, at the last scheduled vi sit or ETV, a patient’s neutrophil count is <1500 cells/ L (<1.50 × 10 3/µL or <1.50 GI/L) and less than the patient's baseline neutrophil count, the following measures should be taken: Patients with concurrent infect ion: If there is a concurrent infect ion that requires systemic anti -infect ive therapy, the patient should receive appropriate medical care and a repeat test for neutrophil count should be performed at least Q4W (or sooner as appropriate) until reso lution of inf ection. Upon resolut ion of infection, the neutrophil count should be monitored using the required study visits in the Post-Treatment Follow-Up P eriod (Period 3) design at Visits 801 (4 weeks after resolut ion of infect ion), 802 (8 weeks after Visit 801), a nd 803 (if necessary; 12 weeks after Visit802); addit ional visits may be requi red depending on the degree of neutropenia. Patients without concurrent infect ion : If there is no concurrent infection that requires systemic anti -infect ive therapy, the neutro phil count should be mo nitored using the requi red study visits in the Post-Treatment Follow -Up P eriod (Period 3) design, Visits801 (4 weeks post ETV or last regularly scheduled visit), 802, and 803 (if necessary ); addi tional visi ts may be requi red dependi ng on the degree of neutropenia. For Vi sit 801 and subsequent visits, the following monitoring applies: oAs long as a pati ent’s neutrophil count is <1000 cells/ L (<1.00 × 10 3/µL or <1.00 GI/L) at any fo llow -up visi t, the patient shoul d return for addit ional visits at least Q4W (unscheduled visits may be required). oAs long as a pati ent’s neutrophil count is ≥1000 cells/ L and <1500 cells/ L (≥1.00 × 10 3/µL and <1.50 × 10 3/µL or ≥1.00 GI/L and <1.50 GI/L) at any follow-up visit, the patient should return fo r addi tional visit(s) at l east every 4to 8weeks (unscheduled visit s may be requi red)."
30,page_30,"I1F-MC-RHCF (a)Clinical Protocol Page 30 LY2439821oIf at Visit 803 the patient’s neutrophil count remains <1500 cells/ L (<1.50 × 10 3/µL or <1.50 GI/L) and less than the patient’s baseline neutrophil count or if the i nvest igator deems addit ional follow-up m ay be necessary , the investigator in consultation wit h Eli Lilly and Co mpany (Lilly) or qualified designee will determine the appropriate management of the patient and the appropriate timing of addit ional contact(s) or visit(s). oIf at Visit 802 or Visit 803 the patient’s neutrophil count is ≥1500 cells/ L (≥1.50 × 10 3/µL or ≥1.50 GI/L) or greater than or equal to the patient’s baseline neutrophil count (whichever is lower), the patient’s participat ion in the study will be considered co mplete unless the invest igator deems addit ional follow-up necessary . For pati ents who com pleted or disc ontinued study treatm ent and have entered the Post-Treatment Follow-Up P eriod (Period 3), PsA therapy with another agent i s allowed, as determined appropriate by the investi gator. 5.2. Number of Participants Approximately 917participants will be screened (assuming a 40% screen failure rate) to achi eve rando mizat ion of 550 participants (275 per treatment group) and approximately 396 pati ents are expected to complete Week 52 (assuming 72% complet ion rate at Week 52) . 5.3. End of Study Definition End of the tria lis the date of the last visit or last scheduled procedure shown in the Schedule of Activities(Secti on 2) for the last randomized patient. 5.4. Scientific Rationale for Study Design See Secti on 3.1for scientific rationale for study design. 5.5. Justification for Dose Protocol RHCF will include a starting dose of ixekizumab 160mg for all pat ients randomized to ixekizumab fo llowed by either i xekizumab 80 mg Q4W for patients not m eetingcriteria for moderate -to-severe plaque Ps or ixekizumab 80 mg Q2W (untilWeek 12 ) and then Q4W for patients wi thmoderate -to-severe Ps. Given the similar benefit /risk profile of the 2 dosing regimens studied in the pivotal Phase 3 studies, the dose just ification for patients with PsA includes the following: Dose Justification for Patients with PsA without Coexistent Moderate -to-Severe Plaque Psoriasis Rationale : Studies RHAP and RHBE examin edthe effect of 2 dose regimens (80 m g Q2W and 80mg Q4W ) of ixekizumab compared to placebo in patients with act ive PsA . Overall, there were no clinically meaningful d ifferences between the ixekizumab 80 mg Q2W and Q4W dosing regimens (Mease et al . 2017) . The less -frequent ixekizumab regimen (Q4W) provided therapeuti c benefit co mparable to the more frequent regimen (Q2W) across a range of efficacy"
31,page_31,"I1F-MC-RHCF (a)Clinical Protocol Page 31 LY2439821endpo ints up to Week 24(Studi es RHBE and RHAP) with efficacy sustained through Week 52 (Study RHAP) (Mease et al . 2016) . While there were some numeric differences, the overall safet y profiles were similar for the Q2W and Q4W dosing regimens. There were no unexpected finding s in safet y analyses, including within subgroups, across the 2 ixekizumab dosing regimens based on the previously recognized safet y profile from the psori asis clinical development program. The findings were confirmed wit h the exposure -response analyses of efficacy and safet y. Dose Justification for Patients with PsA with Coexistent Moderate -to-Severe Plaque Psoriasis Rationale : Evidence fro m the pivotal Phase 3 tri als for moderate -to-severe plaque psoriasis (Studi es RHAZ, RHBA, and RHBC) demonstrated additional clinical benefit on skin measures for the ixekizumab 80 mg Q2W dosing regimen versus the Q4W dosing regimen at Week 12 (Gordon et al. 2016) . In the pivotal Phase 3 studies for PsA, this addit ional clinical benefit was observed in patients with PsA who had higher levels of skin invo lvement ( ie, BSA ≥10%) and those defined as having coexistent moderate -to-severe plaque psoriasis (Studi es RHBE and RHAP) . Given there were no meaningful differences in safet y between these dosing regimens in patients defined as having coexistent moderate -to-severe plaque psoriasis, it is recommended that such patients use the dosing regimen approved for patients with moderate -to-severe plaque psori asis. Dose Justification for the 52 -Week Study Duration In addit ion, long-term efficacy and safet y were evaluated for up to 52 weeks in Study RHAP. For patients who rem ained on ixekizumab after 24 weeks of treatment, durabilit y of the therapeuti c effects was observed for up to 52 weeks of treatment across relevant clinical d omains of PsA, incl uding the signs and symptoms of disease activit y, as represented by ACR20/50/70 responses; physical function, as assessed by HAQ -DI;andskin manifestati ons of psori asis, as assessed by PASI 75/90/100 ,indicat ing clinically meaningful re sponses. The overall efficacy findings when placed in the context of the safet y resul ts from the Extensio n Peri od for the ixekizumab dosing regimens of this global, mult icenter study are consistent with a favorable benefit /risk profile for the long- term treatm ent wi th ixekizumab in pat ients with active PsA (Mease et al. 2016) . Lilly considers it appropriate to evaluate these 2 dose regimens in Study RHC F with regard to: The posi tive efficacy resul ts (eg, primary endpoint achieved in the bDMARD naive patients) and the currently known safet y profile from Study RHAP The overall consistency o f the safet y profile of ixeki zumab across the patient populat ions studi ed thus far, including Ps, RA , and PsA The recommended dose regimen for the treatment of PsA and mo derate -to-severe plaque psori asis, respectively. The evidence indicates a favorable benefit/risk profile that supports the conduct of the proposed PsA study , Study RHCF ."
32,page_32,I1F-MC-RHCF (a)Clinical Protocol Page 32 LY2439821Adalimumab 40 mg subcutaneous (SC)Q2W was selected as the comparator because it is an approved therapy for the treatm ent of PsA and reflects the bDMARD treatment considered to be a standard of care. Adalimumab will be dosedaccording to its approved labelling. The subset of patients wi th PsA associated with moderate -to-severe plaque psor iasis will receive the dosing regimen approved for the treatment of moderate -to-severe plaque psoriasis.
33,page_33,"I1F-MC-RHCF (a)Clinical Protocol Page 33 LY24398216.Study Population Prospective approval o f protocol deviati ons to recrui tment and enro llment criteria, also known as protocol waivers or exempt ions, are not permitted. 6.1. Inclusion Criteria Patients are eligible to be included in the study only if they meet all of the f ollowing criteria at screening: Type of Patient and Disease Characteristics Patients wi th a docum ented di agnosis of PsA for at least 6 months fulfilling the Classificat ion for Psori atic Arthri tis (CASPAR) and the activit y of disease as defined by the presence of at l east 3swollen jo ints (66 j oints) and 3 tender jo ints (68 jo ints) in pat ients who are bDMARD naive. Patients m ust have act ive psoriat ic skin lesio ns (plaque) of pl aque psoriasis wit h a BSA of at least 3%. Patient C haracteristics [1] Are m ale or fe male pat ients 18 y ears or ol der [1a] Male patients agree to use a reliable method of birth control during the study . [1b] Female pat ients: Are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study and for atleast 12 weeks afterthe last dose of invest igational product, whic hever i s longer. Methods of contraception considered acceptable when used properly include oral contraceptives, contraceptive patch, injectable or implantable contraceptives, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom withcontraceptive foam. OR Are women of nonchildbearing potential, defined as: Women who have had surgical sterilizat ion (hysterectomy, bilateral oophorectomy , ortubal ligation); OR Women who are ≥60 years of age; OR Women ≥40 and <60 y ears of age who h ave had a cessat ion of menses for ≥12months and a FSH test confirming nonchildbearing potential ( ≥40mIU/mL)."
34,page_34,"I1F-MC-RHCF (a)Clinical Protocol Page 34 LY2439821[2] Have a docum ented diagnosis of PsA for at least 6 mo nths and current ly meet the CASPAR classificat ion criteria. [3] Have act ive PsA defined as the presence of at least 3/68 tender and at least 3/66 swollen jointsat Vi sit 1 (Screening) and Visit 2 (Week 0). [4] Have act ive psoriat ic skin lesio ns (plaque psoriasis) with a BSA ≥3% at Visit 1 (Screening) and Visit 2 (Week 0). [50] Have had an inadequate response when treated with 1 or more csDMARDs . Informed Consent [ 5] Have given written informed consent approved by Lilly, or its designee, and Institutional Review Board / Ethical Review Board ( ERB ) governing the site. 6.2. Exclusion Criteria Patients will be excluded fro m study enro llment if they meet any o f the following cri teriaat screening: [6] Are current ly enrolled in any other clinical trial invo lving an investigat ional product or any other ty pe of medical research judged not to be scient ifically or medically com patible wit h this study [7] Have received any pr ior, or are currently receiving, treatm ent wi th any bDMARD therapy or small -molecule for PsA or for psoriasis, including investigat ional therapies (such as but not limited to TNF inhibito rs, IL -1 receptor antagonists, IL -6 inhibitor s, anti -IL-12/23p40 therapi es, Tcell or Bcell targeted therapies, or Janus kinase inhibitors) . Except ion:previous treatment of phosphodiesterase ty pe 4 inhibitors will be permitted. Treatment with phosphodiesterase type 4 inhibitors must have been discontinued at least 8 weeks before randomizat ion(Visi t 2). [8] Have previously co mpleted or with drawn from this study or any other study invest igatingixekizumab or other IL -17 inhibitors, eg, anti -IL-17 or anti -IL-17 receptor (anti -IL-17R) monoclonal antibodies . [9] Have a history of drug -induced Ps. [10] Have used csDMARDs other than MTX, lefluno mide, sulfasalazine, or cyclosporine in the 8 weeks prior to randomizat ion (Visit 2). Have discontinued MTX, sulfasalazine, or cy closporine wi thin 12 weeks pri or to rando mizat ion."
35,page_35,"I1F-MC-RHCF (a)Clinical Protocol Page 35 LY2439821If taking MTX, lefluno mide, sulfasalazine, or cyclosporine , must have been treated for at least 12 weeks prior to randomizat ionand on a stabl e dose for at least 8 weeks prior to randomizat ion, as f ollows: oral or parenteral MTX = 10 to 25mg/week, lefluno mide = 20 mg/day, sulfasalazine = up to 3 g/day, or cyclosporine up to 5 mg /kg/day . The dose of these allowed concomitant medicat ions m ust rem ain unchanged during the first 24 weeks of the Open -Label Treatment Period unless changes are required for safet y issues. Local standard of care should be fo llowed for concomitant administration of fo lic acid with MTX. [11] Have discontinued leflunomide within 4 weeks prior to randomization or have received lefluno mide fro m 4 to 12 weeks prior to randomization and have not undergone a drug eliminat ion procedure. [12] Use of oral corticosteroi ds at average daily doses of >10 mg/day of prednisone or its equivalent, or use of variable doses of any oral corticosteroi ds, wi thin 4 weeks pri or to randomizatio n (Vi sit 2). [13] Have received any parenteral glucocortico id administered by intraarti cular, intram uscular, or intravenous (IV) inject ion within 6 weeks prior to randomizat ion, or for whom a parenteral inject ion of glucocorti costeroi ds is ant icipated during the first 24 weeks of the Open -Label Treatm ent Peri od. [14] Concomitant us e of nonst eroidal ant i -inflammatory drugs or cyclooxygenase -2 inhibitors, unl ess the pati ent ison a stable dose for at least 2 weeks prior to randomizat ion (Vi sit 2). [15] Use of any opiate analgesic at average daily doses of >30 m g/day of morphine or i ts equivalent or use of variable doses of any opiate analgesic within 6 weeks pri or to randomizat ion (Visit 2) . [16] Have received systemic nonbio logic Ps therapy other than csDMARDs or corticosteroi ds as indicated above (including, but not limited to oral psoral ens and ul traviolet A light therapy oral retinoi ds, thi oguanine, hydroxyurea, siro limus, azathioprine, fumaric acid derivat ives, or 1, 25dihydroxy vitamin D3 and analog s) or phototherapy (including either oral and topi cal ultraviolet A, ultravioletB or self -treatm ent wi th tanning beds or therapeuti c sunbathing) within 4 weeks prior to randomization (Visit 2); OR Had topi cal Ps treatm ent wi thin the previous 2 weeks pri or to randomizat ion (Visit 2). Except ions: weak potency (WHO Group 1 classification) topical steroids will be permitted. [17] Patients wi th plaque Ps, who cannot avoid use of tanning booths for at least 4 weeks prior to randomizat ion(Visit 2) and during the study ."
36,page_36,"I1F-MC-RHCF (a)Clinical Protocol Page 36 LY2439821[18] Have a known allergy or h ypersensit ivity to any biologic therapy that woul d pose an unacceptable risk to the patient if participat ing in this study . [19] Have ever received efalizumab or natalizumab or other agents that target alpha -4-integrin. [ 20] Had a live vaccinat ion within12 weeks pri or to rando mizat ion(Visi t 2), or intend to have a live vaccinat ion during the course of the study , or wi thin 12 weeks of com pletingtreatm ent in thi s study , or have participated in a vaccine clinical study within 12 weeks prior to randomizat ion. Invest igators should review the vaccinat ion status of their patients and follow the l ocal guidelines for adul t vaccinat ion with nonlive vaccines intended to prevent infect ious di sease pri or to therapy . Note: Killed/inact ive or subunit vaccines are expected to be safe; however, their efficacy with concomi tant ixekizumab treatm ent is unknown. [21] Had a vaccinat ion with Bacillus Calmette -Guérin (BCG) within 12 mo nths prior to randomizat ion (Visit 2), or intend to have this vaccinat ion with BCG during the course of the study , or wi thin 12 m onths of co mpleting treatm ent in this study . [22] Have a diagnosis of other inflammatory arthri tic syndrom es such as RA, ankylo sing spondylit is, reactive arthrit is, or enteropathic arthrit is. [ 23] Have act ive Crohn ’s disease or active ulcerative colit is(UC) . [ 24] Have fibro myalgia or other chronic pain condit ion that would confound evaluat ion of the patient. [25] Have evidence of active vasculit is or uveitis. [26] Have had surgical treatment of a jo int within 8 week s prior to rando mizat ionor will require such up to Week 24. [27] Have had any major surgery within 8 weeks prior to randomizat ion, or will require such during the study that in the opinion of the invest igator and in consultation wit h Lilly or itsdesignee would pose an unacceptable risk to the pati ent. [ 28] Have diagnosis or history of malignant disease within the 5 years prior to rando mizat ion (Visit 2). Note: Patients with successfully treated basal -cell carcino ma (no m orethan 3), squamous -cell carcin oma of the skin (no more than 2) within the 5 y ears pri or to rando mizat ionmay participate in the study ."
37,page_37,"I1F-MC-RHCF (a)Clinical Protocol Page 37 LY2439821[29] Presence of significant uncontrolled cerebrocardiovascular events (for example, myocardial infarct ion [MI], unstable angina, unstable arterial hypertensio n, moderate -to-severe [NYHA cl ass III/IV] heart failure, or cerebrovascular accident), respiratory , hepat ic, renal, gastrointestinal, endocrine, hematologic, neuro logic or neuropsy chiatri c disorders, or abnorm al laboratory values , or illicit drug u se (including cannabino ids, whether legalized or not) at screening that in the opinio n of the investigator pose an unacceptable risk to the patient if participat ing in the study or of interfering with the interpretati on of data. [30] Have a history of unco mpensated heart failure, fluid overload, or MI, or evidence of new-onset ischemic heart disease or other serious cardiac disease, wi thin 12 weeks pri or to randomization (Visit 2). [ 31] Presence of significant uncontrolled neuropsy chiatri c disorder; hav e recent history (within 30 days prior to screening visit (Visit 1)and any t ime between screening visit (Visit 1)and rando mizat ion(Visi t 2)of a sui cide attem pt; or develops act ive suicidal ideat ion with som e intent to act with or wi thout a specific pla n (yes to questi on 4 or 5 on the “Suicidal Ideation” porti on of the C -SSRS) or develops suicide -related behaviors as recorded on the C -SSRS at screening or randomizat ion(Visit 2) ; or are clinically judged by the invest igator to be at risk for suicide. [ 32] Have presence or personal history or family history (first degree rel ative) of demyelinat ing disorder. [ 33] Patients who have: in the past 12 weeks prior to randomizat ion: ohad a serious infect ion (for example, pneumonia, cellulit is) ohave been hospitalize d for an infect ion ohave received IV ant ibiotics for an infect ion or in the past 24 weeks prior to randomizat ion had a serious bone or joint infect ion, or have ever had oan infection o f anartificial joint oan infection that occurs with increased incidence in an immunocom promised host (including, but not limited to, Pneumocystis jirovecii pneum onia, active histopl asmosis, or coccidio idomycosis); or have a known immunodeficiency. [34] Have a known immunodefici ency or are immunocompromised to an extent such that participat ion in the study woul d pose an unacceptable risk to the patient. [35] Have or had a herpes zoster or any other clinically apparent varicella - zoster vi rus infect ionwithin 12 weeks prior to randomizat ion(Visi t 2)."
38,page_38,"I1F-MC-RHCF (a)Clinical Protocol Page 38 LY2439821[36] Have evidence or suspicio n of act ive or latent TB (refer to Section 9.4.4.2 for details on determining full TB exclus ion criteria). [37] Have any other active or recent infect ion other than mentioned above within 4 weeks of rando mizat ion(Visi t 2) that, in the opinion of the investigator, would pose an unacceptable risk to th e pati ent if part icipating in the study . Note: These patients may be rescreened one time ≥4 weeks after documented resol ution of symptoms. [ 38] Have a sitt ing systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg. Note: Determined by 2 consecutive elevated readings. If an init ial sitting blood pressure reading exceeds thi s limit, the blood pressure may be repeated once after the pati ent has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limi ts, the second value may be accepted. [ 39] Are posi tive for hum an immunodeficiency virus serology (HIV), i e, positive for human immunodeficiency virus ant ibody (HIVAb). [40] Have evidence of or test positive for hepatit is B virus (HBV) by testing positive for: 1) HBV surface ant igen (HBsAg+); OR 2) anti -hepat itis B core anti body (HBcAb+) and are HBV deoxy ribonucleic acid (DNA) positive. Note: Patients who are HBsAg -, and HBcAb+ and HBV DNA negat ive may be enrolled in the study . Pati ents who meet these criteria at screening will be ident ified by the central laboratory and m onitored during the study as detailed in Secti on 9.4.5.4 . [41] Have evidence of or test positive for hepatit is C virus (HCV). A posit ive test for HCV is defined as: positive for hepatit is C antibody (ant i - HCVAb) and positive via a confirmatory test for HCV (for example, HCV polymerase chain react ion). [42] Laboratory tests may not be repeated unless there is a technical error or clinic al reason to believe a result may be erroneous .Laboratory tests can be repeated a m aximum of 1 time, and results must be received and reviewed prior to randomizat ion(Visi t 2). For eligibilit y, the m ost recent lab panel must not meet any o f the following criteria: [42a] Neutrophil count <1500 cells/ μ L [42b] Lymphocy te count < 800 cells/ μ L [42c] Platelet coun t <100,000 cells/ μ L [42d] Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times the upper limit of normal (ULN)"
39,page_39,"I1F-MC-RHCF (a)Clinical Protocol Page 39 LY2439821[42e] Total white bloo d cell count <3000 cells/ μL [42f] Hem oglobin <8.5 g/dL (85.0 g/L) for male patients and <8.0 g/dL (80 g/L) for female patients [42g] Serum creatinine >2.0 mg/dL [42h] Have clinical laboratory test resul ts at screening that are outside thenorm al reference range for the populat ion and are considered clinically significant, per invest igator assessment. [43] Have any condit ion or contraindicat ion as addressed in the local label ling for adalimumab that woul d precl ude the patient from participat ing in this protocol . [44] Have any other condit ion that precludes the patient fro m following and completing the protocol , in the opinio n of the investigator. [45] Are women who are breastfeeding. [ 46] Are study site personnel direct ly affiliated with this study and/or thei r immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. [ 47] Are Lilly empl oyees or i ts desi gnee or are emplo yees of third -party organi zationsinvolved in the study . [ 48] Are current ly enrolled in, or discont inued fro m a clinical trial invo lving an investigat ionalproduct or nonapproved use of a drug or device within the last 4 weeks or a period of at least 5 half -lives of the last administration o f the dru g, whichever is lo nger, or are concurrent ly enrolled in any other type of medical research judged not to be scient ificallyor medically compatible with this study. [49] Are unwilling or unable to comply wit h the use of a data collect ion device to directly record data fro m the pati ent. 6.3. Lifestyle Restrictions Patients shoul d be instructed to inform the blood bank of their part icipation in this study and consult with the invest igator before donat ingblood or bl ood products during participati on in the study . 6.4. Screen Failures Individuals who do not meet the criteria for participation in this study (screen failur e) may be rescreened under the fo llowing circumstances: patients who test posit ive for latent TB at screening may be rescreened fo llowing appropri ate trea tment as described in Section 9.4.4.2 . Addit ionally , pati ents who do not qualify at screening under Excl usion Criterion [37] m ay be rescreened once, 4 or more weeks after documented resolution o f symptoms. When rescreening is performed, the individual must sign a new ICF and will be assigned a new study identificat ion number."
40,page_40,"I1F-MC-RHCF (a)Clinical Protocol Page 40 LY24398217.Treatment s 7.1. Treatments Administered This study involves a comparison of ixekizumab withadalimumab . Table RHCF. 7.1shows the treatm ent regimens. Table RHCF. 7 .1. Treatment Regimens Name of Drug Starting Dose Dosage FrequencyRoute of Administration Ixekizumab 160mg for all patients 80 mgQ2W from Week 2to Week 12 and Q4W thereafter for patients with moderate -to- severe plaque Ps SC injection Q4W starting at Week 4 for patients not meeting criteria for moderate -to-severe plaque Ps Adalimumab80 mg for patients with moderate -to-severe plaque Ps 40 mgQ2W starting at Week 1for patients with moderate -to- severe plaque Ps SC injection 40 mg for patients not meeting criteria for moderate -to-severe plaque PsQ2W starting at Week 2 for patients not meeting criteria for moderate -to-severe plaque Ps Abbreviations: Ps = psoriasis; Q2W = ever y 2 weeks; Q4W = every 4 weeks; SC = subcutaneous. The invest igator or his/her designee is responsible for the following: explaining the correct use of the investigational agent(s) to the patient/site personnel verifying that instructions are fo llowed properly maintaining accurate records of investigational product dispensing and co llection at the end of the study returning all unused medication to Lilly ,or its desi gnee , unless the sponsor and sites have agreed all unused medicat ion is to be destroyed by the site, as allowed by local law"
41,page_41,"I1F-MC-RHCF (a)Clinical Protocol Page 41 LY24398217.1.1. Administration of Investigational Product Inject ions will be administered subcutaneously by the pati ent or caregiver after training by the clinical staff. Training: At randomizat ion (Visit 2) ,patients randomized to ixekizumab and patients with moderate -to-severe plaque Ps symptoms rando mized to adalimumab will receive 2 inject ions. For training purposes, the proper procedures for administration of the init ial inject ion will be perform ed by clinical staff . The second inject ion of study drug will be administered by the patient or caregiver under site personnel supervisio n. Thereafter, study drug shoul d be administered by the pat ient or caregiver . If addit ional training is necessary , an injecti on may be administered by the pat ient or caregiver under the supervisio n of clinical staff. Administration : If the patient is unable to administer the inject ion, a caregiver who will also be trained under supervision of site staff may administer the study drug . All subsequent inject ions will be administered by the pat ient orcaregi verand should be administered unsupervised by the clinical staff (see Sect ion 2). It i s recommended that for these subsequent inject ions, the patient/caregiver administer the study drug outsi de the tri al site, preferably at the pati ent’s ho me. If the patient or caregiver is not able to administer the second inject ion of the starting dose or any dose through outthe study , study site personnel may administer that injection. Refer to the appropri atedirections f or use provided by the sponsor for the study drug . Study Drug Administration Logs will be dispensed to each patient as needed for recording pertinent data about each injection; details o f the use of these logs areprovide d in Secti on7.2.1 . Observation : Patients should remain under observat ion for at least 1 hour after dosing at rando mizat ion (Visit 2)to allow for observat ion for any AEs and collect ionofpostinject ion sitting BP and pulse measurements approximately 1 hour after administration of study drug (see Secti on 2). 7.1.2. Packaging and Labeling Clinical trial materials will be labeled according to the country ’s regul atory requi rements. All investigat ional products will be stored, inventoried, reconciled, and destroy ed according to applica ble regulat ions. Ixekizumab will be supplied as an injectable so lution in 1 -mL, single -dose, prefilled, disposable manual syringes wit h study -specific labels. Each syringe of ixekizumab is designed to deliver ixekizumab 80 mg . Adalimumab 40 m gwill be supplied as single -dose, prefilled, disposable manual syringes wit h study -specific labels. Syringes will be supplied in cartons with the appropriate quantit y of syringes specific to the planned dispensing schedule of the invest igational product."
42,page_42,"I1F-MC-RHCF (a)Clinical Protocol Page 42 LY24398217.2. Method of Treatment Assignment Patients who m eet all Visit 1 and Visi t 2 eligibili ty criteria for enrollment will be rando mized at Visit 2 (Week 0) in a 1:1 rati o to open -label treatment with ixekizumab or adalimumab at Week 0 (Visit 2). Assignment to treatment groups will be determined by a co mputer -generated rando m sequence using an interactive web -response system (IWRS). The IWRS will be used to assign invest igational product to each patient. Site personnel will confirm that they have l ocated the correct investigational product by entering a confirmat ion number found on the investigat ional product into the IWRS. The randomizat ion will be stratifi ed by conco mitant csDMARD use at baseline (Yes vsNo) and moderate -to-severe plaque psoriasis involvement (Yes vsNo). 7.2.1. Selection and Timing of Doses Patients taking ixekizumab or adalimumab will receive the open -label study drug beginning on the day of Visi t 2 (Week 0). Study drug shoul d be administered on the same dayof the week, at approximately the same time each day , as m uch as possible. If an inject ion is missed, the missed dose should be administered as soon as possible . Injection(s) for missed dose(s) should not be given within 5 days of the next scheduled dose; injections should be ≥5 days apart. Dates of subsequent study visits shoul d not be modified according to this delay . A paper Study Drug Administration Log will be completed by randomized patients for each inject ion throughout study parti cipat ion. The data fro m the Study Drug Administration Log m ust be transcribed into the electronic case report form (eCRF) by site personnel. Patients will be instructed to contact their study site in the event of an inject ion probl em. In addition, si te personnel review all Study Drug Administrati on Logs at each visit to ident ify any product complaint s, and they will com plete a product com plain t form for each operati on failure reported on a Study Drug Administration Log (see Secti on9.2.2 for addi tional instructi ons regarding complaint han dling). 7.3. Blinding This is an open -label study where treatm ent allocatio n is revealed after randomizat ion. Specifically:"
43,page_43,"I1F-MC-RHCF (a)Clinical Protocol Page 43 LY2439821A blinded assessor will co mpletethe following assessments: oTJC/SJC oPsori asis Area and Severit y Index (PASI) oPercentage of BSA oEnthesit is oLDI-B oNAPSI Fingernails osPGA The blinded rater must not know the patient’s treatment allocat ion and is not allowed to be otherwi se invo lved in the study procedures. The patients will be clearly instructed not to communicate with the blinded assessor except for communication required to conduct the blinded data assessment. During each procedure conducted by a blinded assessor, a third person from the study site (eg, a nurse) will be present to observe and document that blinding o f the assessor is maintained. If a blinded assessor is unintent ionally unblinded, he/she m ust be replaced as an assessor. The availabilit y of a blinded assessor is a prerequisite for study site select ion. 7.4. Dosage Modification Not applicable. 7.5. Preparation/Handling/Storage/Accountability Invest igational products will be supplied by Lilly or its representative, in accordance wit h current Good Manufacturing Practices , and will be supplied with lot numbers, expiry dates, and certificates of analysis , as applicable . Invest igational product will be stored refrigerated ( 2C to 8C; 36F to 46F) in its original carton to protect from light. Invest igational product should not be frozen or shaken. Sites will be required to monitor temperature of the on-site storage condit ions of investigational products. 7.6. Treatment Compliance Every attem pt will be m ade to sel ect pati ents who have the abilit y to understand and co mply with study instructi ons. The invest igator is responsible for discussing methods to e nsure high treatm ent com pliance wi th the pati ent before randomizat ion. Randomized patients will record the date and time of administration of invest igational product in a Study Drug Administrati on Log throughout their participat ion in the study. The data from the Study Drug Administration Log must be transcribed into the eCRF by site personnel. Patient com pliance wi th study medicat ion will be assessed at each visit. Compliance will be assessed by review of the Study Drug Administration Log, return of empty invest igational product packaging, and/or direct questioning ."
44,page_44,"I1F-MC-RHCF (a)Clinical Protocol Page 44 LY2439821The patient should be instructed to retain all empt y study drug packaging after using up the medicat ion and to bring the empt y packaging and any unused medicat ion to the study site at ea ch visit, so that the site staff can record the amount of medicat ion used since the last visit. Deviat ion(s) fro m the prescribed dosage regimen should be docum ented . If a patient is nonco mpliant with study procedures and/or study drug administration, the investigator should assess the patient to determine the reason for noncompliance and educate and/or manage the patient as appropriate to improve compliance. If, in consultat ion with Lilly or its designee, the noncompliance is deemed to be significant or i f further nonco mpliance occurs, the pati ent shoul d be discont inued fro m the study (see Section 10.3.2.4 Treatment Compliance ). In some circumstances ,it may be necessary to temporarily interrupt treatment (see S ection8.1.2 and Sect ion9.4.5 ). Any necessary interrupti on of treatm ent shoul d be consi dered when determining nonco mpliance. 7.7. Concomitant Therapy All concomitant m edicat ion taken during the study must be recorded on the Concomitant Medicat ion case report form (eCRF) at the study visits indicated in the Schedule of Act ivities (Secti on 2) . Treatment with conco mitant PsA therapi es during the study will be permitted only as outlined in the inclusio n and exclusio n criteria (Secti ons 6.1and 6.2, respecti vely) and as described below. Patients taking permitted PsA medications shoul d be on stable doses at rando mizat ion (Vi sit 2)and through the first 24 weeks of the Open -Label Treatment Peri od,as specified below , unless changes are required for safet y reasons . Table RHCF. 7.2,Table RHCF . 7.3, and Table RHCF. 7.4summarize concomitant medications that are and are not permitted and the condit ions for use during the study for those whi ch are permitted. Table RHCF. 7.2. Concomitant Medications Permitted/Not Permitted in the Open -Label Treatment Period from Week 0 to Week 24 for Treatment of PsA and Chronic Conditions Drug Class As Needed Chronic Use Conditions for Use bDMARDs N N Not allowed PDE4 or JAK inhibito rs N N Not allowed csDMARDs N YStable dose allowed .Stable dose s with no dose adjustments , changes, and/o r introductio n of a new csDMARD Allowed doses: Oral or parenteral MTX; 10 to 25 mg/week Leflunomide: up to 20 mg/day Sulfasalazine: up to 3 g/day Cyclosporine: up to 5 mg/kg/day Live vaccines (including BCG)N NNot allowed Phototherapy N N Not allowed"
45,page_45,"I1F-MC-RHCF (a)Clinical Protocol Page 45 LY2439821Drug Class As Needed Chronic Use Conditions for Use NSAIDs, COX -2 inhibito rs N YStable dose s with no dose adjustments , changes, and/o r introductio n of a new NSAID. Allowed up to the maximum recommended doses for pain. Aspirin (doses not exceeding 350 mg/day) may be taken to manage cardiovascular risk. Opiate analgesics N YStable dose s with no dose adjustments , changes, and/o r introductio n of a new opiate analgesic. May be used at av erage daily doses ≤30 mg/day of morphine or its equivalent Nonopiod analgesics (paracetamol and acetaminophen) Y YAllowed up to the maximum recommended doses for pain . May be administered as needed basis during the study, but should be withheld within 24 hours of a visit. May be used at doses ≤1000 mg for premedication for allergic/hypersensitivity reactions from injections (see Section 7.8.3 ) Topical steroids Y YWeak potency (WHO Group 1 classification only as needed, but not within 24 hours of PASI assessment Oral corticosteroids N YStable dose s with no dose adjustments , changes, and/o rintroduction of a new oral corticosteroid Allowed doses: ≤ an average daily dose of 10 mg/day of prednisone or equivalent) Intravascular and IM gluco cortico idN NNot allowed Intra -articular gluco cortico idN NNot allowed Inhaled steroids Y Y As needed or regular use for asthma is permitted Nasal corticosteroids Y Y Use for allergies is permitted Medicated shampoos Topical moisturizers/emollients and other nonprescriptio n topical products Bathoils and oatmeal bath preparationsY YShampoos th at do not contain >3% salicylic acid, corticosteroids, coal tar, or vitamin D3 analog s Topical moisturizers/emollients and other nonprescriptio n topical products that do not contain, urea, >3% salicylic acid, alpha -or beta - hydroxy l acids, corticosteroids, or vitamin D3 analog s Allowed These topical therapies are not to be used within 12 hours prior to a study visit"
46,page_46,"I1F-MC-RHCF (a)Clinical Protocol Page 46 LY2439821Abbreviations: BCG = Bacillus Calmette -Guérin ; bDMARD = biological disease -modifying anti -rheumatic drugs; COX -2 = cycloox ygenase -2; csDMARD = conventional synthetic disease -modifying anti -rheumatic drugs; IM=intramuscular; JAK = Janus kinase ; MTX = methotrexate; N = No; NSAID =nonsteroidal anti - inflammatory drug; PASI = Psoriasis Area and Severity Index; PDE4 =phosphodiesterase type 4; Y = Yes ; WHO = World Health Organization . Table RHCF. 7 .3. Concomitant Medications Permitted/Not Permitted in the Open -Label Treatment Period from Week 24 to Week 52 for Treatment of PsA and Chronic Conditions Drug Class As Needed Chronic Use Conditions for Use bDMARDs N N Not allowed PDE4 or JAK inhibitors N N Not allowed csDMARDs N YAllowed doses: Oral or parenteral MTX; 10 to 25 mg/week Leflunomide: up to 20 mg/day Sulfasalazine: up to 3 g/day Cyclosporine: up to 5 mg/kg/day Live vaccines (including BCG)N NNot allowed Phototherapy N N Not allowed NSAIDs , COX -2 inhibito rsY YAllowed up to the maximum recommended doses for pain. Aspirin (doses not exceeding 350 mg/day) may be taken to manage cardiovascular risk. Opiate analgesics Y Y Allowed Nonopiod analgesics (paracetamol and acetaminophen) Y YAllowed up to the maximum recommended doses for pain . May be administered as needed basis during the study, but should be withheld within 24 hours of a visit. May be used at doses ≤1000 mg for premedication for allergic/hypersensitivity reactions from injections (see Section 7.8.3 ) Topical steroidsY YAllowed as needed, but not within 24 hours of PASI assessment Oral corticosteroids Y YAllowed doses: ≤ an average daily dose of 10 mg/day of prednisone or equivalent) Intravascular and IM gluco cortico idN NNot allowed Intra -articular gluco cortico idN NAllowed on a limited basis: it is recommended that there be no more than 1 injection (one injection = one large joint or up to 5 small joints or one soft tissue) Inhaled steroids Y Y As needed or regular use for asthma is permitted Nasal corticosteroids Y Y Use for allergies is permitted"
47,page_47,"I1F-MC-RHCF (a)Clinical Protocol Page 47 LY2439821Drug Class As Needed Chronic Use Conditions for Use Medicated shampoos Topical moisturizers/emollients and other nonprescriptio n topical products Bathoils and oatmeal bath preparationsY YAllowed Topical moisturizers/emollients and other nonprescriptio n topical products that do not contain, urea, >3% salicylic acid, alpha -or beta - hydroxy l acids, corticost eroids, or vitamin D3 analogs Allowed These topical therapies are not to be used within 12 hours prior to a study visit Abbreviations: BCG = Bacillus Calmette -Guérin ; bDMARD = biological disease -modifying anti -rheumatic drugs; COX -2 = cyclooxygenase -2; csDMARD = conventional synthetic disease -modifying anti -rheumatic drugs; IM=intramuscular; JAK = Janus kinase ; MTX = methotrexate; N = No; NSAID =nonsteroidal anti - inflammatory drug; PASI = Psoriasis Area and Severity Index; PDE4 =phosphodiesterase type 4 ; Y = Yes; WHO = World Health Organization . Table RHCF. 7.4. Allowed Concomitant Medications in the Post -Treatment Follow -Up Period (Period 3) Drug Class As Needed Chronic Use Conditions for Use bDMARDs Y YAllowed Follow local guidance; at the discretion of investigator PDE4 or JAK inhibitors Y YAllowed Follow local guidance; at the discretion of the investigator csDMARDs Y Y Allowed Live vaccines (including BCG)N NNot allowed Phototherapy Y Y Allowed NSAIDs , COX -2 inhibito rsY YAllowed Opiate analgesics Y Y A llowed Nonopiod analgesics (paracetamol and acetaminophen)Y YAllowed Topical steroids Y Y Allowed Oral corticosteroids Y Y Allowed Intravascular and IM gluco cortico idY YAllowed Intra -articular gluco cortico idY YAllowed Inhaled steroids Y Y As needed or regular use for asthma is permitted Nasal corticosteroids Y Y Use for allergies is permitted"
48,page_48,"I1F-MC-RHCF (a)Clinical Protocol Page 48 LY2439821Drug Class As Needed Chronic Use Conditions for Use Medicated shampoos Topical moisturizers/emollients and other nonprescriptio n topical products Bathoils and oatmeal bath preparationsY YAllowed Abbreviations: BCG = Bacillus Calmette -Guérin ; bDMARDs = biological disease -modifying anti -rheumatic drugs; COX -2 = cyclooxygenase -2; csDMARD = conventional synthetic disease -modifying anti -rheumatic drugs; IM=intramuscular; JAK = Janus kinase ; MTX = methotrexate; N = No; NSAID =nonsteroidal anti - inflammatory drug; PASI = Psoriasis Area and Severity Index; PDE4 =phosphodiesterase t ype 4 ; Y = Yes ; WHO = World Health Organization . To avoi d any possible drug interacti ons for those patients rando mized to adalimumab, please refer to the product labeling for adalimumab for further concomitant therapy restri ctions. Addit ional drugs are to be avo ided during the study unless required to treat an AE or for the treatm ent of an ongoing medical problem. If the need for concomitant medication arises, the investigator should base decisio ns on the patient and clinical factors. Patients should be instructed to consult the invest igator or other appropriate study personnel at the site before taking any new medicat ions or supplements. Any changes in medicat ions not addressed above should be discussed by the investigator with the sponsor. 7.8. Treatment after the End of the Stu dy 7.8.1. Study Extensions Not applicable. 7.8.2. Continued Access Invest igational product w ill not be m ade available to patients after the concl usion of the study ."
49,page_49,"I1F-MC-RHCF (a)Clinical Protocol Page 49 LY24398217.8.3. Special Treatment Considerations All biological agents carry the risk of systemic allergi c/hypersensit ivity reacti ons. Clinical manifestations of these reactions may include, but are not limited to: skin rash pruri tus (i tching) urticaria (hives) angioedema ( eg, swelling of the lips and/or tongue) anaphylactic reaction Sometimes these react ions can be life -threatening. Proteins may also cause redness, itching, swelling, or pain locally at the inject ion site. Therefore, all pat ients should be closely mo nitored for signs or symptoms that could result from such reactions, be educated on the signs or symptoms of these ty pes of react ions, and be instructed to contact the study site immediately if any of the symptoms are experienced after an injection. If a patient experiences an acute allergic/hypersensit ivity react ion after an inject ion of investigational product, he or she should be managed appropriately and given instruction to receive relevant supportive care. For pati ents who experience a potential allergic/hypersensit ivity react ion, consideration for any prem edicat ion for future inj ections will be agreed upon between the investigator and sponsor and/or its designee. Examples o f potenti al allergi c/hypersensit ivity react ions that might merit prem edicat ion include mild -to-moderate skin rashes, mild -to-moderate generalized pruritus and/or urti caria, and mild -to-moderate inject ion-site reacti ons (eg, injection -site ery thema, inject ion-site pruri tus). Pati ents who develop clinically significant sy stemic allergic/hypersensit ivity react ions after administratio n of invest igational product wh o do not respond to symptomat ic medicat ion or resul t in clinical sequelae should be discont inued fro m study treatm ent and not receive further doses of investigational product, with or without prem edicat ion (see Section 8). Medi cations considered appropriate for premedication include (but are not restricted to) acetaminophen/paracetamo l up to 1000 m g and ant ihistamines (eg, oral diphenhydramine, 50 mg ) given 30 to 60 minutes before investigational product inject ion. Patients m ay self-premedicate at hom e before administration of invest igational product, as directed by the invest igator. All such premedicat ions will be recorded as concomitant therapy. Corti costeroi ds are not permitted as agents for premedicat ion."
50,page_50,"I1F-MC-RHCF (a)Clinical Protocol Page 50 LY24398218.Discontinuation Criteria 8.1. Discontinuation from Study Treatment 8.1.1. Permanent Discontinuation from Study Treatment Discontinuati on of the invest igational product for abnormal liver tests should be co nsidered by the invest igator when a pat ient meets one of the fo llowing condi tions af ter consul tation wi th the Lilly -designated m edical m onitor: alanine aminotransferase (ALT) or aspartate amino transferase (AST) >8X upper limit of normal (ULN) alanine amino transferase or AST >5X ULN for more than 2 weeks alanine aminotransferase or AST >3X ULN and total bilirubin level (TBL) >2X ULN or prothrombin time >1.5X ULN alanine aminotransferase or AST >3X ULN with the appearance o f fatigue, nausea, vo miting, right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) alkaline phosphatase (ALP) >3X ULN alkaline phosphatase >2.5X ULN and TBL >2X ULN alkaline phosphatase >2.5 XULN wi th the a ppearance o f fatigue, nausea, vomiting, right quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) In addi tion, pati ents will be discont inued fro m the investigat ional product in the fo llowing circumstances : Neutrophil (segmented) counts (see Section 9.4.5.3 for information on monitoring for neutropeni a) o<500 cells/ uL o≥500 and <1000 cells/uL (based on 2 test results; the second test performed within 1 week fro m knowledge of the init ial result). o≥1000 and <1500 cells/uL (based on 3 test results) and an infection that is not fully reso lved. Total white blood cell count <2000 cells/μL. Lymphocy te count < 500 cells/μL. Platelet coun t <50,000 cells/μL. Changes in blood pressure defined as sitting systol ic blood pressure at ≥160 mm Hg plus ≥20mm Hg increase from baseline (Visi t 2[Week 0] ), and/or diastolic blood pressure at ≥100 mm Hg plus ≥10 mm Hg increase fro m baseline, that do not respond fo llowing maximal allowed intervent ion(see Section 9.4.5.1 for inform ation on m onitoring hypertensio n)."
51,page_51,"I1F-MC-RHCF (a)Clinical Protocol Page 51 LY2439821The patient experiences a severe AE, an SAE, or a clinically significant change in a laboratory value occurs that, in the opinio n of the investiga tor, m erits the di scontinuati on of the invest igational product and appropriate measures being taken . In this case, Lilly or its designee i s to be notified immediately . Clinically significant sy stemic hypersensit ivity reacti on afterSC administration of investi gational product that does not respond to symptomat ic med ication or resul ts in clinical sequelae. The patient beco mes pregnant. The patient develops a malignancy . Note : Patients may be allowed to con tinue if they develop no more than 2 nonmelano ma skin cancers over any 12-month peri odduring the study . The patient develops symptoms suggest ive of a lupus -like syndro me and is posit ive for antibodies against double -stranded DNA. If the patient, for any reason, requi res treatm ent with another therapeuti c agent that has been demo nstrated to be effective for the treatment of PsA or Ps, discont inuat ion from the study occurs pri or to introducti on of the new agent. Enrollment in any other clinical trial invo lving an investigational product or enrollment in any other ty pe of medical research judged not to be scient ifically or medically co mpat ible with this study . The patient d evelops act ive suicidal ideat ion with som e intent to act with or without a specific plan (y es to questi on 4 or 5 on the “Suicidal Ideatio n” porti on of the C -SSRS) or develops suicide -related behaviors as recorded on the C -SSRS. It i s recommended that the subject be assessed by a psychiatrist or appropriately trained professio nal to assist in deciding whether the subject is to be discont inued from the study . The patient develops any condit ion or contraindication as addressed in the local labelling for adalimumab that would preclude the patient from continuing in this protocol. The invest igator or attending physician decides that the patient shoul d be wi thdrawn from the study . The patient requests to be withdrawn fro m the study. The invest igator or Lilly stops the patient’s participation in the study or Lilly stops the study for m edical, safet y, regul atory , or other reasons consistent with app licable laws, regul ations, and good clinical pract ice (GCP ). The patient beco mes HBV DNA posit ive. The patient should be referred to a specialist physician. The p atient is diagnosed wi th an act ive TB infect ion. Ifin consultat ion with Lilly or its designe e noncompliance is deemed to be significant or if further nonco mpliance occurs, the patient maybe discontinued fro m the study (see Secti on10.3.2.4 Treatment C ompliance ). Any pat ient who permanent lydiscontinues the study treatm ent for any reason will stop treatm ent and cont inue to the ETV prior to entering the Post -Treatment Follow -Up P eriod (Period 3)."
52,page_52,"I1F-MC-RHCF (a)Clinical Protocol Page 52 LY24398218.1.2. Temporary Discontinuation from Study Treatment In some circumstances ,it may be necessary to temporarily interrupt treatment as a result of abnorm al laboratory values (see Section 8.1.1 ), AEs (see Section 9.2), hypertensio n (see Secti on9.4.5.1 ) abnormal hepat ic laboratory values (see Sectio n 9.4.5.2 ),neutropenia (see Secti on9.4.5.3 ), hepatit is B laboratory findings (see Section 9.4.5.4 ), or inflammatory bowel disease (IBD) events (see Section 9.2.1.1 )that may have an unclear relationship to investigat ional product. See Section 9.4.4.2 for details regarding managing patients who test positive for TB at any time during the study . Patients requi ring surgery at any time during the study shoul d interrupt administration of the investigat ional product beginning 8 weeks before the surgery, or as early as possible wit hin 8weeks of surgery , and resume administration of t he invest igational product only after com plete wound healing. 8.1.3. Discontinuation of Inadvertently Enro lled Patients If the sponsor or invest igator ident ify a pat ient who did not meet enrollment criteria and was inadvertent ly enro lled, a discussio n must occur between the sponsor CRP and the invest igator to determine if the pat ient may cont inue in the study . If both agree i t is medically appropriate to continue, the invest igator must obtain documented approval fro m the sponsor CRP to allow the inadvertent ly enr olled pat ient to conti nue in the study with or wi thout treatm ent wi th investigat ional product. 8.2. Discontinuation from the Study Some possible reasons that may lead to perm anent di scontinuat ion include: enrollment in any other clinical trial invo lving an investigational product or enrollment in any other ty pe of medical research judged not to be scient ifically or medically co mpat ible with this study participat ion in the study needs to be stopped for medical, safet y, regul atory , or other reasons consistent with applicable l aws, regul ations, and good clinical pract ice (GCP) investigator decisio n othe invest igator decides that the patient should be discontinued from the study oif the pat ient, for any reason, requires treatment with another therapeutic agent thathas been demo nstrated to be effect ive for treatment of the study indicat ion, discontinuat ion from the study occurs pri or to introducti on of the new agent subject decisio n othe patientor the patient’s designee requests to be withdrawn from the study Any pa tient who discont inues the study for any reason will stop treatm ent and continue to the ETV prior to entering the Post- Treatment Follow -Up Peri od (Peri od 3)."
53,page_53,"I1F-MC-RHCF (a)Clinical Protocol Page 53 LY24398218.3. Lost to Follow -Up A pat ient willbe considered lost to fo llow-up if he or she repeatedly fails to return for scheduled visits and is unable to be con tacted by the study site. Site personnel are expected to make diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise unable to be fo llowed up by the si te. Site personnel must, at a minimum, make 2 phone attempts and send a certified letter or its equivalent in that region."
54,page_54,"I1F-MC-RHCF (a)Clinical Protocol Page 54 LY24398219.Study Assessments and Procedures Secti on 2 lists the Schedule of Act ivities, wi th the study procedures and their timing (including tolerance limit s for timing). Appendix 2 lists the laboratory tests that wi ll be perform ed for this study . Appendix 4 liststhe hepat ic monitoring tests for treatment -emergent abnorm ality. All study assessments except for the C -SSRS, Self -Harm, and Self -Harm Follow-Up will be completed el ectroni cally . For all assessments, the same assessor should perform each assessment for a given pat ient during thestudy to minimize interobserver variat ion. 9.1. Efficacy Assessments 9.1.1. Primary Efficacy Assessments 9.1.1.1. Combined Endpoint of American College of Rheumatology 50 Respo nder Index and Psoriasis Area and Severity Index 100 In order to be considered a responder to the primary efficacy measure at Week 24 in this study , a patient m ust sim ultaneously achieve both ACR50 and PASI 100 responses. ACR50 response is anefficacy me asure for which a patient must satisfy the following: 1)≥50% improvement from baseline in TJC and 2)≥50% improvement from baseline in SJCand 3)≥50% improvement from baseline in at least 3 of the fo llowing 5 ACR Core Set criteria: a.Patient’s Assessment of Pain Vi sual Analog Scale (VAS) b.PatGA VAS c.PGA VAS d.patient’s assessment of physical funct ion as measured by the HAQ -DI e.acute -phase reactant as measured by high sensit ivity (assay) CRP (hs -CRP) PASI 100 is described in Sect ion9.1.2.1 . Patients achieving PASI 100 are defined as having an improvement of 100% in the P ASIcompared to baseline . 9.1.2. Secondary Efficacy Assessments 9.1.2.1. Psoriasis Area and Severity Index (PASI 75, PASI 90 , PASI 100) The PASI will be administered by a blinded assessor. The PASI is an accepted primary efficacy measurement for this phase of development of psoriasis treatments (EMA 2004). The PASI combines assessments of the extent of body -surface involvemen t in 4 anatomical regions (head, trunk, arms, and legs) and the severit y of desquamati on (scaling), ery thema, and pl aque induration/infiltration (thickness) in each regio n, yielding an overall score from 0 for no psoriasis up to 72 for the most severe dise ase (Fredri ksson and Pettersson 1978). The PASI has been the most frequent ly used endpo int and m easure of psoriasis severit y in clinical trials (EMA 2004;"
55,page_55,"I1F-MC-RHCF (a)Clinical Protocol Page 55 LY2439821Menter et al . 2008). A clinically meaningful response is a PASI 75, which represents at least a 75% decrease (improvement) from the baseline PASI score. As minimum treatment response, the European and German guidelines ment ion a PASI 50 response. Higher levels of clearance (PASI 90), as well as co mplete resol ution of psoriasis (PASI 100), have beco me additional endpo ints because of the increasing recognit ion of the associat ion of higher clearance wit h greater health -related QoL (Pui g 2015). Patients achieving PASI 75, 90, or 100 are defined as having an improvement of at least 75% , 90%, or 100%, respectively, in the P ASIcompared to baseline . Absolute PASI scores of ≤1, ≤2, or ≤3 may be consi dered as treatm ent targets for the management of plaque psoriasis. 9.1.2.2. Percentage of Body Surface Area The blinded assessor will evaluate the percentage invo lveme nt of psori asis on each pat ient’s BSA on a continuous scale from 0% (no invo lvement) to 100% (full invo lvement), in which 1% corresponds to the size of the patient’s hand (including the palm, fingers, and thumb) (National Psori asis Foundat ion [NPF] 2009). 9.1.2.3. American College of Rheumatology 20 Responder Index ACR20 response is a secondary efficacy measure for which a patient must satisfy the fo llowing: 1) ≥20% improvement from baseline in tender j oint count ( TJC )and 2) ≥20% improvement from baseline in swollen j oint count ( SJC)and 3) ≥20% improvement from baseline in at least 3 of the fo llowing 5 ACR Core Set criteria: a.Patient’s Assessment of Pain VAS b.PatGA VAS c.PGA VAS d.patient’s assessment of physical funct ion as measured by the HAQ -DI e.acute -phase reactant as measured by high sensit ivity (assay) CRP (hs -CRP) 9.1.2.3.1. American College of Rheumatology Core Set a. Tender Joint Count TJC joint assessments will be performed by a blinded assessor. For ACR measures, the number of tender and painful jo ints will be determined by examinat ion of 68 joints (34 jo ints on each side of the patient’s body ). Any joints that requi re intra -articular inject ions during the study (according to Section 7.7) should be excluded fro m evaluation fro m the time o f the inject ion to the conclusio n of the study . Joints will be assessed for tenderness by pressure and jo int manipulati on on physical examinat ion. The patient will be asked for pain sensations on these manipulat ions and watched for spontaneous pain reactions. Any posit ive response on pressure, movement, or both will then be translated into a single tender -versus -nontender di chotomy . Missing, replaced, ankylo sed, or arthrodesed jo ints will be identified by the invest igator at the Screening Visit and will be excluded fro m evaluat ion during the trial."
56,page_56,"I1F-MC-RHCF (a)Clinical Protocol Page 56 LY2439821b. Swollen Joint Count SJC j oint assessments will be performed by a blinded assessor. For ACR measures, the number of swo llen jo ints will be determined by examinat ion of 66 jo ints (33 joints on each side of the patient’s body ). Any jo ints that require intra- articular inject ions during the study (according to Section 7.7) should be excluded fro m evaluat ion from the time of the inject ion to the conclusio n of the study . Joints will be classified as eit her swollen or not swollen. Swelling is defined as palpable fluctuating syno vitis of the jo int. Swelling secondary to osteoarthrit is will be assessed as not swollen, unless there is unmistakable fluctuation. Dactylit is should be counted as 1 swollen joint. Missing, replaced, ankylo sed, or arthrodesed jo ints will be identified by the invest igator at the Screening Visit and will be excluded fro m evaluat ion during the trial. c. Patient’s Assessment of Pain Visual Analog Scale The patient will be asked to assess his or her current level of joint pain by marking a vert ical tick on a 100 -mm horizontal VAS where the l eft end represents no joint pain and the right end represents worst possible jo int pain. The Patient’s Assessment of Pain VAS shoul d be administered prior to the TJC and SJC e xaminat ions. Results will be expressed in millimeters measured between the left end of the scale and the crossing point of the vert ical line o f the tick; this procedure is applicable for all VAS used in the trial. d. Patient’s Global Assessment of Disease Activity Visual Analog Scale The patient’s overall assessment of his or her PsA activit ywill be recorded using the 100- mm horizontal VAS. Pati ents will be asked, “Considering all the ways y our PsA has affected y ou, how do y ou feel your PsA is today?” whe re the l eft end represents “very well” and the right end represents “very poor.” e. Physician’s Global Assessment of Disease Activity Visual Analog Scale The invest igator, who must be a physician, will be asked to give an overall assessment of the severit yof the patient’s current PsA activit yusing a 100 -mm horizontal VAS, where 0 represents no disease act ivity and 100 represents extremely active disease. f. Patient’s Assessment of Physical Function as Assessed by the Health Assessment Questionnaire -Disa bility Index The HAQ -DI is a patient -reported standardized questionnaire that is commo nly used in PsA to measure disease -associ ated di sabili ty (assessment of physical funct ion). It consists of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other daily act ivities (Fries et al . 1980; Fries et al. 1982)."
57,page_57,"I1F-MC-RHCF (a)Clinical Protocol Page 57 LY2439821The disabilit y secti on of the questi onnaire scores the pat ient’s self -percept ion on the degree of difficult y (0 = without any difficul ty, 1 = wi thsome difficult y, 2 = wi th much difficult y, and 3 =unable to do), covering the 8 domains. The reported use of special aids or devices and/or the need for assistance of another person to perform these activit ies is also assessed. The scores for each of t he functional do mains will be averaged to calculate the functional disabilit y index. An MCID i s a clinically relevant change in a pat ient’s status. The HAQ -DI MCID has been estimated to be about 0.35 for patients with PsA (Mease et al . 2011 ). Details of scoring and calculat ions are presented in the statistical analysis plan (SAP). g. C- Reactive Protein CRP will be the ACR Core Set measure of acute -phase reactant. It will be measured with a high sensit ivity assay at the central laboratory to hel p assess the effect of ixekizumab on the patient’s PsA. 9.1.2.4. American College of Rheumatology 50 and 70 Responder Index ACR50 and ACR70 responses are secondary efficacy endpoints and are improvements of at least 50% and of at least 70%, respectively, in the mult iple disease assessment ACR criteria. The ACR50 and ACR70 are calculated similarly to ACR20, as described in Sect ion 9.1.2.3 . 9.1.2.5. Individual Components of the American College of Rheumatology Core Set The individual co mponents of the ACR Core Set will be measured including TJC (68 jo int count), SJC (66 jo int count), Patient’s Assessment of Pain VAS, PatGA VAS, PGA VAS, Patient’s Assessment of Physical Funct ion as measured by the HAQ -DI, and CRP (Secti on9.1.2.3.1 ). 9.1.2.6. Psoriatic Arthritic Response Criteria The PsARC is a composite criteria reported in terms of the percentage of pati ents achieving response according to the following criteria: PGA, PatGA, TJC, and SJC. Overall response is defined by improvement from the baseline assessment in 2 of the 4 criteria, 1 of which must be a joint count; there m ust not be worsening in any of the 4 criteria: 1.At least 30% reduction in TJC 2.At least 30% reduction in SJC 3.At least a 1 point reduction in physician’s assessment 4.At least a 1 point reduction in pat ient’s assessment The PsARC response was modified in this study by using the PGA and the PatGA on a 100 mm VAS described in Sect ion 9.1.2.3.1 instead of a 5- point Li kert scal e in the ori ginal criteria. The results from the 2 VAS m easures were assessed as a difference fro m baseline (in mm), but criteria 3 and 4, above, were changed to “at least a 20 mm reduct ion” (Clegg1996). 9.1.2.7. Minimal Disease Activity The MDA score has been developed based on current expert op inion and uses a composite of 7key outcom e measures used in PsA to encompass all o f the dom ains o f the disease to m easure"
58,page_58,"I1F-MC-RHCF (a)Clinical Protocol Page 58 LY2439821the overall state of a patient’s disease (Coates et al. 2010a; Coates and Helliwell 2010b). The overall state of disease act ivity is deemed a useful target of treatment by both the patient and the physician, given current treatment possibilit ies and limitat ions. Preliminary validation work supports the use of the MDA criteria in both observat ional cohorts and in intervent ional tri al coho rts. The PsA MDA criteria have evidence supporting their use within the OMERACT filter of truth, di scriminat ion, and feasibilit y. MDA : Patients are classified as achieving MDA if they fulfill 5 o f 7 outcom e measures: TJC ≤1; SJC≤1; psori asis act ivity and severit y index (PASI total score) ≤1 or BSA ≤3; patient pain VAS score of ≤15; pat ient global disease activit y VAS score of ≤20; HAQ -DIscore ≤0.5; and tender entheseal po ints ≤1. 9.1.2.8. Modified Composite Psoriatic Disease Activity Index The Modified CPDAI is avalidated instrument intended to assess co mposite psoriat ic disease activit y and response to therapy (Mum taz et al. 20 11). Thi s instrum ent assesses individual domains invo lved as well as the global effect of disease in all dimensio ns by which each pati ent may be affected. Domains include peripheral arthrit is as assessed by the number of tender and swollen jo ints and the HAQ -DI, skin as assessed by the PASI and the DLQI, enthesit is as assessed by the number of si tes wi th enthes itisand the HAQ -DI, and dactylitis as assessed by the number of digits affected and the HAQ -DI. Scores range from 0 to 12, with a higher score indicat ing higher disease act ivity. 9.1.2.9. Leeds Enthesitis Index If the patient has enthesit is,the LEI will be administered by a blinded asses sor. The LEI has been developed specifically for use in PsA. It measures enthesit is at 6 sites (lateral epicondyle, left and right, medial femoral condyle, left and right, Achilles tendon insertion, left and right) (Healy and Helliwell 2008). Each site is assigned a score of 0 (absent) or 1 (present); the results from each sit e are then added to produce a total score (range 0 to 6). 9.1.2.10. Spondyloarthritis Research Consortium of Canada If the patient has enthesit is,the SPARCC will be administered by a blinded assessor. The SPARCC enthesit is index evaluat es tenderness in a total of 16 enthesit is sites: the greater trochanter (right/left [R/L]), quadriceps tendon insertion into the patella (R/L), patellar ligament inserti on into the patella and tibial tuberosi ty (R/L), Achilles tendon insert ion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L) ,and the supraspinatus insertion (R/L) (Mease 2011 ). Tenderness at each site isquant ified on a dichotomous basis : 0 =nontender and 1 = tende r. The results from each site are then added to produce a total score (range 0 to 16). 9.1.2.11. Leeds Dactylitis Index -Basic If the patient has dactylit is,the LDI-B will be administered by a blinded assessor. The LDI -B has been developed to measure the severit y of dactyli tis. Once the presence of dact ylitis is established in each digit, the ratio of the circumference of theaffected digit to the circumference of the di git on the opposi te hand or foot is measured (Helliwell et al. 2005 ). Each dactylit ic digit is defined by a minimum increas e of 10% in circumference over the contra -lateral digit. If the"
59,page_59,"I1F-MC-RHCF (a)Clinical Protocol Page 59 LY2439821same di gitson each hand or foot are thought to be invo lved, the clinician will refer to a table o f norm ative values (provided to study sites) for a value which will be used to provide the comparison. If the ratio is >1.1, then subtract 1 from the calculated ratio and mult iply it by 100 and the tenderness score of 0 (not tender) or 1 (tender). Otherwise, if the ratio of the circumference o f the digit is ≤1.1, then the LDI -B score i s set to 0. Tenderness is assessed in the area between the jo ints. The results of each digit are then added to produce a total score (Healy andHelliwell 2007). 9.1.2.12. Nail Psoriasis Severity Index Fingern ails If the patient has fingernail Ps , the NAPSI Fingernails will be administered by a blinded assessor. Site personnel should ensure that the patient makes their nails available for assessment during the study . The NAPSI Fingernails is a numeric, reprod ucible, object ive tool for evaluat ion of nail Ps. This scale is used to evaluate the severit y of nail bed Ps and nail matrix Ps by area of invo lvement in the nail unit. In this study , only fingernail involvement will be assessed. The fingernail is divid ed wi th imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for nail bed Ps (0 to 4) and nail matrix Ps (0 to 4) depending on the presence (1) or absence (0) of any o f the features of nail Ps in each quadrant. TheNAPSI Fingernails score of a nail is the sum of scores in nail bed and nail matrix from each quadrant (thus a maximum of 8). Each fingernail is evaluated, and the sum of all the nails is the total NAPSI Fingernails score. Thus, the sum of the scores fro m all fingernails is 0 to 80. 9.1.2.13. Disease Activity Score based on C -Reactive Protein TheDAS28 -CRP is a measure of disease act ivity in 28 j oints that consists of a composite numerical score utilizing the fo llowing variables: TJC, SJC, hs -CRP (m easured in mg/L ), and PatGA recorded by patients on a 0 to 100 mm VAS. For DAS28- CRP, the 28 jo ints to be examined and assessed as tender or not tender for TJC and as swo llen or not swollen for SJC ( Section 9.1.2.3.1 )are a subset of those assessed for the TJC and SJC, and include 14joints on each side of the patient’s body : the 2 shoul ders, the 2 elbows, the 2 wri sts, the 10 metacarpophalangeal jo ints, the 2 interphalangeal jo ints of the thumb, the 8proximal interphalangeal jo ints, and the 2 knees ( Smolen et al . 1995). The fol lowing equat ion will be used to calculate the DAS28 (Vander Cruyssen et al. 2005) :    96. 0 014. 0 1 ln36. 0 28 28. 0 28 56. 0 28        VAS CRP SJC TJC CRP DAS 9.1.2.14. Static Physician Global Assessment If the patient has plaque Ps, the static Physician Global Assessment of psoriasis (sPGA) will be administered by the blinded assessor. The sPGA is the assessor’s determin ation of the patient’s Pslesions overall at a given time point . The s PGA is recommended as an endpoint to use to assess efficacy in the treatm ent of Ps ( EMEA 2004). Overall lesio ns are categori zedby descript ions for induration, ery thema, and scaling . For the analysis of respon ses, the pati ent’s Ps is assessed at a given time po int on a 6 point scale in which 0 = cleared, 1 = minimal, 2 = mild, 3= moderate; 4 = severe, 5 = very severe ."
60,page_60,"I1F-MC-RHCF (a)Clinical Protocol Page 60 LY24398219.1.3. Appropriateness of Assessments All o f the clinical and safet y assessments/measures included in the primary and maj or secondary objectives in this study are standard, widely used, and generally recognized as reliable, accurate, and relevant. 9.2. Adverse Events Invest igators are responsible for monitoring the safety of patients who have entered this study and for al erting Lilly or its designee to any event that seems unusual, even if this event may be considered an unant icipated benefit to the patient. The invest igator is responsible for the appropri ate medical care of pat ients during the study. Invest igators must document their review of each laboratory safety report. The invest igator remains responsible for fo llowing, through an appropriate health care option, AEs that are serious or otherwi se medically important, considered rel ated to the invest igational product or the study , or that caused the patient to discontinue the invest igational product before completing the study. The patient should be fo llowed unt il the event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The frequency o f follow-up evaluat ions of the AE is left to the discret ion of the invest igator. Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical s tudy is to establish treatment effect. After the informed consent form (ICF) is signed, study site personnel will record vi a eCRF the occurrence and nature of each patient’s preexist ing conditions, including clinically significant signs and symptoms of the disease under treatment in the study . In addi tion, si te personnel will record any change in the condit ion(s) and any new condit ions as AEs. Invest igators should record their assessment of the potential relatedness of each AE to protocol procedure, inves tigational product, via eCRF. The invest igator will interpret and document whether or not an AE has a reasonable possibilit y of being related to study treatm ent, study device, or a study procedure, taki ng into account the disease, concomitant treatment, o r pathologies. A “reasonable possibilit y” means that there is a cause and effect relat ionship between the investigat ional product, study device and/or study procedure and the AE. The invest igator answers yes/no when making this assessment. Planned surger ies and nonsurgical intervent ions should not be reported as AEs unless the underlying medical condit ion has worsened during the course of the study . If a patient’s investigational product is discontinued as a result of an AE, study site personnel must repo rt this to Lilly or its designee via eCRF, clarifying if possible, the circumstances leading to any dosage m odificati ons, or di scontinuati ons of treatm ent."
61,page_61,"I1F-MC-RHCF (a)Clinical Protocol Page 61 LY24398219.2.1. Serious Adverse Events An SAE is any AE from this study that resul ts in one of the fo llowing outco mes: death initial or prolonged inpatient hospitalizat ion a life- threatening experience (that is, immediate risk of dying) persistent or significant disabilit y/incapacit y congenital ano maly/birth defect considered significant by the invest igator for any ot her reason: important medical events that may not resul t in death, be life -threatening, or require hospitalization may be considered serious, based upon appropriate medical judgment. Although all AEs occurring after signing the ICF are recorded in the eCR F, SAE reporting begins after the patient has signed the ICF and has received invest igational product. However, if an SAE occurs after signing the ICF, but prior to receiving invest igational product, it needs to be reported ONLY if it is considered reason ably possibly related to study procedure. Study site personnel must al ert Lilly or i ts desi gnee of any SAE within 24 hours of invest igator awareness o f the event via a sponsor -approved method. If alerts are issued via telephone, they are to be immediately followed wi th official notificati on on stu dy-specific SAE forms. This 24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE inform ation. Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the definit ion of an AE. However, to fulfill regulatory requirements any pregnancy should be reported fo llowing the SAE process to collect data on the outcome for both mother and fetus. Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have discontinued and/or completed the study (the patientsummary eCRF has been completed). However, if the invest igator learns of any SAE, including a death, at any time after a subject has been discharged from the study , and he/she considers the event reasonably possibly related to the study treatm ent or study parti cipat ion, the invest igator m ust prom ptly notify Lilly . 9.2.1.1. Adverse Events of Special Interest The fo llowing a dverse events of special interest will be evaluated in part icular to determine the safet y and tolerabilit y of ixekizumab over the range of doses selected for this clinical study ."
62,page_62,"I1F-MC-RHCF (a)Clinical Protocol Page 62 LY2439821Adverse event sof special interest for ixekizumab are: cytopeni as (leukopenia, neut ropeni a, and thrombocy topeni a) liver funct ion test ch anges/enzyme elevat ions (ALT, AST, bilirubin, and ALP) infect ions inject ion-site reacti ons allergi c reacti ons/hypersensi tivities cerebrocardiovascular events malignancies depressio n and suicide/self -injury inflammatory bowel disease (Crohn’s disease and U C) interstitial lung disease (ILD) Sites will provide details on so me of these AEs as instructed on the eCRF . Invest igators will also educate patients and/or caregivers about the symptoms of allergic/hypersensit ivity reacti ons and will provide instructio ns on dealing with these reactions (see Section 7.8.3 ). Data on cerebrocardiovascular events will be collected and the events will be adjudicated by an external Clinical Events Committee (CEC) made up of a chai rman, 2 cardi ologists ,and a neuro logist. Cerebrocardi ovascular events are defined as: oDeath (Cardi ovascular) oMI oHospitalization for Unstable Angina oHospitalization for Heart Failure oSerious Arrhyt hmia oHospitalization for Hy pertensio n oResuscitated Sudden Death oCardi ogenic Shock due to MI oCoronary Revasculari zation Procedure Neurol ogic oCerebrovascular Event: Tran sient Ischemic Attack or Stroke (Hemorrhagic , Ischemic and Undetermined) Peripheral Vascular Events oPeripheral Arterial Event oPeripheral Revascularizat ion Procedure Data on suspected IBD, as identified by events possibly indicat ive of UCand Crohn’s disea se, will be co llected and the events will be adjudicated by an external CEC made up of gastroenterologists with expertise in IBD . The rol e of the CEC i s to adj udicate defined clinical events, in a blinded, consistent, and unbiased manner throughout the c ourse of a study .The importance of the CEC is to ensure that all events that have been reported are evaluated uniformly by a single group."
63,page_63,"I1F-MC-RHCF (a)Clinical Protocol Page 63 LY24398219.2.1.2. Suspected Unexpected Serious Adverse Reactions Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed in the IB and that the investigator ident ifies as related to investigational product or procedure. United States 21 Code of Federal Regulat ions312.32 and European Unio n Clinical Trial Directive 200 1/20/EC and the associated detailed guidances or nati onal regulatory requi rements in parti cipat ing countries requ ire the reporting of SUSARs. Lilly has procedures that will be followed for the recording and expedited reporting of SUSARs that are consisten t with global regul ations and the associated detailed guidances. 9.2.2. Complaint Handling Lilly co llects product complaints on invest igational products and drug delivery systems used in clinical studies to ensure the safet y of study participants, monitor qualit y, and to facilitate process and product improvements. Patients will be instructed to contact the investigator as soon as possible if he or she has a complaint or probl em wi th the invest igational product so that the situation can be assessed. Com plaint s related to concomitant medicat ions are reported directly to the manufacturers of those m edicat ions/devices in accordance with the package insert. The invest igator or his/her designee is respo nsible for handling the fo llowing aspects of the product complain t process in accordance wit h the instructions provided for this study : Reviewing all Study Drug Administrati on Logs to ident ify any product complaints Recording a complete description of the product complaints reported and any associ ated AEs using the stud y-specific co mplaint form s provided for this purpose Faxing the completed product complaint form wit hin 24 hours to Lilly or its designee If the invest igator is asked to return the product for invest igation, he/she will return a copy of the product complai nt form with the product. 9.3. Treatment of Overdose Refer to the ixekizumab IBand product l abeling and the adalimumab product l abeling . 9.4. Safety 9.4.1. Vital Signs For each patient, vital signs m easurements should be conducted according to the Schedule of Activities (Secti on 2). Vital signs (si tting blood pressure and pulse rate) will be measured after the patient has been resting for a minimum o f 10 minutes a t times indicated in the study schedule ( Section 2). At rando mizat ion(Visit 2), sitting blood pressure and pulse rate mustbe measured before admi nistrati on of the investi gational product and again approximately 1 hour after administration. Any clinically significant findings from vital signs m easurement sthat result in a diagnosis and that occur after the patient receives the first dose of study treatm ent should be"
64,page_64,"I1F-MC-RHCF (a)Clinical Protocol Page 64 LY2439821reported to Lilly or its designee as an AE via eCRF. Addi tional measurements of vital signs may be perform ed at the discret ion of the invest igator. 9.4.2. Laboratory Tests For eac h patient, lab oratory testsdetailed in Appendix 2 shoul d be conducted accordi ng to the Schedule of Activities (Section 2). Any clinically significant findings from laboratory tests that resul t in a di agnosis and that occur after the patient rece ives the first dose of invest igatio nal product should be reported to Lilly or its design ee as an AE viaeCRF . 9.4.3. Columbia Suicide Severity Rating Scale The C-SSRS (Posner et al. 2007; Columbia Universit yMedical Center [WWW]) is a scale that captures the occurrence, severit y, and frequency of sui cide-related i deati ons and behaviors during the assessment period. The C -SSRS m ust be administered by appropri ately trained site personnel. The tool was developed by the Nat ional Ins titute of Mental Heal th Treatm ent of Adolescent Sui cide Attem pters (TASA) trial group for the purpose of being a counterpart to the Columbia Classificat ion Algori thm of Suicide Assessment (C -CASA) categorizat ion of suicidal events . Pati ents will be assessed according to the Schedule of Act ivities (Section 2). The Sel f -Harm Supplement Form, completed according to the Schedule of Act ivities, is a one - question formthat asks for the number of suicidal or non suicidal self -injuri ous behaviors the patienthasexperienced since the last assessment. For each uniq ue event i dentified, a questionnaire (Self -Harm Follow-Up Form ) which collects suppl emental informat ion on the self - injuri ous behavi or is to be completed. This informati on is then docum ented in the eCRF. 9.4.4. Other Tes ts 9.4.4.1. Physical Examination One co mplete physical examinat ion (excluding pelvic, rectal, and breast examinat ions) will be perform ed at Visit 1 ( screening ). This examinat ion will determine whether the patient meets the criteria requi red to parti cipate in the study and will al so serve as a monitor for preexist ing condi tions and as a baseline for treatment -emergent AE(TEAE) assessment. All physical examinat ions throughout the study are indicated in the Schedule of Act ivities(Secti on 2) and shoul d include a symptom -directed physical evaluati on as well as an examinat ion of the heart, lungs, and abdo men and a visual examinat ion of the skin . 9.4.4.2. Chest X -Ray and Tuberculosis Testing X -ray: At Visit 1, a posteri or-anterior view chest x -raywill be obtained l ocally , unless the x -ray or results from a chest x -rayobtained wi thin 6 months before rando mizat ion (Vi sit 2) are available . The chest x -ray or resul tswill be reviewed by the invest igator or designee to exclude patients wi th active TB infect ion. TB testing: Patient history of TB test resul ts should be ass essed pri or to screening (Vi sit 1)."
65,page_65,"I1F-MC-RHCF (a)Clinical Protocol Page 65 LY2439821Patients with no TB test results on file: Patients will be tested at screening ( Secti on 2) . A PPD skin test re sponse of ≥5mm induration, between approximately 48 and 72 hours after test applicat ion, regardl ess of BCG vaccinat ion history, will be considered a posit ive result. In countri es where the Quant iFERON -TB®Gold test or T-SPOT.TB test is available and in the judgment of the investigator preferred as an alternative to the PPD skin test for the evaluat ion of TB infect ion, it may be used instead of the PPD test and willbe perform ed and read l ocally . If the Quant iFERON -TB®Gold test or the T-SPOT.TB test is indeterminate, 1 retest using the same TB test method is allowed. If the retest is indeterminate, then the patient is excluded fro m the study . Patients wi tha posi tiveTB test performed at screening but withno other evidence o f activ e TB may be rescreened 1 time and may be enro lled without repeating the TB test based on the following requirements: after receiving at least 4 weeks of appropriate latent TB infection therapy with no evidence o f hepatotoxicit y (ALT/AST must remain ≤2xULN) upon retesting of serum ALT/AST pri or to randomization. Such patients must complete appropriate latent TB infect ion therapy during the course of the study to rem ain eligible meet all other inclusio nand e xclusion criteria for participat ion If rescreeni ng occurs wi thin 6 m onths of the date of the screening chest x -ray, there i s no need for repeat of chest x -ray for consi dering enro llment . Patients with negative TB test results on file: Pati ents wi th documentati on of a negat ive test resul t within 3 m onths before rando mizat ion (Visit2) should n ot be administered a TB testat Visit 1. Documentati on of PPD test result smust include a record of the size of the indurat ion response ; otherwise a retest at screening (Visit 1) will be required to determine pat ient eligibilit y. Patients with positive TB test results on file : Patients with prior history of a posi tive TB test shoul d not perform a TB test at Visit 1. Documentation of this history and of at l east 4 weeks of appropriate latent TB treatment prior to randomization (Visit 2) is required for study eligibilit y. Patients who have a documented history of com pleting an appropriate TB treatment regimen with no history of re-exposure to TB since their treatment was completed and no evidence of active TB will be eligible to participate in the study . Pati ents who have had household contact with a person wi th active TB will be excluded, unless appropriate and documented prophylaxis for TB was given. 9.4.5. Safety Monitoring Lilly will periodically review evolving aggregate safet y data wi thin the study by appropri ate methods. 9.4.5.1. Hypertension Patients who expe rience changes in sitting blood pressure defined as systolic blood pressure at ≥160 mm Hg plus ≥20 mm Hg increase from baseline (Week 0 ,Visit 2 )and/or diastolic blood pressure at ≥100 mm Hg plus ≥10 mm Hg increase from baseline (Week 0, Visit 2) on"
66,page_66,"I1F-MC-RHCF (a)Clinical Protocol Page 66 LY24398212consecutive visit s should receive intervent ion for the m anagement of hypertensio n. Intervention could include the maximal intervent ion of wit hholding the dose of invest igational product and/or the introduction o f an ant i-hypertensive agent (see Section 8.1.1 for criteria for patient discont inuat ion related to h ypertension). 9.4.5.2. Hepatic Monitoring If a study patient/subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL ≥2X ULN, clinical and laboratory monitoring should be init iated by the invest igator. Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory test abnorm alities. To ensure patient/subject safet y and com ply wit h regulatory guidance, the investigator is to consult with the Lilly CRP regarding collect ion of specific reco mmended clinical informat ion and fo llow-up laboratory tests (seeAppendix 4 ). 9.4.5.3. Neutropenia Patients wi th neutrophil counts <1500 cells/ L shoul d be m anaged for neutropenia as fo llows: <500 cells/ L, see D iscont inuat ion Cri teria (Secti on 8.1.1 ) ≥500 cells/ L and<1000 cells/ L, see Di scont inuation Criteria (Section 8.1.1 ) ≥1000 cells/ L and<1500 cells/ L(based on 3 test results) ,and the patient has a concurrent infect ion that requires syste mic ant i-infectiv e therapy (for example , antibiotic, antifungal agent, antiviral agent): oThe dose of invest igational product should be withheld, the patient should receive appropriate medical care ,and a repeat test for neutrophil count should be performed within 4 weeks f rom knowl edge of the init ial report. If the repeat neutrophil count has returned to ≥1500 cells/ L and the infect ion has resolved or is reso lving, the patient may resume dosing of invest igational product and evaluation at scheduled visits. If the neutrop hil count rem ains ≥1000 cells/ L and <1500 cells/ L, investigat ional product should cont inue to be withheld and a repeat neutrophil count shoul d again be performed wit hin another 4 weeks. If, after 2 repeat tests, the neutrophil count still r emains ≥1000 cells/L and <1500 cells/L,and: a.the infect ion has not fully resolved, the pati ent will be discontinued from the study . b.the infect ion hasresolved, the pati ent m ay resume dosing and evaluat ion at scheduled visits. However, if resumpt ion of dosing is not deemed appropriate by the invest igator, the patient will be discont inued from the study. ≥1000 cells/L and <1500 cells/ L(based on 3 test results) ,and the patient has no concurrent infect ionthatrequires syste mic ant i-infective therapy (for example , antibiotic, antifungal agent, antiviral agent):"
67,page_67,"I1F-MC-RHCF (a)Clinical Protocol Page 67 LY2439821oDosing may continue ,and a repeat neutrophil c ount shoul d be perform ed 4 to 8weeks from knowledge of the init ial report. Testing may be at a regularly scheduled visit or at an unscheduled visit, as necessar y. Repeat testing should be performed at 4- to 8-week intervals unt il the neutrophil count has returned to ≥1500 cells/L. If the patient has 3 or more postbaseline neutrophil counts of ≥1000 cells/L and <1500 cells/L, no value of <1000 cells/ L, and no postbaseline infection requiring systemic ant i-infect ive therapy, the patient may continue or resum e further evaluat ion at scheduled visits, as deemed appropriate by the investigator. If a patient without init ial concurrent infection develops an infection that requi res systemic anti -infective therapy, then the patient should be managed as indicated above for patients with concurrent infect ion. Management of neutropenia during the Post -Treatment Follow -Up Peri od is described i n Sect ion 5.1.3 . 9.4.5.4. Hepatitis B Monitoring Patients who are HBsAg -and HBcAb+ at screening, regardless of other hepat itis B testing resul ts, will have a serum HBV DNA specimen obta ined to be analyzed by the central laboratory . Such patients who are determined to be HBV DNA negat ive (undetectable) may be enrolled into the study wit h required HBV DNA monitoring every 3 to 4 months during treatm ent and 12 weeks after the last dose of ixekizumab. Patients who are found to be HBV DNA posit ive (detectable) at screening will be excluded fro m the trial. Any enrolled pat ient with a posi tiveHBV DNA test resul t at any time must be discont inued fro m the study and shoul d receive appropri ate follow-up medical care, incl uding considerat ion for antiviral therapy . Study investigators should consult with a specialist physician in the care of patients with hepat itis (for example, infectious disease or hepatologist subspecialists) on whether to cont inue any immunosuppressant therapy including invest igational product for a period of time while antiviral therapy is being ini tiated. Timing o f withdrawal from investigational product should be based on recommendat ion of the consult ing specialist physicia n in conjunct ion with the investigator and local or regi onal medical guidelines or standards of care. Upon discont inuat ion from investigational product, the patient should be discont inued fro m the study . Any patient who di scont inued the study for any reas on will complete the ETV before entering the Post-Treatment Follow -Up P eriod (Period 3). 9.5. Pharmacokinetics Not applicable. 9.6. Pharmacodynamics Not applicable."
68,page_68,"I1F-MC-RHCF (a)Clinical Protocol Page 68 LY24398219.7. Genetics Not applicable. 9.8. Biomarkers Not applicable. 9.9. Health Outcome/Quality of Life Measures 9.9.1. Itch Numeric Rating Scale The Itch NRS is a pati ent-administered , 11 point horizontal scale anchored at 0 and 10, with 0represent ing “no itch” and 10 represent ing “worst itch imaginable.” Overall severit y of a patient’s itching from Psis indicated by select ing the number that best describes the worst level of itching in the past 24 hours. 9.9.2. Fatigue Severity Numeric Rating Scale Score The Fat igue Severi ty NRS is a pati ent-administered single -item 11-point horizontal scale anchored at 0 and 10, with 0representing “no fat igue” and 10 represent ing “as bad as y ou can imagine.” Patients rate their fatigue ( weariness, tiredness )by select ingthe one number that describes their worst level of fat igue during the past 24 hours. 9.9.3. Medical Outcomes Study 36 -Item Short Form Health Survey Physical Component Summary and Mental Component Summary Scores The SF -36 is a 36 -item, pati ent-completed m easure desi gned to be a short, m ultipurpose assessment of healt h in the areas of physical functioning, role -physical, role -emotional, bodily pain, vitalit y, social functi oning, m ental health, and general healt h. The 2 overarching do mains of mental well -being and physical well -being are captured by the Mental Com ponent Summary and Physical Co mponent Summary scores, respectivel y. The summary scores range from 0 to 100, wi th higher scores indicat ing better levels of funct ion and/or better health. Items are answered on Likert scales of varying lengths. The SF -36 acute version (Version 2) will be used, which has a 1 week recall period (SF -36Health Survey Update page [WWW]). 9.9.4. European Quality of L ife—5 Dimensions 5 Level [EQ -5D-5L]) The EQ -5D- 5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and econo mic appraisal. The EQ-5D- 5L consists of 2 components: a descri ptive system o f the respondent’s healt h and a rating of his/her current health state using a 0-to 100 -mm VAS. The descriptive system comprises the fo llowing 5 dimensi ons: m obilit y, self-care, usual act ivities,pain/disco mfort, and anxiet y/depressi on. Each dimensio n has 5 levels: no probl ems, slight probl ems, m oderate probl ems, severe probl ems, and extrem e probl ems. The respondent is asked to indicate his/her healt h state by select ing in the box associated wi th the most appropri ate statement in each of the 5 dimensio ns. It should be noted that the numerals 1 to 5 have no arithmetic properties and should not be used as a cardinal score. The VAS records the"
69,page_69,"I1F-MC-RHCF (a)Clinical Protocol Page 69 LY2439821respondent’s self -rated heal th on a vert ical VAS, in which the endpo ints are labeled “best imaginable healt h state” and “worst imaginable health state.” This informat ion can be used as a quant itative measure of healt h outcome. The EQ-5D- 5L healt h states, defined by the EQ -5D- 5L descript ive system, may be c onverted into a single summary index by applying a formula that essent ially attaches values (also called weights) to each of the levels in each dimensio n (EuroQol Group [WWW]). 9.9.5. Dermatology Life Quality Index The DLQI is a simple, patient -administered, 10 q uestion, validated, qualit y-of-life quest ionnaire that covers 6 domains: symptoms and feelings, daily act ivities, leisure, work and school, personal relat ionships, and treatment. Response categories include “not at all,” “a litt le,” “a lot,” and “very much,” wi th corresponding scores of 0, 1, 2, and 3, respectively, and “not relevant” responses scored as “0.” Totals range fro m 0 to 30 (less to more impairment). 9.9.6. Treatment Satisfaction Questionnaire The Treatm ent Sati sfact ion Quest ionnaire is a clinician - administered questionnaire which provi des an assessment of the patient’s opinio n of the effect iveness, safet y, and overall satisfact ion of the study medicat ion.Patients will be asked to respond to questionnaire items using a 4 -point Li kert scal e (from “very satisfied” to “very dissat isfied”)."
70,page_70,"I1F-MC-RHCF (a)Clinical Protocol Page 70 LY243982110. Statistical Considerations 10.1. Sample Size Determination Approximately 550 pat ientswho meet all criteria for enrollment at Visits 1 and 2 will be rando mized in a 1:1 ratio a t Week 0 (Visit 2)in Period 2 to ixekizumab or adalimumab ( 275patients per treatment group). Sample size was calculated assuming the proporti on of patients simultaneously achieving ACR50 and PASI 100 as 13. 6% and 31.3% in the adalimumab and ixekizumab treatm ent groups, respectively , as observed in the csDMARD -experienced popul ation fromStudy RHAP . According to the nQuery software, a total sample size of 550 (with 275 per treatm ent group ) using a 2 -sided Fisher's exact test at 0.05 level o f significance woul d yield 99% power for tes ting ixekizumab versus adalimumab. This sample size would yield 78% power for testing the noninferiorit y of ixekizumab to adalimumab at a one -sided 0.025 level of significance based on a noninferiorit y margin of –12% and using ACR50 response rates of 43.8%and 44.1% as observed for the ixekizumab and adalimumab treatment groups, respectively, in the csDMARD -experi enced popul ation from Study RHAP . For testing superiorit y of ixekizumab to adalimumab based on PASI 100 response rates of 46.9% and 23. 7% as obse rved for ixekizumab and adalimumab in the csDMARD - experienced populat ion from Study RHAP, this sample size would yield 99% power using a 2-sided Fisher's exact test at 0.05 level of significance . 10.2. Populations for Analyses For purposes of analysis, the following popul ations are defined: Population Description Entered All participants who sign informed consent Randomized Participants who met all entry criteria and were assigned a study treatment Intent -to-treat (ITT) The ITT population consists of all randomized patients. Even if the patients do not take the assigned treatment, do not receive the correct treatment, or otherwise do not follow the protocol, they will be analyzed according to the treatment group to which they were assigned. Unless otherwise specified, efficacy and health outcomes analyses for Period 2 will be conducted on the ITT populatio n. Safety The safety population consists of all randomized patients who receive dat least 1 dose of study treatment in Period 2. Patients will be analyzed according to the treatment group to which they were assigned. Safety analyses for Period 2 will be conducted on this analysis set . Post-treatment follow -up The post -treatment follow -up population consists of all r andomized patients who received at least 1 dose of study treatment during Period 2 and have entered the Post -Treatment Follow -Up Period. Patients will be analyzed according to the treatment group to which they were assigned in Period 2. Safety analyses for Period 3 (Post -Treatment Follow -Up Period) will be conducted on this analy sis set."
71,page_71,"I1F-MC-RHCF (a)Clinical Protocol Page 71 LY243982110.3. Statistical Analyses 10.3.1. General Statistical Considerations Statistical analysis o f this study will be the responsibilit y of Lilly. Any changes to the data analysis methods related to the primary and maj or secondary endpoints described in the protocol, and the just ificat ion for making the change, will be documented in the SAP and/or the clinical study report (CSR). Additional explorat ory analyses of the data may be conducted as deemed appropriate. Com plete details of the planned analyses will be documented in the SAP. 10.3.1.1. General Considerations for Analyses during Period 2 (Open -Label Treatment Period) Baseline will be defined as the last available value before the first inject ion of the study drug f or both efficacy , heal th outcom es,and safet y analyses. In most cases, this will be the measurement recorded at Week 0 (Visit 2). Categorical data for baseline variables will be summarized as frequency counts and percentages . Continuous data for baseline variables will be summarized using the mean, standard deviat ion, minimum, maximum, median, and number of observat ions. Com parisons of ixekizumab versus adalimumab will be performed for all outcome variables at all visits in Period 2; however, the primary timepoint of interest is Week 24 . Change from baseline at a particular visit will be calculated as the value at that visit minus the baseline value. For outcome measures that are not collected at each post -baseline visit, data may exist at visits where the outcome measure was not scheduled to be co llected, due to early discont inuat ion visits. In these situat ions, data f rom the early discontinuat ion visit that does not correspond to the planned collection schedule will be excluded from any mixed-effects models for repeated measures (MMRM) analysis. However, the data will still be used in other analyses, including shift a nalyses, change fro m baseline analyses using last observat ion carried forward (LOCF) imputati on m ethod, and other categorical analyses. 10.3.1.2. Missing Data Imputation The m ethods for imputati on of missing data to be used in this study are described below. 10.3.1.2.1. Nonresp onder Imputation Missing data for categorical efficacy and healt h outcom e measures will be imputed using the nonresponder imputation ( NRI) method. Patients will be considered nonresponders if they do not m eet the clinical response criteria or have missing clinical response data at the time po int of analysis. Rando mized pat ients without at l east one post -baseline observat ion will also be defined as nonresponders for the NRI analysis."
72,page_72,"I1F-MC-RHCF (a)Clinical Protocol Page 72 LY243982110.3.1.2.2. Last Observation Carried Forward Missing data for continuous efficacy and health outcom es variables will be impute dusing LOCF method . For patients discont inuing investigational product or having missing data at a visit, the last nonmissing post -baseline observation before discontinuat ion or before the visit with missing data will be carried forward to the corresponding time point. Randomized patients without at least one post -baseline observation will not be included in LOCF analyses. In addit ion to NRI and LOCF, other imputation methods may be used as deemed appropriate. 10.3.1.3. Adjustment for Multiple Comparisons A multiple testing strategy for the primary and major secondary endpo ints will be implemented to con trol the f amily -wise ty pe I error rate at a 2 -sided α level o f 0.05. The primary and major secondary endpoints will be seq uentially tested in the fo llowing order to com pare ixekizumab vs adalimumab, using the primary analysis method. 1.Test 1 for Primary Endpoint –Proportion of patients simultaneously achieving ACR50 and PASI 100at Week24:A superiorit y test of the primary endpoint will be performed at an overall 2 -sided α = 0.05 using the methods described in Sect ion 10.3.3.1.1 . 2.Test 2 for Major Secondary Endpoint #1 –Proportio n of patients achieving ACR50 at Week 24 : If the test for the primary endpoint is significant, then a noninferiorit y test f or the major secondary endpo int#1 will be performed using the methods described in Secti on 10.3.3.3 . 3.Test 3 for Major Secondary Endpoint #2 –Propo rtion of patients achieving PASI 10 0 at Week 24 : If the test for major secondary endpo int #1 is significant, then a superiority test for major secondary endpoint #2 will be performed using the methods described in Secti on 10.3.3.1.1 . If a test in this sequence is not si gnificant, all subsequent tests will be considered no nsignificant . There will be no adjust ment for multiple com parisons for any other analyses. 10.3.2. Treatment Group Comparability 10.3.2.1. Patient Disposition A detailed description o f patient di sposi tion will be provided at the end of the study . All pat ients who discont inue from the study treatment and the study will be ident ified, and the extent of their participat ion in the study will be reported. Patient disposit ion will be summarized and will include reasons for discont inuat ion.The reasons for discontinuation during Period 2 will be tested between treatment groups using Fisher’s exact test. 10.3.2.2. Patient Cha racteristics Baseline characterist ics, clinical, and health outcome measurements will be summarized for the ITT population. Baseline characteristics will include sex, age, age category , wei ght, BMI, race, geographi c regi on, baseline disease severit y, duration of disease, previous nonbio logic systemic therapy , and previous bio logic therapy . Baseline clinical measurements will include ACR component scores, PASI total score, DAS28 -CRP, CRP, Modified CPDAI, HAQ -DI, Itch NRS score, NAPSI Fingernails, SPARCC Enthesit is Index, LEI, LDI -B, and other QoL score s."
73,page_73,"I1F-MC-RHCF (a)Clinical Protocol Page 73 LY2439821Treatment group comparisons between ixekizuma b and adalimumab will be conducted using Fisher’s exact test for categorical data and an analysis o f variance m odel with treatm ent as a factor for continuous data . 10.3.2.3. Concomitant Therapy Previous and concomitant medicat ions (including concomitant topical product s such as emollients and other nonprescription topical products) will be summarized for patients who enter each treatment period and will be presented by World Heal th Organizat ion Anatomic Therapeut ic Class (WHOATC) Level 1 and generic name. Treatment gro up comparisons between ixekizumab and adalimumab in Period 2 will be conducted using Fisher’s exact test. 10.3.2.4. Treatment Compliance Treatment compliance wit h investigational product will be summarized for patients who enter Period 2. A patient will be consider ed com pliant overall to ixekizumab or adalimumab if he/she is missing no more than 20% of the expected doses, does not miss 2 consecut ivedoses , and does not double -dose (that is, take more inject ions at the same time po int than specified in the protocol ). Proportions of pat ients com pliant by visit and overall will be com pared between treatm ent groups during Period 2 using Fisher’s exact test. 10.3.3. Efficacy Analyses 10.3.3.1. Primary Analys is Method 10.3.3.1.1. Categorical Variables Unless specified otherwise, the primary analys is method for thecategori calefficacy and heal th outcom e variables will be using a logist ic regressio n model with treatm ent, concomitant csDMARD use at baseline (Yes vs No),and moderate -to-severe plaque psoriasis involvement (Yes vs No )as factors and NRI method. Treatment group comparisons willbe made at all visits up to Wee k 52 and odds rati os and the ircorresponding 95% confidence interval s (CIs) will be reported . 10.3.3.1.2. Continuous Variables Unless specified otherwise, t he primary analys ismethod for all con tinuous efficacy and heal th outcom e variables will be using a MMRM analysis . The m odel will include treatm ent group, concomitant csDMARD use (Yes vs No) at baseline , moderate -to-severe plaque psoriasis involvement (Yes vs No) , baseline value, visit, baseline-by- visitinteracti on, and treatment -by- visit interaction as fixed factors. The covariance structure to model the within -patient errors will be unstructured. If the unstructured covariance matrix results in a lack of convergence, the heterogeneou s Toeplitz covariance structure, fo llowed by the heterogeneous autoregressive covari ance structure will be used . The Kenward -Roger m ethod will be used to estimate the deno minator degrees of freedo m. Type III tests for the least squares means will be used for the statist ical comparison; the 95% CI will also be reported . Treatment group comparisons at all visits up to Wee k 52 will be made ."
74,page_74,"I1F-MC-RHCF (a)Clinical Protocol Page 74 LY243982110.3.3.2. Secondary Analys is Method 10.3.3.2.1. Categorical Variables Secondary analys es for treatm ent com parisons on the categori cal efficacy variables will be conducted using a Fisher’s exact test. 10.3.3.2.2. Continuous Variables Secondary analyses for treatment comparisons on continuous outcome variables will be perform ed using an analysis of covariance (ANCOVA) model and LOCF imputati on m ethod . The details o f the analysis model will be presented in the SAP . 10.3.3.3. Methodology for Noninferiority Test For assessing noninferiorit y of ixekizumab to adalimumab, missing data will be imputed using the NRI m ethod. Noninferiorit y analysis will be performed on the ITT populat ionusing a prespecified fixed margin approach . There i s no universally accepted value for what is considered to be a clinically unimportant difference between 2 treatments for a particular efficacy measure. We will consider the points fro m EMEA Committee for Medicinal Products for Hum an Use ( CHMP )(CHMP 2005) and FDA guidance (201 6) which statethat an appropriate noninferiorit y margin should be based on both clinical and statist ical grounds . The null hypothesis will be rejected if the l ower bound of the 2- sided 95% CI for the difference in proporti ons of responders on ixekizumab minus adalimumab is greater than the prespecified margin, meaning ixekizumab will be deemed noninferior to adalimumab . If the lower bound of the CI exceeds 0 (the corresponding p -value will also be produced), then ixekizumab will be deem ed superi or to adalimumab . The 95% CIs for the difference in proportions will be calculated using the simple asymptotic method, without continuit y correcti on (that i s, norm al approximat ion to the bino mial distribut ion). Based on EMEA CHMP (CHMP 2005) ,FDA guidance (2016 ),and Weinblatt et al. (2013), a noninferiorit y margin o f −12.0% for ACR50 between ixekizumab and adalimumab (ie, response rate of ixekizumab –response rate of adalimumab) is considered appropri ate. This noninferiorit y margin represents a napproximately 50% preservati on of the adalimumab treatm ent effect (based on the difference between adalimumab and placebo) observed in a historical Phase 3 stud yfor adalimuma b 40 m g twice weekly com pared wi th placebo (Mease et al 2005) and Study RHAP . If it is deemed appropriate to perform noninferiorit y tests on endpoints other than ACR50, the details about select ion of noninferiorit y margins for the other endpoints will be p resented in the SAP. 10.3.4. Safety Analyses Safety will be assessed by summarizing and analyzing AEs, laboratory analy tes including neutrophil counts, vital signs, and conco mitant m edications. The durati on of exposure will also be summarized. The primary safety analyses will focus on comparisons of ixekizumab versus adalimumab in Period 2. Fisher's exact test will be used for all AEs and other categorical safet y data. Continuous vital sign and laboratory values will be analyzed using ANCOVA method wit h"
75,page_75,"I1F-MC-RHCF (a)Clinical Protocol Page 75 LY2439821treatm ent and baseline value in the model. Other continuous safet y variables will be analyzed by t-tests, unless otherwise stated. Summaries of safet y data collected during the Post- Treatment Follow -Up Peri od (Peri od 3) will be presented separately . Unless o therwise specified, the fo llow-up baseline is defined as the last nonmissing assessment on or prior to the Week 52 (Visit 11) or early discontinuati on visi t. The categorical safet y measures will be summarized with incidence rates . The m ean change of the continuous safet y measures will be summarized by visits. 10.3.4.1. Adverse Events AEsare cl assified based on the Medical Dict ionary for Regulatory Activities (MedDRA). A TEAE is defined as an event that first occurred or wor sened in severit y after the first dose of study treatm entand on or prior to the date of the last visit within the treatment period. Both the date/time of the event and th e date/time of the dose (ie , inject ion) are considered when determining TEAEs. For each TEAE, the severit y is recorded acc ording to the patient’s or physician’s perceived severit y of the event (mild, moderate, or severe). A follow-up em ergent adverse event (FE AE)is defined as an event that first occurred or worsened in severit y after the date of Week 52 (Visit 11) or the ET V. For events that are sex-specific, the deno minator and computati on of the percentage will only include subjects from the given sex. An overall summary o f AEs will be provided for Period 2, including the number and percentage of subjects who experienced TEAE s, TEAEs by maximum severit y, death, SAEs , TEAEs related to study drug, di scont inuat ions from treatm ent due to an AE, and treatment -emergent adverse event sof special interest . TEAEs (all, by maximum severi ty, and TEAE s possibly related to study drug by the investi gator), SAE s including deaths, and AEs that lead to treatment discontinuat ion will be summarized and analyzed by MedDRA system organ cl ass(SOC) and preferred term. In addit ion to general safet y param eters, safet y inform ation on specific topics of adverse event s of special interest will also be presented. Potential adverse event sof special interest will be ident ified by a standardized MedDRA query (SMQ) or a Lilly -defined MedDRA preferred term listing. Follow-Up em ergent AEs, SAE s incl uding deaths, and AEs that lead to study discont inuat ion will be summarized by MedDRA system organ class and preferred term for Period 3. 10.3.4.2. Clinical Laboratory Tests Laboratory assessments will be analyzed as mean changes from baseline and as incidence of treatm ent-emergent abnormal, high, or low laboratory values (see bel ow). Shift tables will be presented for selected parameters. For categorical laboratory tests: oTreatment -emergent abnormal value = a change from norm al at all baseline visi ts to abnorma l at any time postbaseline. For continuous laboratory tests:"
76,page_76,"I1F-MC-RHCF (a)Clinical Protocol Page 76 LY2439821oTreatment -emergent high value = a change fro m a value less than or equal to the high limit at all baseline visits to a value greater than the high limit at any time postbaseline. oTreatment -emergent lowvalue = a change from a value greater than or equal to the low limi t at all baseline visi ts to a value l ess than the l ow limi t at any time postbaseline. 10.3.4.3. Vital Signs, Physical Findings, and Other Safety Evaluations Vital signs will beanalyzed as mean changes from base line and as incidence of abnormal values and will be summarized for both predose and postdose at Week 0 (Week 2) and Week 52 (Visit11), as applicable . Suicide-related thoughts and behaviors and self- injuri ous behavior wi th no sui cidal intent, based on the C -SSRS, will be listed by patient. 10.3.5. Pharmacokinetic/Pharmacodynamic Analyses Not applicable . 10.3.6. Other Analyses 10.3.6.1. Subgroup Analyses Subgroup analysis will be conducted using the ITT population. Subgroups to be evaluated will i nclude conco mitant csDMARD use at baseline (Yes vs No), concomitant MTX use at baseline (Yes vsNo), sex(male vs female), age group (<65 vs ≥65) . A detailed descript ion of the subgroup variables will be provided in the SAP. A logistic regressio n model with treatm ent, subgroup, and the interaction of subgroup by treatm ent included as factors will be used. The subgroup-by- treatm ent interacti on will be tested at the significance level of 0.10. Treatment group differences will be evaluated within each categ ory of the subgroup using Fisher’s exact test, regardless of whether the interaction is statist ically significant. Missing data will be imputed using NRI. If any group within the subgroup is less than 10% of the total populat ion, only summaries of the ef ficacy data will be provi ded ( ie,no inferent ial testing will be perf ormed). 10.3.7. Interim Analyses An interim database lock will occur, and the analysis will be performed at the time (that is, a cutoff date) when the last patient completes Visit 8 (Week 24), co mpletes ETV, or discont inues from Period 2. Thi s database l ock will include all data collected by the cutoff date including data after Week 24 fro m the Open- Label Treatment Peri od (Peri od 2) and follow -up data from patients who have begun Post -Treatment F ollow-Up Peri od (Peri od 3). This interim database lock at Week 24 will be considered the primary database l ock f or this study because all primary and major secondary study object ives will be assessed at this t ime. Since the primary timepoint of interes t is Week 24, efficacy and healt h outcom es data will be"
77,page_77,"I1F-MC-RHCF (a)Clinical Protocol Page 77 LY2439821repor ted up to Week 24 because of the lack of co mplete data for all pat ients beyo nd this visit . However, allsafet y data collected up to the cutoff date will be reported. A final database lock will occur after all enrolled patients have co mpleted or di scont inued the Post-Treatment Follow -Up Peri od(Peri od 3) . After the final database lock ,all efficacy, healt h outcom es,and safet y data collected untilstudy complet ion will be reported. There will be no data monitoring co mmittee."
78,page_78,"I1F-MC-RHCF (a)Clinical Protocol Page 78 LY243982111. References Amjevita [ package insert]. Thousand Oaks, CA: Amgen Inc; 2016. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A. IMPACT 2 Invest igators. Infliximab improves signs and symptoms of psoriat ic arthri tis: resul ts of the IMPACT 2 trial. Ann Rheum Dis. 2005a ;64(8):1150 –1157. Antoni C E,Kavanaugh A, Kirkham B Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Key stone E, Gl adman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smo len J. Sustained benefits of infliximab therapy for derm atologic and articular manifestations of psoriat ic arthrit is: result s from the Infliximab Mult inational Psori atic Arthri tis Controlled Trial (IMPACT). Arthritis Rheum . 2005 b;52(4):1227 -1236. AshZ, Gauj oux-Viala C, Gossec L, Hensor EM, FitzGerald O, Wint hrop K, van der Heijde D, Emery P, Sm olen JS, Marzo -Ortega H. A systematic literature review of drug therapies for the treatm ent of psoriatic arthrit is: current evidence and meta -analysis informin g the EULAR recommendat ions for the m anagement of psoriat ic arthri tis.Ann Rheum Dis . 2012; 71(3) :319- 326. [CHMP ] Committee for Proprietary Medicinal Products for Hum an Use. Gui deline on the Choice of the Noninferiori ty Margin. European Medicines Agency web site. EMEA/CPMP/EWP/2158/99. Available at http://www.ema.europa.eu/docs/en_GB/document_library /Scient ific_guideline/2009/09/WC50 0003636.pdf . 27 July 2005. A ccessed 27 Feb 2017. CleggD O, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman -Mak E, Blackburn WD, Vassey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen M R, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Co mpar ison of sulfasalazine and placebo in the treatment of psoriatic arthrit is. A Depart ment of Veterans Affairs Cooperative Study . Arthritis Rheum . 1996;39(12):2013 -2020. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activit y in psoriat ic arthrit is: a proposed object ive target for treatment. Ann Rheum Dis. 2010a;69(1):48 -53. Coates LC, Helliwell PS. Validat ion of minimal disease act ivity criteria for psori atic arthrit is using interventional trial data. Arthritis Care & Res. 2010b;62(7):965 -969. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta- Felquer M, Armstrong AW, Bautista -Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdi e A, Orbai AM, Parkinson A, O’Sullivan D, Rosen CF, Schwartz man S, Si egel EL, Toloza S, Tuong W, Ritchlin CT. Group for Research and Assessment of Psoriasis and Psori atic Arthri tis 2015 Treatment Recommendations for Psoriatic Arthrit is. Arthritis Rheumatol. 2016;68(5):1060 -1071. Columbia Universit y Medical Center. Columbia –Suicide Severi ty Rating Scale (C -SSRS) web site. Available at: http://www.cssrs.columbia.edu. Accessed 21 April 2011 . Deepak P, Stobaugh DJ, Ehrenpreis ED. Infect ious com plicat ions of TNF -α inhibitor monotherapy versus combination therapy wit h immuno modulators in inflammatory bowel"
79,page_79,"I1F-MC-RHCF (a)Clinical Protocol Page 79 LY2439821disease: analysis o f the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis. 2013;22(3):269 -276. Dougados M, vam der Linden S, Leirisalo -Repo M, Hui tfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, et al . Sulfasalazine in the treatment of spondylarthropathy . Arando mized, mult icenter, double -blind, pl acebo -controlled study .Arthritis Rheum . 1995;38(5):618 -627. The EuroQol Group. EQ-5D- 5L user guide, versio n 2.0. October 2013. Available at: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyers/UserGuide_ EQ-5D-5L_v2.0_October_2013.pdf . Accessed 02 April 2015. [EMA] European Medicines Agency. Committee for medici nal products for human use (CHMP). Guideline on clinical invest igation of medicinal products indicated for the treatment of psori asis. November 2004 . Available at: http://www.ema.europa.eu/docs/en_GB/document_library /Scient ific_guideline/2009/09/WC50 0003329.pdf . Accessed 17 March 2015. [FDA] Food and Drug Administration, Center for Drug Evaluat ion and Research (CDER), Center for Bio logics Evaluat ion and Research (CBER). Guidance for industry, non -inferiorit y clinical trials to establish effect iveness. Novem ber 2016. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformat ion/guidances/u cm202140.pdf . Accessed 02 March 2017. Fredri ksson T, Pettersson U. Severe psoriasis —oral therapy wi th a new retino id. Dermatologica . 1978;157(4) :238-244. FriesJF, Spi tz P, Kraines RG, Holman HR. Measurement of patient outcome in arthrit is. Arthritis Rheum .1980;23 (2):137-145. FriesJF, Spi tz PW, Young DY. The dimensio ns of healt h outcomes: the healt h assessment questionnaire, disabilit y and pain scales. J Rheumatol .1982;9(5):789 -793. Gladman DD, Antoni C, Mease P, Cl egg DO, Nash P. Psoriat ic arthrit is: epidemio logy,clinical featur es, course, and outcome. Ann Rheum Dis . 2005;64(suppl 2):ii14- ii7. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger TL, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nicko loff BJ, Osuntokun OO, Secrest RJ, Zh aoF, Mallbris L, Leonardi CL, for the UNCOVER- 1, UNCOVER -2, and UNCOVER -3 Study Groups. Phase 3 trials of ixekizumab in moderate -to-severe plaque psori asis. N Engl J Med . 2016;375:345-356. Gossec L, Sm olen JS, Gauj oux-Viala C, Ash Z, Marzo -Ortega H, van de r Heijde D, Fi tzGeral d O, Al etaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, R itchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Wint hrop KL, Zink A, Emery P; European League Against Rheumatism. European League Against Rheumat ismrecommendations for the management of psori aticarthri tis with pharmaco logical therapies . Ann Rheum D is.2012;71 (1):4-12. Gossec L, Sm olen JS, Ramiro S, deWit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald"
80,page_80,"I1F-MC-RHCF (a)Clinical Protocol Page 80 LY2439821O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo -Ortega H, McGo nagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wo llenhaupt J, Zink A, van der Heijde D. European League Against Rheumat ism (EULAR) recommendations for the management of psoriat ic arthrit is wit h pharmaco logical therapi es: 2015 update. Ann Rheum Dis .2016;75(3):499 -510. Healy PJ, Helliwell PS. Measuring dact ylitis in clinical trials: which is the best instrument to use? J Rheumatol .2007;34:1302 -1306. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriat ic arthri tis: assessment of exist ing measures and development of an instrument specific to psoriat ic arthrit is. ArthritisRheum. 2008;59(5):686 -691. Helliwell PS, Fi rth J, Ibrahim GH, Melso m RD, Shah I, Turner DE . Development of an assessment tool for dacty litis in pat ients with psoriati c arthri tis. J Rheumatol. 2005; 32:1745 -1750. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validat ing the SF -36 healt h survey questionnaire in pat ients with psori atic arthrit is. J Rheumatol . 1997;24(3):511 -517. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidit y on qualit y of life in pat ients with psoriati c arthri tis. J Rheumatol. 2013;40(8):1349 - 1356. Kaltwasser JP,Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P; Treatment of Psoriat ic Arthri tis Study Group. Efficacy and safet y of lefluno mide in the treatment of psoriat ic arthrit is and psoriasis: a multinational, double - b lind, rando mized, placebo -controlled clinical trial. Arthritis Rheum . 2004 ;50(6):1939 –1950 . Kavanaugh A , Helliwell P, Ri tchlin CT. Psori atic arthrit is and burden o f disease: pat ient perspectives fro m the Popul ation-Based Mult inational Assessment of Psoriasis and Psoriat ic Arthri tis (MAPP) Survey . Rheumatol Ther. 2016;3 (1):91-102. Kavan augh A, A ntoniCE, G ladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smo len J, van der Heijde D. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 y ear. Ann Rheum Dis .2006;65 (8):1038 -1043 . Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez -Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Vi svanathan S, Beutler A. Golimumab, a new human tumor necrosis factor alpha antibody , administered every four weeks as a subcutaneous inject ion in psori atic arthrit is: Twent y-four–week efficacy and safet y resul ts of a randomized, placebo -controlled study . ArthritisRheum . 2009;60(4):976 –986. Kingsle yGH, Kowa lczyk A, Taylor H, Ibrahim F , Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O’Keeffe AG, Maddison PJ, Scott DL. A randomized placebo -controlled trial o f MTX in PsA . Rheumatology . 2012;51(8):1368- 1377. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. En teracept in the treatment of psori atic arthrit is and psoriasis: a rando mized trial. Lancet . 2000;356(9227):385 -390. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Sal onen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriat ic arthrit is safet y, efficacy , and effect on disease progression. ArthritisRheum . 2004;50(7):2264–2272."
81,page_81,"I1F-MC-RHCF (a)Clinical Protocol Page 81 LY2439821Mease PJ, Gl adman DD, Ri tchlin CT, Ruderm an EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ , Weinberg MA; Adalimumab Effectiveness in Psoriat ic Arthrit is Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriat ic arthri tis:resul ts of a doubl e-blind, rando mized, placebo -controlled trial. ArthritisRheum. 2005;52(10):3279 –3289. Mease PJ, Woolley JM, Bit man B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriat ic arthrit is: relat ing thresho lds of improvement in funct ional abilit y to pati ent-rated impo rtance and sat isfaction. J Rheumatol . 2011;38(11):2461 - 2465. Mease PJ. Measures of psoriatic arthrit is: Tender and Swollen Jo int Assessment, Psoriasis Area and Severit y Index (PASI), Nail Psoriasis Severit y Index (NAPSI), Modified Nail Psoriasis Severit y Index (mNAPSI), Mander/Newcastle Enthesit is Index (MEI), Leeds Enthesit is Index (LEI), Spondyloarthrit is Research Consortium o f Canada (SPARCC), Maastricht Ankylosing Spondylit is Enthesis Score (MASES), Leeds Dactylit is Index (LDI), Patient Global for Psori atic Arthri tis, Derm atology Life Qualit y Index (DLQI), Psoriat ic Arthri tis Quali ty of Life (PsAQOL), Funct ional Assessment of Chronic Illness Therapy –Fatigue (FACIT -F), Psori atic Arthri tis Response Cri teria (PsARC), Psoriatic Arthrit is Joint Activit y Index(PsAJAI), Disease Act ivity in Psoriatic Arthrit is (DAPSA), and Co mposite Psoriatic Disease Act ivity Index (CPDAI). Arthritis Care Res . 2011;63( S11):S64–S85 . Mease PJ, Armstrong AW . Managing patients with psoriatic disease: the diagnosis and Pharmaco logic treatment of psori atic arthritis in patients wi th psori asis. Drugs . 2014;74(4);423 -41. Mease PJ, Okada M, Kishimoto M, Shuler CL, Carlier H, Lin CY, Mou J, Moriarty SR, Lee CH, Gladman DD. Efficacy and safet y of ixekizumab in patients with act ive psoriat ic arthri tis: 52 week results from a phase 3 study (Spi rit-P1). Ann Rheum Dis. 2016;75 (suppl 2):96. Abstract OP0109. Mease PJ, van der Heijde D , Ritchlin CT , Okada M , Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT -P1Study Group. Ixekizumab, an interleukin- 17A specific monoclonal antibody , for the treatm ent of bio logic-naive patients with act ive psoriat ic arthri tis: resul ts from the 24 -week randomised, double -blind, placebo -controlled and act ive (adalimumab) -controlled period of th e phase III trial SPIRIT -P1.Ann Rheum Dis. 2017;76(1):79 -87. Menter A, Gottlieb A, Feldman SR, VanVoorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and p soriatic arthrit is: section 1. Overview of psoriasis and guidelines o f care for the treatment of psoriasis wit h bio logics. J Am Acad Dermatol . 2008;58(5):826 -850. Mum taz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, Helliwell P, FitxGerald O. Dev elopment of a preliminary composi te disease act ivity index in psoriat ic arthri tis. Ann Rheum Dis. 2011;70(2):272 -277. Nash P, Clegg DO. Psoriat ic arthrit is therapy: NSAIDs and tradit ional DMARDs. Ann Rheum Dis. 2005;64(suppl 2):ii74- ii77."
82,page_82,"I1F-MC-RHCF (a)Clinical Protocol Page 82 LY2439821[NPF] Nati onal Psoriasis Foundat ion. The psoriasis and psoriat ic arthritis pocket guide. 2009. Available at: www.psoriasis.org/document.doc?id=354. Accessed 07 April 2015. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classificat ion Algorithm o f Suicide Ass essment (C -CASA): classificat ion of sui cidal events in the FDA’s pediatric suicidal risk analysis of ant idepressants. Am J Psychiatry. 2007;164(7):1035 -1043. Puig L. PASI90 response: the new standard in therapeutic efficacy for psori asis. J Eur Acad Dermat ol Venereol . 2015;29(4):645 -648. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psori atic arthrit is have worse qualit y of life than those with psoriasis alo ne. Rheumatology . 2012;51(3):571 -576. Ruderm an EM. Overview of safet y of non-biologic and bio logic DMARDs. Rheumatology . 2012; 51(Suppl 6):vi37-43. Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effect iveness and safet y of adalimumab in pat ients with ankylo sing spondylit is or psoriat icarthri tis and history of anti-tumor necrosi s factor therapy . Arthritis Res Ther . 2010;1 2(3):R117. SF-36 Heal th Survey Update page . SF-36 web site. Available at: http://www.sf -36.org/tool s/sf36.sht ml. Accessed 12 June 2011. Smolen JS, Braun J, Dougados M, Emery P, Fi tzgeral d O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, Wit Md, Baraliakos X, Betteridge N, Burgos -Vargas R, Collantes -Estevez E, Deodhar A, Elewaut D, G ossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JC, Wint hrop K, van der Heijde D. Treating spondyloarthrit is, including ankylosing spondylit is and psori atic arthritis, to target: recommendat ions of an internati onal task f orce. Ann Rheum D is. 2014;73(1):6 -16. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guy att GH, Schmi tt J, La Mant ia L, Weberschock T, Roos JF, Si ebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R . Adverse effects of bio logics: a network meta -analysis and Cochrane overview. Cochrane Database Syst Rev . 2011 16;(2):CD008794. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, Kirkpatrick J. Validit y and reliabilit y of the twent y-eight-joint count for the assessment of rheumatoid arthritis activit y. Arthr itisRheum. 1995; 38(1):38 - 43. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Vey s EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Key ser F. DAS28 best reflects the physician’ s clinical judgment of response to infliximab therapy in rheumatoi d arthri tis pat ients: validation o f the DAS28 score in patients under infliximab treatment. Arthr itisResTher. 2005;7(5):R1063 -R1071. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head -to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoi d arthri tis: findings of a phase IIIb, mult inational, prospective, rando mized study. Arthri tis Rheum. 2013;65(1):28 -38."
83,page_83,I1F-MC-RHCF (a)Clinical Protocol Page 83 LY243982112. Appendices
84,page_84,"I1F-MC-RHCF (a)Clinical Protocol Page 84 LY2439821Appendix 1. Abbreviations and Definitions Term Definition ACR American College of Rheumatology ACR Core Set Consists of 7 disease activity measurements: tender joint count, swollen joint count, patient’s assessment of pain, Patient’s Global Assessment of Disease Activity, Physician’s Global Assessment of Disease Activity, Patient’s Assessment of Physical Functi on, and an acute -phase reactant value. ACR Responder ACR20 Responder A patient who has at least 20% improvement in both tender and swollen joint counts and at least 20% improvement in a minimum of 3 of the following 5 criteria: patient’s assessment of arthritis pain, Patient’s Global Assessment of Disease Activity, Physician’s Global Assessment of Disease Activity, Patient’s Assessment of Physical Function (Health Assessment Questionnaire -Disability Index), and an acute -phase reactant value (CRP or ESR). ACR50 Responder A patient who has at least 50% improvement in both t ender and swollen joint counts and at least 50% improvement in a minimum of 3 of the following 5 criteria: patient’s assessment of arthritis pain, Patient’s Global Assessment of Disease Activity, Physician’s Global Assessment of Disease Activity, Patient’ s Assessment of Physical Function (Health Assessment Questionnaire -Disability Index), and an acute -phase reactant value (CRP or ESR). ACR70 Responder A patient who has at least 70% improvement in both tender and swollen joint counts and at least 70% impr ovement in a minimum of 3 of the following 5 criteria: patient’s assessment of arthritis pain, Patient’s Global Assessment of Disease Activity, Physician’s Global Assessment of Disease Activity, Patient’s Assessment of Physical Function (Health Assessment Questionnaire -Disability Index), and an acute -phase reactant value (CRP or ESR). AE adverse event: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a cau sal relatio nship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whethe r or not related to the medicinal (investigational) product. ALP alkaline phosphatase ALT alanine aminotransferase AST aspartate aminotransferase audit A systematic and independent examination of the trial -related activities and documents to determine whether the evaluated trial -related activities were conducted, and the data were recorded, analyzed, and accurately reported according to the protocol, applicable standard operating procedures, good clinical practice (GCP), and the applicable regulato ry requirement(s). BCG Bacillus Calmette -Guérin bDMARD Biologic disease -modifying anti -rheumatic drug (see also DMARD); examples of biologics include —but are not limited to —etanercept (Enbrel®), adalimumab (Humira®), and infliximab (Remicade®)"
85,page_85,"I1F-MC-RHCF (a)Clinical Protocol Page 85 LY2439821blinding A procedure in which one or more parties to the trial are kept unaware of the treatment assignment(s). A single -blind study is one in which the investigator and/or his staff are aware of the treatment but the patient is not, or vice versa, or when the spons or is aware of the treatment but the investigator and/his staff and the patient are not. A double - blind study is one in which neither the patient nor any of the investigator or sponsor staff who are involved in the treatment or clinical evaluation of the subjects are aware of the treatment received. BSA body surface area ;measured in 1% increments with area of patient’s hand including palm, fingers and thumb = 1% CASPAR Classification for Psoriatic Arthritis CEC Clinical Events Committee ;responsible fo r adjudicating cerebrocardiovascular AEs to achieve consistency in reporting CI confidence interval clinical research physicianIndividual responsible for the medical conduct of the study. Responsibilities of the CRP may be performed by a physician, clinical research scientist, global safety physician or other medical officer. complaint A complaint is any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, purity, durability, reliability, safety or e ffectiveness, or performance of a drug or drug delivery system. compliance Adherence to all the trial -related requirements, good clinical practice (GCP) requirements, and the applicable regulatory requirements. confirmatio n A process used to confirm that laboratory test results meet the quality requirements defined by the laboratory generating the data and that Lilly is confident that results are accurate. Confirmation will either occur immediately after initial testing or will require that samples be he ld to be retested at some defined time point, depending on the steps required to obtain confirmed results. consent The act of obtaining informed consent for participation in a clinical trial from patients deemed eligible or potentially eligible to partici pate in the clinical trial. Patients entered into a trial are those who sign the informed consent form directly or through their legally acceptable representatives. CRP C-reactive protein CSR clinical study report C-SSRS Columbia –Suicide Severity Rating Scale DAS28 - CRP Disease Activity Score (28 diarthrodial joint count) based on C -reactive protein DLQI Dermatology Life Quality Index DNA deoxyribonucleic acid eCRF Case report form (electronic case report form). Sometimes referre d to as clinic al report form. A printed or electronic form for recording study participants’ data during a clinical study, as required by the protocol. efficacy Efficacy is the ability of a treatment to achieve a beneficial intended result. end of study (trial) End of study (trial) is the date of the last visit or last scheduled procedure shown in the Study Schedule for the last active subject in the study. enroll The act of assigning a patient to a treatment. Patients who are enrolled in the trial are those who ha ve been assigned to a treatment. enter Patients entered into a trial are those who sign the informed consent form directly or through their legally acceptable representatives. enthesitis Inflammation of tendons and ligaments that can manifest as localized pain and tenderness. EQ-5D-5L European Quality of Life –5 Dimensions 5 Level"
86,page_86,"I1F-MC-RHCF (a)Clinical Protocol Page 86 LY2439821ERB Ethical Review B oard; aboard or committee (institutional, regional, or national) composed of medical and nonmedical members whose responsibility is to verify that the safety, welfare, and human rights of the patients participating in a clinical study are protected. ETV Early Termination Visit EU European Union FSH follicle -stimulating hormone GCP good clinical practice HAQ -DI Health Assessment Questionnaire -Disability Index HBcAb+ positive for anti -hepatitis B core antibody HBsAb+ positive for anti -hepatitis B surface antibody HBsAg+ positive for hepatitis B surface antigen HBV hepatitis B virus HCV hepatitis C virus HIV human immunodeficiency virus HIVAb human immunodeficiency virus antibody hs-CRP high sensitivity (assay) C -reactive protein IB Investigator’s Brochure IBD inflammatory bowel disease ICF informed consent form ICH International Conference on Harmonisation IL Interleukin (eg, IL-17; a proinflammatory cytokine produced by Th17 cells) informed consent A process by which a patient voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relev ant to the patient’s decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form. interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, that is conducted before the final reporting database is created/locked. investigational product A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including products already on the market when used or assembled (formulated or packaged) in a way different from the authorized form, or marketed products used for an unauthorized indication, or marketed products used to gain further information about the authorized form. investigator A person respon sible for the conduct of the clinical study at a study site. If a study is conducted by a team of individuals at a study site, the investigator is the responsible leader of the team and may be called the principal investigator. ITT intention to treat ; the principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of the intention to treat a patient (that is, the planned treatment regimen) rather than the actual treatment given. It has the consequence th atpatients allocated to a treatment group should be followed up, assessed ,and analyzed as members of that group irrespective of their compliance to the planned course of treatment. ERB Ethical Review Board ; aboard or committee (institutional, regional, o r natio nal) composed of medical and nonmedical members whose responsibility is to verify that the safety, welfare, and human rights of the patients participating in a clinical study are protected. IV intravenous IWRS interactive web -response sy stem LDI-B Leeds Dactylitis Index —Basic"
87,page_87,"I1F-MC-RHCF (a)Clinical Protocol Page 87 LY2439821legal representative An individual, judicial, or other body authorized under applicable law to consent on behalf of a prospective patient, to the patient’s participation in the clinical study. LEI Leeds Enthesitis Index LOCF last observation carried forward MDA Minimal Disease Activity MedDRA Medical Dictionary for Regulatory Activities MI myocardial infarction MMRM mixed-effects model repeated measures Modified CPDAI Modified Composite Psoriatic Disease Activity Index MTX methotrexate NAPSI Fingernails Nail Psoriasis Severity Index Fingernails NRI nonresponder imputation NRS numeric rating scale PASI Psoriasis Area and Severity Index patient A study participant who has the disease or condition for which the investigational product is targeted. PPD purified protein derivative Ps psoriasis PsA psoriatic arthritis PsARC Psoriatic Arthritic Response Criteria QoL quality of life Q2W every 2 weeks Q4W every 4 weeks RA rheumatoid arthritis randomize Refers to a method of treatment assignment. The point of randomization in this trial is the point at which treatment is assigned and the patient begins treatment; thus, patients who are randomized in the trial are those who have been assigned to a treatment. registration The act of assigning a registration number to the subject indicating that the registration center/sponsor/principal investigator or subinvestigator has verified that the subject meets the inclusion criteria and none of the exclusion criteria. rescreen To screen a patient who was previously declared a screen failure for the same study. SAE serious adverse event SAP statistical analysis plan SC subcutaneous screen The act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study. SF-36 Medical Outcomes Study 36 -Item Short Form Health Survey SJC swollen joint count sPGA static Physician Global Assessment of psoriasis SUSAR suspected unexpected serious adverse reaction TB tuberculosis TBL total bilirubin level TEAE Treatment -emergent adverse event ; an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, which and does not necessarily have to have a causal relatio nship with this treatment. TJC tender joint count TNF tumor necrosis factor UC ulcerative colitis"
88,page_88,I1F-MC-RHCF (a)Clinical Protocol Page 88 LY2439821ULN upper limit of normal VAS visual analog scale
89,page_89,"I1F-MC-RHCF (a)Clinical Protocol Page 89 LY2439821Appendix 2. Clinical Laboratory Tests Assay sto be perform ed by the central laboratory unless otherwise noted. Clinical Laboratory Tests Hematology Clinical Chemistry Hemoglobin Serum Concentrations of: Hematocrit Sodium Erythrocy te count (RBC) Potassium Mean cell volume Total bilirubin Mean cell hemoglobin concentration Direct bilirubin Leukocytes (WBC) PlateletsAlkaline phosphatase Alanine aminotransferase (ALT) Absolute counts of: Neutrophils, segmented Lymphocy tes Monocytes Eosinophils BasophilsAspartate aminotransferase (AST) Triglycerides Total cholesterol HDL/LDL cholesterol GGT Proteins (total) Blood urea nitrogen (BUN) Other Tests Creatinine Human immunodeficiency virus antibody (HIV) Hepatitis B Surface antigen (HBsAg) Anti-Hepatitis B Surface antibody (HBsAb) Anti-Hepatitis B Core antibody (HBcAb) Anti-Hepatitis C antibody Purified Protein Derivative (PPD)a QuantiFERON ®-TB Golda T-SPOT.TBa HBV DNA HCV RNA Rheumatoid factor (RF)Uric acid Calcium Glucose, fasting at Visit 2 but nonfasting throughout study, if clinically indicated Albumin Creatine Phospho kinase (C PK) hs-CRP Urinalysis Specific gravity pH Protein Glucose Ketones Blood Urine leukocyte esterasePregnancy Test (females only ) Serum Urineb FSH Abbreviations: FSH = follicle -stimulating hormone; GGT = gamma -glutamyl transferase ;HDL = high -density lipoprotein; HIVab =human immunodeficiency virus antibody ;LDL = low -density lipoprotein; RBC = red blood cells; WBC = w hite blood cells. aTest may be done by the physician, nurse ,or at the local laboratory . bAssay to be performed by study site or self -administered by patient . Additional urine pregnancy testing can be performed at the investigator’s discretion. If required per lo cal regulations, testing can occur at other intervals during the study treatment period and/or follow -up period."
90,page_90,"I1F-MC-RHCF (a)Clinical Protocol Page 90 LY2439821Appendix 3. Study Governance Considerations Appendix 3.1 .Regulatory and Ethical Considerations, Including the Informed Consent Process Appendix 3.1.1 .Informed Consent The invest igator is responsible for ensuring: that the patient understands the potential risks and benefits of part icipating in the study that informed consent is given by each patient or legal representative. This includes obtaining the appropriate signatures and dates on the informed consent form (ICF prior to the performance of any protocol procedures and prior to the administration o f investigational product. answering any quest ions the pati ent m ay have throughout the study and sharing in a t imely manner any new informat ion that m ay be relevant to the patient’s willingness to continue his or her participation in the trial. Appendix 3.1.2. Ethical Review The invest igator or an appropriate local representative must give assurance that the ERB was properly const ituted and convened as required by Internati onal Conf erence on Harm onisat ion (ICH) gui delines and other applicable laws and regulat ions. Docum entati on of ERB approval of the protocol and the ICF must be provided to Lilly before the study may begin at the investi gative si te(s). Lilly or its representatives must approve the ICF, including any changes made by the ERBs, before it is used at the invest igative site(s). All ICFs must be compliant with the ICH guideline on Good Clinical Pra ctice (GCP). The study site’s ERB(s) shoul d be provided wi th the f ollowing: the current IB and updates during the course of the study inform ed consent form relevant curri cula vi tae Appendix 3.1.3. Regulatory Considerations This study will be conducted in accordance wit h: consensus ethics principles derived fro m internat ional ethics guidelines, including the Decl aration of Helsinki and Council forInternational Organizati onsof Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines applicable ICH GCP Guidelines applicable laws and regulations"
91,page_91,"I1F-MC-RHCF (a)Clinical Protocol Page 91 LY2439821Some of the obligat ions of the sponsor will be assigned to a third party . Appendix 3.1.4. Investigator Information Physicians with a specialt y inrheumatol ogywill participate as invest igators in this clinical tri al. Appendix 3.1.5. Protocol Signatures The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best of his or her knowledge, the protocol accurately describes the pl anned design and conduct of thestudy . After reading the protocol , each principal invest igator will sign the protocol signature page and send a copy of the signed page to a Lilly representative. Appendix 3.1.6. Final Report Signature The CSR coordinat ing invest igator will sign the final CSR for this study , indicating agreement that, to the best of his or her knowledge, the report accurately describes the conduct and results of the study . The CSR coordinat ing invest igator will be selected by the sponsor. If this investigator is unable to fulfill this funct ion, another invest igator will be chosen by Lilly to serve as the CSR coordinat ing investigator. The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this study , confirming that, to the best of his or her knowledge, the report accurately describes the conduct and results of the study . Appendi x 3.2. Data Quality Assurance To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing: provi de instructi onal materi al to the study sites, as appropriate sponsor start -up training to instruct the invest igators and study coordinators. This training will give instructi on on the protocol, the complet ion of the eCRFs, and study procedures make periodic visit s to the study site be available for consultation and stay in contact with the study site personnel by mail, tel ephone, and/or fax review and evaluate eCRF data and use standard computer edits to detect errors in data co llection conduct a qualit y review of the database In addit ion, Lilly or its representatives willperiodically check a sample of t he patient data recorded against source documents at the study site. The study may be audi ted by Lilly or i ts representatives, and/or regulatory agencies at any time. Invest igators will be given notice before an audit occurs."
92,page_92,"I1F-MC-RHCF (a)Clinical Protocol Page 92 LY2439821The invest igator will keep records of all original source data. This might include laboratory tests, m edical records, and clinical notes. If requested, t he invest igator will provide the sponsor, applicable regulatory agencies, and applicable ERBs with direct access to original source docum ents. Appendix 3.2.1. Data Capture System An electronic data capture sy stem will be used in this study . The si te maintains a separate source for the data entered by the si te into the sponsor -provided electronic data capture system. Electronic pat ient-reported outcome (ePRO) measures (for example, a rating scale) are entered into an ePRO instrum ent (tablet) at the time tha t the inform ation is obtained. In these instances where there is no prior written or electronic source data at the site, the ePRO instrument record will serve as the source. In these instances where there are prior written source data that are subsequent ly entered into ePRO, the written record will serve as the source. If ePRO records are stored at a third party site, study sites will have continuous access to the source documents during the study and will receive an archival copy at the end of the study for retenti on. Any data for which the ePRO instrument record will serve to collect source data will be ident ified and documented by each site in that site’s study file . Case report form da ta will be encoded and st ored in a clinical trial database. Da ta managed by a central vendor, such as laboratory test data, will be stored electronically in the central vendor’s database system. Data will subsequent ly be transferred from the central vendor to the Lilly data warehouse . Any data for which paper docume ntation provi ded by the patient will serve as the source docum ent will be i dentified and documented by each si te in that si te’s study file. Paper docum entati on provi ded by the patient will include a paper diary to co llect a dosing schedule. Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product complaint m anagement sy stem . Appendix 3.3. Study and Site Closure Appendix 3.3.1. Discontinuation of Study Sites Study site parti cipat ion may be discont inued if Lilly or its designee , the invest igator, or the ERB of the study sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent with applicable l aws, regul ations, and GCP. Appendix 3.3.2. Discontinuation of the Study The study will be di scontinue d if Lilly or i ts desi gnee judges it necessary for m edical, safet y, regul atory , or other reasons consistent with applicable laws, regul ations, and GCP."
93,page_93,"I1F-MC-RHCF (a)Clinical Protocol Page 93 LY2439821Appendix 4. Hepatic Monitoring Tests for Treatment - Emergent A bnormality Selected tests m ay be obtained in the event of a treatm ent-emergent hepatic abnormalit y and may be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, clinical research physician. Hepatic Monitoring Tests Hepatic Hematology a Haptoglobin a Hemoglobin Hematocrit Hepatic Coagulation a RBC Prothrombin Time WBC Prothrombin Time, INR Neutrophils, segmented Lymphocy tes Hepatic Serologies a,b Monocytes Hepatitis A antibody, total Eosinophils Hepatitis A antibody, IgM Basophils Hepatitis B surface antigen Platelets Hepatitis B surface antibody Hepatitis B Core antibody Hepatic Chemistry a Hepatitis C antibody Total bilirubin Hepatitis E antibody, IgG Direct bilirubin Hepatitis E antibody, IgM Alkaline phosphatase ALT Anti -nuclear antibody a AST GGT Alkaline Phosphatase Isoenzymes a CPK Anti -smooth muscle antibody (or anti -actin antibody) a Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatinine phosphokinase; GGT = gamma -glutamyl transferase; Ig= immunoglobulin; INR = international normali zed ratio; RBC = red blood cells; WBC = white blood cells. aAssay ed by Lilly -designated or local laboratory. bReflex/confirmation dependent on regulatory requirements and/or testing availability."
94,page_94,"I1F-MC-RHCF (a)Clinical Protocol Page 94 LY2439821Appendix 5. Protocol A mendment I1F-MC-RHCF(a) Summary : A 52-Week Multicenter, Randomized, Open - Label, Parallel -Group Study Evaluating the Efficacy and Safety of Ixekizumab versus A dalimumab in Patients with Psoriatic A rthritis Who A re Biologic Disease - Modify ing A nti-Rheumatic Drug Naive Overview Protocol I1F-MC-RHCF (A 52 -Week Mult icenter, Rando mized, Open -Label, Parallel -Group Study Evaluat ing the Efficacy and Safet y of Ixekizum ab versus Adalimumab in Patients with Psori atic Arthri tis Who Are Bi ologic Disease -Modifying Ant i-Rheumat ic Drug Naive )has been amended. The new protocol is indicated by amendment ( a) and will be used to conduct the study in place of any preceding versio n of the protocol. The overall changes and rationale for the changes made to this protocol are descr ibed in the following table:"
95,page_95,"I1F-MC-RHCF (a)Clinical Protocol Page 95 LY2439821Amendment Summary for Protocol I1F-MC-RHCF Amendment ( a) Section # and Name Description of Change Brief Rationale All protocol sections Minor editorial changes. Minor corrections made as needed. 1. Sy nopsis Replaced “<” with “ ≤” for PASI score 1, 2, or 3 Updated Statistical Analysis section Corrected symbols. Modified based on observations from the csDMARD -experienced population from Study RHAP . 2. Schedule of Activities Footnote e: Removed that study drug will be administered by the patient or caregiver “at home” . Footnote j: Added a missing letter “A” to the beginning of the sentence. Footnote m: Added that additional pregnancy could be perfor med at the investigator’s discretion or per applicable regulations/guidance . Deleted reference to local regulations.Removed “at home” to make the instruction less specific . Minor editorial correction. Updated language to allow for more frequent pregnancy testing for any reason. Table RHCF.2.1 Study Drug Administration ScheduleAdded “plaque” before Ps. Corrected footnote order.Minor editorial corrections. 3.3 Benefit/Risk Assessment Replaced “SPC” with “product labeling.” SPC is specific to EU; “product labeling” is more general. 4. Objectives and EndpointsReplaced “<” with “ ≤” for PASI score 1, 2, or 3 Corrected symbols. 5.2 Number of ParticipantsClarified wording . Minor editorial change. 6.1. Inclusion Criteria Added Inclusion Criterion 50: Have had an inadequate response when treated with 1 or more csDMARDs .Patients must meet this additio nal inclusion criterion. Number 50 is the next number in the inclusion/exclusion list; however, this criterion was included in the inclusion criteria section. 6.2. Exclusion Criteria Exclusion Criterion 10: Clarified that the dose of the allowed concomitant medications MTX, l eflunomide, sulfasalazine, or cyclosporine must remain unchanged during the first 24 weeks only of the Open -Label Treatment Period. Deleted hydroxy chloroquine. Exclusion Criterion 13: Clarified that patients anticipating needing a parenteral injection of glucocorticosteroids during the first 24 weeks only of theOpen -Label Treatment Period are excluded . Exclusion Criterion 33: Clarified that patients who have had an infection of Exclusion Criteria 10 and 13 apply to the first 24 weeks only of the 52 -week Open -Label Treatment Period. Hydroxychloroquine was removed as a csDMARD. Minor editorial changes . Exclusion Criterion 33 was changed to exclude patients with infection of an artificial joint."
96,page_96,"I1F-MC-RHCF (a)Clinical Protocol Page 96 LY2439821Section # and Name Description of Change Brief Rationale an artificial joint are excluded. 7. Treatments Added Section 7.1.1 Administration of Investigational Product. Packaging and Labeling was renumbered to Section 7.1.2.Added to provide specific information regarding the administration of study drug. Minor editorial changes. 7.2. Method of Treatment AssignmentClarified that the randomization will be stratified by “concomitant ” csDMARD use “at baseline .”Stratification will occur by conc omitant csDMARD use at baseline . Minor editorial changes. 7.3. Blinding Added sPGA and Percentage of Body Surface Area to the list of blinded assessor rated assessment .Previously missing from the list. 7.7. Co ncomitant Therapy Added a sentence clarifying that PsA medications should remain at a stable dose for the first 24 week sof Open -Label Treatment unless changes are required for safety reasons. Replace SPC with product labeling.Added for consistency. Table RHCF.7.2 Concomitant Medications Permitted/Not Permitted in the Open -Label Treatment Period from Week 0 to Week 24 for Treatment of PsA and Chro nic Conditio ns Table RHCF.7.3 Concomitant Medications Permitted/Not Permitted in the Open -Label Treatment Period from Week 24 to Week 52 for Treatment of PsA and Chro nic Conditio ns Table RHCF.7.4 Allowed Concomitant Medications in the Post -Treatment Table RHCF.7.2 :For opiate analgesics, added stable doses with no dose adjustments, changes, and/or introduction of new opiate analgesics as a conditio n for use . Table RHCF.7.2 and 7.3: Removed hydroxy chloroquine. All 3 tables: Removed the abbreviation IV from the abbreviations lists and spelled out intravascular in each table.Previously inconsistent compared to oral steroids and to the exclusion criteria . Hydroxychloroquine was removed as a csDMARD. The abbreviation IV is defined as intravenous. Minor format ting changes."
97,page_97,"I1F-MC-RHCF (a)Clinical Protocol Page 97 LY2439821Section # and Name Description of Change Brief Rationale Follow -Up Period (Period 3) 8.1.1. Permanent Discontinuation from Study TreatmentAdded an “X” to the final bullet in the list of permanent discontinuation for study treatment. “alkaline phos phatase >2.5 XULN wit h the appearance of fatigue, nausea, vomiting, right quad rant pain o r tenderness, fever, rash, and/or eosinophilia (>5% )”Corrected typo. 9.1.2.1. Psoriasis Area and Severity Index (PASI 75, PASI 90, PASI 100) Replaced “<” with “ ≤” for PASI score 1, 2, or 3 . Corrected symbols. 9.1.2.3.1 American College of Rheumatology Core SetMove d/added a sentence to the beginning of each assessment descri ption stating that TJC and SJC assessments will be performed by a blinded assessor.Minor editorial change s. 9.1.2.11. Leeds Dactylitis Index -Basic Added the derivation for this assessment from the Statistical Analysis Plan (SAP) for Study I1F -MC -RHBE (RHBE).The derivation was updated in this SAP. 9.1.2.14. Static Physician Global AssessmentReplaced physician with assessor for the d etermin ation of the patie nt’s Ps lesions overall at a given time point .Assessor is theappropriate role for this . 9.3. Treatment of OverdoseReplace SPC with product labeling. SPC is specific to EU; “product labelling” is more general. 10.1. Sample Size DeterminationUpdated language . Modified based on observations from the csDMARD -experienced population from Study RHAP. 10.3.1.1. General Considerations for Analy ses during Period 2 (Open -Label Treatment Period)Included a statement that the primary time point of interest is Week 24. Clarification. 10.3.1.3. Adjustment for Multiple ComparisonsModified number 3 to remove noninferiority. The major secondary endpoint is superiority rather than noninferiority. Minor editorial changes. 10.3.2.2. Patient CharacteristicsRem oved C ASPAR as a baseline clinical measurement. Not collecting CASPAR scores at baseline ; CASPAR is only an inclusion criteri on. 10.3.3.1.1. Categorical VariablesAdded “concomitant” csDMARD use at “baseline”. Included that t reatment group comparisons will be made at all visits up to Clarified that the model will include concomitant csDMARD use at baseline."
98,page_98,"I1F-MC-RHCF (a)Clinical Protocol Page 98 LY2439821Section # and Name Description of Change Brief Rationale Week 52 and odds ratios and their corresponding 95% confidence interval s (CIs) will be reported .Added a dditional information to clarify that treatm ent group comparisons will be made at Week 52 and that odds ratios and their corresponding 95% CI swill be reported . 10.3.3.1.2. Continuous VariablesAdded “concomitant” csDMARD use at “baseline”. Clarified that the model will include concomitant csDMARD use at baseline. Minor editorial changes. 10.3.3.3. Methodology for Noninferiority TestPercent preservation of the adalimumab treatment effect was modified from 60% to 50% .Correction. 10.3.6.1. Subgroup Analy sisAdded that s ubgroups to be evaluated will include “concomitant ”csDMARD useand MTX use “at baseline ”.Clarified . Minor editorial changes. 10.3.7 Interim Analysis Added “(Period 2)” after Open -Label Treatment Period. Added a statement that since Week 24 is the primary timepoint of interest efficacy and health outcomes data will be reported up to Week 24 because of the lack of complete data for all patients beyond this visit. However, all safety data collected up to the cutoff date will be reported. Added a stat ement that after the final database lock, all efficacy, health outcomes, and safety data collected until study completion will be reported.Minor editorial change. Clarified. Appendix 1. Abbreviations and Definitio nsRem oved SPC. SPC is no longer used in the protocol. Appendix 2. Clinical Laborato ry TestsDeleted one instance of “cholesterol” from the table as it was included twice. Repetitive."
99,page_99,"I1F-MC-RHCF (a) Clinical Protocol Page 99 LY2439821Revised Protocol Sections Note: Deletions have been ident ified by strikethroughs . Addit ions have been identified by the use of underscore . Note: The numbering system used for inclusio n and exclusio n criteria provi des a unique number for each criterion and allows for efficiency in data collect ion. In case an amendment to the protocol adds a cri terion, that cri terion will receive the next available number, regardless of whether it is an inclusio n or exclusio n criterion. In this amendment, the addit ional inclusio n criterion is numbered 50, but remains in the inclusion criteria sect ion. 1. Synopsis Objective(s)/Endpoints: Psoriasis/Nail Endpoints Time course of response to treatment over 52 weeks as measured by: Change f rom baseline in body surface area (BSA) Proportio n of patients who ac hieve the following PASI score s: PASI 75, PASI 90, or PASI 100 (defined as 75%, 90%, and 100% improvement from baseline in PASI criteria, respectively) Proportio n of patients achieving an absolute PASI score < ≤1 or < ≤2 or < ≤3 Change f rom baseline in the Nail Psoriasis Severity Index (NAPSI) Fingernails score in the subgroup of patients with fingernail involvement at baseline (ie, baseline NAPSI Fingernails score >0) Statistical Analysis: A significance level of 0.05 is assumed for testing each dosing regimen of ixekizumab v ersus adalimumab . Sample size was calculated assuming the proportion of patients simultaneously achieving ACR50 and PASI 100as 13.2 13.6% and 28.8 31.3 %in the adalimumab and ixekizumab treatment groups, respectively ,as observed in the conventional synthetic disease -modifying anti -rheumatic drug ( csDMARD )-experienced population from Study RHAP . According to the nQuery sof tware, a total sample size of 550 patients (with 275 patients per treatment group) using a 2 -sided Fisher's exact test at a0.05 leve l of significance would yield approximately 99% power for testing ixekizumab versus adalimumab. This sample size would yield 79 78% power for testing the noninferiority of ixekizumab to adalimumab at a one - sided 0.025 level of significance based on a noninferiority margin of –12% and using ACR50 response rates of 42.5 43.8% and 44.1% as observed for inthe ixekizumab and adalimumab treatment groups , respectively, in the csDMARD -experienced population from Study RHAP ,respectively . For testing superiority of ixekizumab to adalimumab based on PASI 100 response rates of 42.5 46.9% and 23.5 23.7 % as observed for ixekizumab and adalimumab in the csDMARD -experienced population from Study RHAP, this sample size would yield 99% power using a 2 -sided Fisher's exact test at 0.05 level of significance. 2. Schedule of A ctivities Table footnotes:"
100,page_100,"I1F-MC-RHCF (a) Clinical Protocol Page 100 LY2439821eAt randomization (Visit 2) for patients randomized to ixekizumab and for patients with moderate -to-severe plaque Ps sy mptoms randomized to adalimumab, the second injection of study drug will be administered by the patient or caregiver under site personnel supervision for injection training purposes. Thereafter, study drug will be administered by the patient or caregiver at home . jAll patients will be tested for HBV. mOnly for females of childbearing potential. Additional urine pregnancy testing can be performed at the investigator’s discretion or per applicable regulations/guidance . If required per local regulations, testing can occur at other intervals during the study treatment period and/or follow -up period."
101,page_101,I1F-MC-RHCF (a) Clinical Protocol Page 101 LY2439821Table RHCF. 2.1. Study Drug Administration Schedule Visit 2 3 4 5 6 7 8 Weeks 0a1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Ixekizumab 80 mg Q2W/Q4W Moderate -to-Severe Plaque PsbX (160 mg)X X X X X X X X X Ixekizumab 80 mg Q4WcX (160 mg)X X X X X X Adalimumab 40mg Q2WdX (40mg)X X X X X X X X X X X X Adalimumab 40 mg Q2W Moderate -to-Severe Plaque PseX (80mg)X X X X X X X X X X X X Visit 9 10 11 Weeks 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 Ixekizumab 80 mg Q2W/Q4W Moderate -to-Severe Plaque PsbX X X X X X Ixekizumab 80 mg Q4Wc X X X X X X Adalimumab 40 mg Q2Wd X X X X X X X X X X X X X Adalimumab 40 mg Q2W Moderate -to-Severe Plaque PseX X X X X X X X X X X X X X Abbreviations: BSA =body surface area; PASI =Psoriasis Area and Severity Index ; Ps= pso riasis; Q2W = ever y 2 weeks; Q4W = every 4 weeks ; SC=subcutaneous; sPGA =static Physician Global Assessment of psoriasis . aStarting dose .
102,page_102,"I1F-MC-RHCF (a) Clinical Protocol Page 102 LY2439821Study Drug Administration Schedule bPatients with moderate -to-severe plaque Ps, defined as PASI ≥12, sPGA ≥3,and BSA ≥10%, will receive ixekizumab 80 mg given as 1 SC injection Q2W from Week 2 toWeek 12 and Q4W thereafter . cPatients not meeting criteria for moderate -to-severe plaque Ps will receive ixekizumab 80 mg given as 1 SC injection Q4W starting at W eek 4 . dePatients not meeting criteria for moderate -to-severe plaque Ps will receive a starting dose of adalimumab 40 mg given as 1 SC injection at randomization (Visit 2 [Week 0]) followed by 40 mg given as 1 SC injection Q2W starting at Week 2. edPatients with moderate -to-severe plaque Ps, defined as PASI ≥12, sPGA ≥3, and BSA ≥10%, will receive a starting dose of adalimumab 80 mg (two 40 -mg SC injections) administered at randomization (Visit 2 [Week 0]) followed by 40 mg given as 1 SC injection Q2W starting at Week 1. d Patients with moderate -to-severe plaque Ps, defined as PASI ≥12, sPGA ≥3, and BSA ≥10%, will receive a starting dose of adalimumab 80 mg (two 40 -mg SC injections) administered at randomization (Visit 2 [Week 0]) followed by 40 mg given as 1 SC injection Q2W starting at Week 1. ePatients not meeting criteria for moderate -to-severe plaque Ps will receive a starting dose of adalimumab 40 mg given as 1 SC injection at randomization (Visit 2 [Week 0]) followed by 40 mg given as 1 SC injection Q2W starting at Week 2."
103,page_103,"I1F-MC-RHCF (a) Clinical Protocol Page 103 LY24398213.3. Benefit/Risk Assessment More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) and reasonably ant icipated adverse events (AEs) of ixekizumab are to be found in the Invest igator’s Brochure (IB) and the product labeling Summary of Product Chara cteristics (SPC) . More detailed informat ion about the known and expected benefits and risks of adalimumab may be found in the SPC product labeling. 4. Objectives and Endpoints Table RHCF.4.1. Psoriasis/Nail Endpoints Time course of response to treatment over 52 weeks as measured by: Change from baseline in body surface area (BSA) Proportio n of patients who achieve the following PASI scores: PASI 75, PASI 90, or PASI 100 (defined as 75%, 90%, and 100% improvement from baseline in PASI criteria, respectively) Proportio n of patients achieving an absolute PASI score < ≤1 or < ≤2 or < ≤3 Change f rom baseline in the Nail Psoriasis Severity Index (NAPSI) Fingernails score in the subgroup of patients with fingernail involvement at baseline (ie, baseline NAPSI Fingernails score >0) 5.2. Number of Participants Approximately 917participants will be screened (assuming a 40% screen failure rate) to achi eve rando mizat ion of 550 participants (275 per treatment group) and approximately 396 pati ents are expecte d to com plete Week 52 have approximately 396 part icipants evaluable (assuming 72% completion rate at Week 52) at the complet ion of the study . 6.1. Inclusion Criteria Patient Characteristics … [4] Have act ive psoriat ic skin lesio ns (plaque psoriasis) with a BSA ≥3% at Visit 1 (Screening) and Visit 2 (Week 0). [50] Have had an inadequate response when treated with 1 or more csDMARDs. 6.2. Exclusion Criteria … [10] Have used csDMARDs other than MTX, lefluno mide, sulfasalazine, or cyclosporine or hy droxychl oroquine in the 8 weeks prior to randomizat ion (Visit2)."
104,page_104,"I1F-MC-RHCF (a) Clinical Protocol Page 104 LY2439821Have discontinued MTX, sulfasalazine, hydroxychloroquine, or cy closporine within 12 weeks pri or to randomizat ion. If taking MTX, lefluno mide, sulfasalazine, or cyclosporine ,must have been treated for at least 12 weeks prior to randomizat ionand on a stabl e dose for at least 8 weeks prior to randomizat ion, as f ollows: oral or parenteral MTX = 10 to 25mg/week, lefluno mide = 20 mg/day, sulfasalazine = up to 3 g/day, hydroxychloroquine = up to 400 mg /day,or cy closporine up to 5 m g/kg/day . The dose of these allo wed concomitant medicat ions must rem ain unchanged during the first 24 weeks of the Open -Label Treat ment Period unless changes are requi red for safet y issues. Local standard of care should be followed for concomitant administration o f folic acid wit h MTX. … [13] Have received any parenteral glucocortico id administered by intraarti cular, intram uscular, or intravenous (IV) inject ion within 6 weeks prior to randomizat ion, or for whom a parenteral inject ion of glucocorti costeroi ds is ant icipated during the first 24 weeks of the Open -Label Treatm ent Peri od. … [33] Patients who have: in the past 12 weeks prior to randomizat ion: ohad a serious infect ion (for example, pneumonia, cellulit is) ohave been ho spitalized for an infect ion ohave received IV ant ibiotics for an infect ion or in the past 24 weeks prior to randomizat ion had a serious bone or joint infect ion, or have ever had oan infection o f an artificial joint oan infection that occurs with increased incidence in an immunocom promised host (including, but not limited to, Pneumocystis jirovecii pneum onia, active histopl asmosis, or coccidio idomycosis); or have a known immunodeficiency. 7.1.1. Administration of Inves tigational Product Inject ions will be administered subcutaneously by the patient or caregiver after training by the clinical staff. Training: At randomizat ion (Visit 2), patients randomized to ixekizumab and patients with moderate -to-severe plaque Ps symptom s randomized to adalimumab will receive 2 inject ions. For training purposes, the proper procedures for administration of the init ial inject ion will be perform ed by clinical staff. The second inject ion of study drug will be administered by the patient or caregiver under site personnel supervisio n. Thereafter, study drug shoul d be"
105,page_105,"I1F-MC-RHCF (a) Clinical Protocol Page 105 LY2439821administered by the pat ient or caregiver. If addit ional training is necessary , an injecti on may be administered by the pat ient or caregiver under the supervisio n of clinical staff. Administration : If the pati ent is unable to administer the inject ion, a caregiver who will also be trained under supervision of site staff may administer the study drug. All subsequent inject ions will be administered by the pat ient or caregi ver an d shoul d be administered unsupervised by the clinical staff (see Sect ion 2). It is recommended that for these subsequent inject ions, the patient/caregiver administer the study drug outsi de the tri al site, preferably at the pati ent’s ho me. If the patient or caregiver is not able to administer the second inject ion of the starting dose or any dose through outthe study , study site personnel may administer that injection. Refer to the appropriate directions for use provided by the sponsor for the study drug. Study Drug Administration Logs will be dispensed to each patient as needed for recording pertinent data about each injection; details o f the use of these logs are provided in Section 7.2.1 . Observation : Pati ents shoul d rem ain under observat ion for at least 1 hour after dosing at rando mizat ion (Vi sit 2) to all ow for observat ion for any AEs and collect ion of postinject ion sitting BP and pulse measurements approximately 1 hour after administration of study drug (see Secti on 2). 7.1.1. 7.1.2. Packaging and Labeling 7.2. Method of Treatment A ssignment Patients who m eet all Visit 1 and Visi t 2 eligibili ty criteria for enrollment will be rando mized at Visit 2 (Week 0) in a 1:1 rati o to open -label treatment with ixekizumab or adalimumab at Week 0 (Visit 2). Assignment to treatment groups will be determined by a co mputer -generated rando m sequence using an interactive web -response system (IWRS). The IWRS will be used to assign invest igational product to each patient. Site personnel will confirm that they have located the correct invest igational product by entering a confirmat ion number found on the investigat ional product into the IWRS. The randomizat ion will be stratifi ed by conco mitant csDMARD use at baseline (Yes ,vsNo) and moderate -to-severe plaque psoria sisinvolvement (Yes ,vs No)severit y of plaque psori asis m oderate -to-severe (Yes, No) . 7.3. Blinding This is an open -label study where treatm ent allocatio n is revealed after randomizat ion. Specifically:"
106,page_106,"I1F-MC-RHCF (a) Clinical Protocol Page 106 LY2439821A blinded assessor will co mpletethe following assessments: oTJC/SJC oPsori asis Area and Severit y Index (PASI) oPercentage of B SA oEnthesit is oLDI-B oNAPSI Fingernails osPGA 7.7. Concomitant Therapy All conco mitant m edicat ion taken during the study must be recorded on the Concomitant Medicat ion case report f orm (eCRF) at the study visits indicated in the Schedule of Act ivities (Secti on 2). Treatment with conco mitant PsA therapi es during the study will be permitted only as outlined in the inclusio n and exclusio n criteria (Secti ons 6.1and 6.2, respecti vely) and as described below . Patients taking permitted PsA medicat ions shoul d be on stable doses at rando mizat ion (Vi sit 2) and through the first 24 weeks of the Open -Label Treatment Peri od,as specified below, unless changes are required for s afety reasons . Table RHCF.7.2, Table RHCF.7.3, and Table RHCF.7.4 summarize concomitant medicat ions that are and are not permitted and the condit ions for use during the study for those whi ch are permitted. Table RHCF .7.2. Concomitant Medications Permitted /Not Permitted in the Open -Label Treatment Period from Week 0 to Week 24 for Treatment of PsA and Chronic Conditions Drug Class As Needed Chronic Use Conditions for Use … csDMARDs N YStable dose allowed .Stable dose s with no dose adjustments , changes, and/or introduction of a new csDMARD Allowed doses: Oral or parenteral MTX; 10 to 25 mg/week Leflunomide: up to 20 mg/day Sulfasalazine: up to 3 g/day Hydroxychloroquine: up to 400 mg/day Cyclosporine: up to 5 mg/kg/day … Opiate analgesics N YStable doses with no dose adjustments, changes, and/o r introductio n of a new opiate analgesic. May be used at average daily doses ≤30 mg/day of morphine or its equivalent … Intravascular Vand IM gluco cortico idN NNot allowed …"
107,page_107,"I1F-MC-RHCF (a) Clinical Protocol Page 107 LY2439821Abbreviations: BCG = Bacillus Calmette -Guérin ; bDMARD = biological disease -modifying anti -rheumatic drugs; COX -2 = cyclooxygenase -2; csDMARD = conventional synthetic disease -modifying anti -rheumatic drugs; IM=intramuscular; IV = intravascular; JAK = Janus kinase ; MTX = methotrexate; N = No; NSAID =nonsteroidal anti -inflammatory drug; PASI = Psoriasis Area and Severity Index ; PDE4 =phosphodiesterase type 4; Y = Yes ; WHO = World Health Organization . Table RHCF .7.3. Concomitant Medications Permitted/N ot Permitted in the Open -Label Treatment Period from Week 24 to Week 52 for Treatment of PsA and Chronic Conditions Drug Class As Needed Chronic Use Conditions for Use … csDMARDs N YAllowed doses: Oral or parenteral MTX; 10 to 25 mg/week Leflunomide: up to 20 mg/day Sulfasalazine: up to 3 g/day Hydroxychloroquine: up to 400 mg/day Cyclosporine: up to 5 mg/kg/day … Intravascular Vand IM gluco cortico idN NNot allowed … Abbreviations: BCG = Bacillus Calmette -Guérin ; bDMARD = biological disease -modifying anti -rheumatic drugs; COX -2 = cyclooxygenase -2; csDMARD = conventional synthetic disease -modifying anti -rheumatic drugs; IM=intramuscular; IV = intravascular; JAK = Janus kinase ; MTX = methotrexate; N = No; NSAID =nonsteroidal anti -inflammatory drug; PASI = Psoriasis Area and Severity Index ; PDE4 =phosphodiesterase type 4 ; Y = Yes; WHO = World Health Organization . Table RHCF .7.4. Allowed Concomitant Medications in the Post -Treatment Follow -Up Period (Period 3) Drug Class As Needed Chronic Use Conditions for Use … Intravascular Vand IM gluco cortico idY YAllowed … Abbreviations: BCG = Bacillus Calmette -Guérin ; bDMARDs = biological disease -modifying anti -rheumatic drugs; COX -2 = cyclooxygenase -2; csDMARD = conventional synthetic disease -modifying anti -rheumatic drugs; IM=intramuscular; IV = intravascular; JAK = Janus kinase ; MTX = methotrexate; N = No; NSAID =nonsteroidal anti -inflammatory drug; PASI = Psoriasis Area and Severity Index ; PDE4 =phosphodiesterase type 4 ; Y = Yes ; WHO = World Health Organization . To avoi d any possible drug interacti ons for those patients rando mized to adalimumab, please refer to the SPC product labeling for adalimumab for further concomitant therapy restricti ons."
108,page_108,"I1F-MC-RHCF (a) Clinical Protocol Page 108 LY24398218.1.1. Permanent Discontinuation from Study Treatment Discontinuati on of the invest igational product for abnormal liver tests should be considered by the invest igator when a pat ient meets one of the fo llowing condi tions af ter consul tation wi th the Lilly -designated m edical m onitor: … alkaline ph osphatase >2.5X ULN wi th the appearance o f fatigue, nausea, vomiting, right quadrant pain or tenderness, fe ver, rash, and/or eosinophilia (>5%) 9.1.2.1. Psoriasis A rea and Severity Index (PA SI 75, PASI 90, PA SI 100) … Absolute PASI scores of < ≤1, < ≤2, or< ≤ 3 may be consi dered as treatm ent targets for the management of plaque psoriasis. 9.1.2.3.1. American C ollege of Rheumatology Core Set a. Tender Joint Count TJC joint assessments will be performed by a blinded assessor. … b. Swollen Joint Count SJC j oint assessments will be performed by a blinded assessor. … Missing, replaced, ankylo sed, or arthrodesed joints will be identified by the invest igator at the Screening Visit and will be excluded fro m evaluat ion during the trial. TJC/SJC j oint assessments will be performed by a blinded assessor. 9.1.2.11. Leeds Dactylitis Index -Basic If the patient has dact ylitis,the LDI-B will be administered by a blinded assessor. The LDI -B has been developed to measure the severit y of dactyli tis. Once the presence of dact ylitis is established in each digit, the ratio of the circumference of theaffected digit to the ci rcumference of the di git on the opposi te hand or foot is measured (Helliwell et al. 2005 ). Each dactylit ic digit is defined by a minimum increas e of 10% in circumference over the contra -lateral digit. If the same di gitson each hand or foot are thought t o be invo lved, the clinician will refer to a table o f norm ative values (provided to study sites) for a value which will be used to provide the comparison. The calculated ratio is then mult iplied by a tenderness score of 0 (not tender) or 1(tender). If the ratio is >1.1, then subtract 1 from the calculated ratio and mult iply it by 100 and the tenderness score of 0 (not tender) or 1 (tender). Otherwise, if the ratio of the circumference of the digit is ≤1.1, then the LDI -B score i s set to 0. Tenderness is assessed in the area between the jo ints. The results of each digit are then added to produce a total score (Healy andHelliwell 2007)."
109,page_109,"I1F-MC-RHCF (a) Clinical Protocol Page 109 LY24398219.1.2.14. Static Physician Global Assessment If the patient has plaque Ps, the static Physician Global Assessment of psoriasis (sPGA) will be administered by the blinded assessor. The sPGA is the assessor’s physician’s determin ation of the pati ent’s Ps lesions overall at a given time point . The sPGA is recommended as an endpo int to use to assess efficacy in the treatm ent of Ps (EMEA 2004). Overall lesio ns are categorized by descript ions for induration, ery thema, and scaling. For the analysis of responses, the patient’s Ps is assessed at a given time po int on a 6 point scale in which 0 = cleared, 1 = minim al, 2 = mild, 3 = moderate; 4 = severe, 5 = very severe. 9.3. Treatment of Overdose Refer to the ixekizumab IBand product l abeling SPC and the adalimumab product l abeling SPC. 10.1. Sample Size Determination Sample size was calculated assuming the proporti on of patients simultaneously achieving ACR50 and PASI 100 as 13.2 13.6 % and 28.8 31.3%in the adalimumab and ixekizumab treatm ent groups, respectively ,as observed in the csDMARD -experienced popul ation from Study RHAP . According to the nQuery so ftware, a total sample size of 550 (with 275 per treatm ent group ) using a 2 -sided Fisher's exact test at 0.05 level of significance would yield 9 9% power for testing ixekizumab versus sadalimumab. This sample size would yield 79 78 %power for testing the noninferiorit y of ixekizumab to adalimumab at a one-sided0.025 level of significance based on a noninferiorit y margin of –12% and using ACR50 response rates of 42.5 43.8 %and 44.1% as observed for the ixekizumab and adalimumab treat ment groups, respecti vely, in the csDMARD -experienced popul ation from Study RHAP in the ixekizumab and adalimumab treatment groups, respectively . For testing superi ority of ixekizumab to adalimumab based on PASI 100 response rates of 42.5 46.9 %and 23.5 23.7% as observed for ixekizumab and adalimumab in the csDMARD -experienced popul ation fromStudy RHAP, this sample size would yield 99% power using a 2 -sided Fisher's exact test at 0.05 level o f significance . 10.3.1.1. General Considerations for Analyses during Period 2 (Open -Label Treatment Period) … Com parisons of ixekizumab versus adalimumab will be performed for all outcome variables at all visitsin Period 2; however, the primary timepoint of interest is Week 24 . 10.3.1.3. Adjustment for Multiple Comparisons …"
110,page_110,"I1F-MC-RHCF (a) Clinical Protocol Page 110 LY24398213. Test 3 for Major Secondary Endpoint #2 –Propo rtion of patients achieving PASI 10 0 at Week 24 : If the test for major secondary endpo int #1 is significant, then a superi ority noninferiorit ytest for m ajor secondary endpoint #2 will be pe rformed , followed by a test for superi ority. The noninferi ority test will be perform ed using the m ethods described in Secti on10.3.3.3 , and the superiorit y test will be performed using the m ethods described in Section 10.3.3.1.1 . 10.3.2.2. Patient Charac teristics Baseline characterist ics, clinical, and health outcome measurements will be summarized for the ITT population. Baseline characteristics will include sex, age, age category , wei ght, BMI, race, geographi c regi on, baseline disease severit y, duration of disease, previous nonbio logic systemic therapy , and previous bio logic therapy . Baseline clinical measurements will include CASPER, ACR component scores, PASI total score, DAS28 -CRP, CRP, Modified CPDAI, HAQ -DI, Itch NRS score, NAPSI Fingernails, SPARCC Enthesit is Index, LEI, LDI -B, and other QoL score s. 10.3.3.1.1. Categorical Variables Unless specified otherwise, the primary analys ismethod for thecategori calefficacy and heal th outcom e variables will be using a logist ic regressio n model with treatm ent, concomitant csDMARD use at baseline (Yes vs No) (yes or no),and severit y of plaque psori asismoderate -to- severe plaque psoriasis invo lvement (Yes vs No ) (yes or no )as factors and NRI method. Treatment group comparisons will be made at all visit s up to Week 52 and odds ratios and their corresponding 95% confidence intervals (CI s) will be reported. 10.3.3.1.2. Continuous Variables Unless specified otherwise, t he primary analys ismethod for all cont inuous efficacy and healt h outcom e variables will be using a MMRM analysis . The m odel will include treatm ent group, concomitant csDMARD use (Yes vs No) at baseline , moderate -to-severe plaque psoriasis involvement (Yes vs No) severit y of plaque psori asis, baseline value, visit, baseline-by- visit interact ion, and treatment -by-visit interacti on as fixed factors. The covariance structure to model the within-patient errors will be unstructured. If the unstruc tured covariance matrix results in a lack of convergence, the heterogeneous Toeplitz covariance structure, followed by the heterogeneous autoregressive covariance structure will be used . The Kenward -Roger m ethod will be used to estimate the deno minator de grees of freedo m. Type III tests for the least squares means will be used for the statist ical com parison; the 95% confidence interval ( CI)will also be reported . Treatment group comparisons at all visits up to Wee k 52 will be tested made . 10.3.3.3. Methodology for Noninferiority Test … Based on EMEA CHMP (CHMP 2005) ,FDA guidance (2016 ),and Weinblatt et al. (2013), a noninferiorit y margin o f −12.0% for ACR50 between ixekizumab and adalimumab (ie, response rate of ixekizumab –response rate of adalim umab) is considered appropri ate. This noninferiorit y margin represents a napproximately 60 50% preservat ion of the adalimumab treatment effect"
111,page_111,"I1F-MC-RHCF (a) Clinical Protocol Page 111 LY2439821(based on the difference between adalimumab and placebo) observed in a historical Phase 3 studyfor adalimumab 4 0 mg twi ce weekly com pared wi th placebo (Mease et al 2005) and Study RHAP . 10.3.6.1. Subgroup Analyses … Subgroups to be evaluated will include conco mitantcsDMARD use at baseline (Yes vs No), concomitant MTX use at baseline (Yes orvsNo), sex(male vs female), age group (<65 vs ≥65) . A detailed description o f the subgroup variables will be provided in the SAP. 10.3.7. Interim Analyses An interim database lock will occur, and the analysis will be performed at the time (that is, a cutoff date) when the last patient completes Visit 8 (Week 24) ,completes ETV , or discont inues from Period 2. Thi s database l ock will include all data collected by the cutoff date including data after Week 24 fro m the Open- Label Treatment Peri od (Peri od 2) and follow -up data from patients who have begun Post -Treatment Fo llow-Up Peri od (Peri od 3). This interim database lock at Week 24 will be considered the primary database l ock f or this study because all primary and major secondary study object ives will be assessed at thi s time. Since the primary timepoint of interest is Week 24, efficacy and healt h outcom es data will be reported up to Week 24 because of the lack of co mplete data for all pat ients beyo nd this visit. However, all safet y data collected up to the cuto ff date will be reported. A final database lock will occur after all enro lled patients have co mpleted or di scont inued the Post-Treatment Follow -Up Peri od(Peri od 3) . After the final database lock, all efficacy, healt h outcom es, and safet y data collected until study complet ion will be reported. Appendix 2. Clinical Laboratory Tests … Other Tests Creatinine Human immunodeficiency virus antibody (HIV) Hepatitis B Surface antigen (HBsAg) Anti-Hepatitis B Surface antibody (HBsAb) Anti-Hepatitis B Core antibody (HBcAb) Anti-Hepatitis C antibody Purified Protein Derivative (PPD)a QuantiFERON ®-TB Golda T-SPOT.TBa HBV DNA HCV RNA Rheumatoid factor (RF)Uric acid Calcium Glucose, fasting at Visit 2 but nonfasting throughout study, if clinically indicated Albumin Cholesterol Creatine Phospho kinase (C PK) hs-CRP"
112,page_112,I1F-MC-RHCF (a) Clinical Protocol Page 112 LY2439821Appendix 1. A bbreviations and Definitions … Term Definition SPC Summary of Product Characteristics
113,page_113,Leo Document ID = 77544431-841d-40bb-b76d-8d2be706f300 Approver: Approval Date & Time: 26-May-2017 13:01:47 GMT Signature meaning: Approved Approver: Approval Date & Time: 26-May-2017 13:26:53 GMT Signature meaning: Approved PPD PPD
